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Abstract
Regulation of the Epidermal Growth Factor Receptor (EGFR) by its growth factor ligands is critical in many
biological processes, including development and tissue maintenance and growth. Aberrant overexpression or
activation by mutation of EGFR is associated with many human tumors. In these contexts, constitutive
signaling can lead to cellular transformation and oncogenesis, thereby driving the cancer. The EGFR is the
target of several existing or developing cancer therapies or immunotherapies, including monoclonal
antibodies that prevent its activation. Activating mutations in cytoplasmic tyrosine kinase domain have been
identified in many cancers, and have been the focus of mechanistic work. In this dissertation, I focus on the
mode of oncogenic dysregulation by novel extracellular mechanisms.
Extracellular oncogenic variants of EGFR include point mutations and alternative splice variants of EGFR. I
find through biochemical analysis of the activating missense mutations in the extracellular region of EGFR
that the soluble extracelluar region of EGFR (sEGFR) harboring these mutations bind ligands with elevated
affinities. The dimerization energetics of these sEGFR mutants is not measurably altered, which suggests that
additional interactions from the membrane and/or the intracellular region are important to this novel mode
of extracellular oncogenic dysregulation of EGFR. I present preliminary progress towards the application of
hydrogen/deuterium exchange coupled to mass spectrometry to analyze such allosteric (dys)regulation of the
EGFR.
In a second focus, I studied mechanisms of antibody targeting of EGFR. There are several monoclonal
therapeutic antibodies that are in clinical development or use that target the EGFR/ErbB/HER family of
receptor tyrosine kinases, including cetuximab/Erbitux™, panitumumab/Vectibix™, and necitumumab/
Portrazza™, which all target EGFR, as well as trastuzumab/Herceptin™ and pertuzumab/Perjeta™, which target
ErbB2/HER2. Unfortunately, as observed for most targeted therapies for cancer, resistance to these antibody
therapies limits the duration of their effective treatment. Recent exome sequencing analyses of KRAS-WT
colorectal cancer patients resistant to cetuximab treatment has identified epitope mutations as a mechanism of
resistance. Whereas these mutated receptors bind cetuximab with dramatically decreased affinities, I report
that they retain high affinity binding for necitumumab, a humanized IgG1 anti-EGFR antibody that shares the
same epitope as cetuximab and panitumumab, and was recently FDA approved for squamous non-small cell
lung carcinoma. I determined an X-ray crystal structure of the Fab fragment of necitumumab with the most
commonly found resistance mutation—S492R (or S468R using the numbering scheme that starts at the
beginning of the mature EGFR protein). This structure reveals a relatively hydrophobic cavity in the paratope
of necitumumab that can accommodate the arginine at position S492/468 in the EGFR epitope. Further I
find that other cetuximab and panitumumab resistance variants of EGFR are also permissive for necitumumab
binding, suggesting significant plasticity in binding of necitumumab to EGFR. A survey of structures of
therapeutic antibodies bound to their targets suggests that paratope shape may be an important property to
consider in the selection of monoclonal antibodies in therapeutic strategies.
Another mechanism of oncogenic dysregulation is the gene rearrangement of EGFR that results in EGFR
variant III (EGFRvIII), an important target of many classes of immunotherapies for glioblastoma multiforme
(GBM). I show in small angle X-ray scattering analyses of the ectodomain of EGFRvIII some evidence of
structural flexibility in domain II that may be important for its documented transactivation of other receptor
tyrosine kinases. I also report an X-ray crystal structure of the ectodomain of EGFRvIII in complex with the
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antigen binding or VHH domain of a camelid heavy-chain only antibody (HCAb), that has ~25-fold
specificity for EGFRvIII compared to wild type EGFR. The structure reveals that the VHH gains specificity
for EGFRvIII by targeting an epitope on domain IV that is sterically occluded in wild type EGFR by the
intramolecular ‘tether’. This structure provides the direct evidence of dynamic uncoupling of the ‘tether’. My
work corroborates the utility of the ‘tether’ as a source of antibody specificity for oncogenic EGFR, and is the
first structural view of specific antibody targeting of an oncogenic EGFR variant.
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ABSTRACT 
 
MECHANISMS OF EXTRACELLULAR ONCOGENIC DYSREGULATION AND ANTIBODY 
TARGETING OF THE EPIDERMAL GROWTH FACTOR RECEPTOR 
Atrish Bagchi 
Kathryn M. Ferguson 
 
Regulation of the Epidermal Growth Factor Receptor (EGFR) by its growth factor ligands 
is critical in many biological processes, including development and tissue maintenance and 
growth.  Aberrant overexpression or activation by mutation of EGFR is associated with many 
human tumors.  In these contexts, constitutive signaling can lead to cellular transformation and 
oncogenesis, thereby driving the cancer.  The EGFR is the target of several existing or 
developing cancer therapies or immunotherapies, including monoclonal antibodies that prevent its 
activation. Activating mutations in cytoplasmic tyrosine kinase domain have been identified in 
many cancers, and have been the focus of mechanistic work.  In this dissertation, I focus on the 
mode of oncogenic dysregulation by novel extracellular mechanisms.   
Extracellular oncogenic variants of EGFR include point mutations and alternative splice 
variants of EGFR.  I find through biochemical analysis of the activating missense mutations in the 
extracellular region of EGFR that the soluble extracelluar region of EGFR (sEGFR) harboring 
these mutations bind ligands with elevated affinities.  The dimerization energetics of these 
sEGFR mutants is not measurably altered, which suggests that additional interactions from the 
membrane and/or the intracellular region are important to this novel mode of extracellular 
oncogenic dysregulation of EGFR.  I present preliminary progress towards the application of 
hydrogen/deuterium exchange coupled to mass spectrometry to analyze such allosteric 
(dys)regulation of the EGFR.   
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In a second focus, I studied mechanisms of antibody targeting of EGFR.  There are 
several monoclonal therapeutic antibodies that are in clinical development or use that target the 
EGFR/ErbB/HER family of receptor tyrosine kinases, including cetuximab/Erbitux®, 
panitumumab/Vectibix®, and necitumumab/Portrazza®, which all target EGFR, as well as 
trastuzumab/Herceptin® and pertuzumab/Perjeta®, which target ErbB2/HER2.  Unfortunately, as 
observed for most targeted therapies for cancer, resistance to these antibody therapies limits the 
duration of their effective treatment.  Recent exome sequencing analyses of KRAS-WT colorectal 
cancer patients resistant to cetuximab treatment has identified epitope mutations as a mechanism 
of resistance.  Whereas these mutated receptors bind cetuximab with dramatically decreased 
affinities, I report that they retain high affinity binding for necitumumab, a humanized IgG1 anti-
EGFR antibody that shares the same epitope as cetuximab and panitumumab, and was recently 
FDA approved for squamous non-small cell lung carcinoma.  I determined an X-ray crystal 
structure of the Fab fragment of necitumumab with the most commonly found resistance 
mutation—S492R (or S468R using the numbering scheme that starts at the beginning of the 
mature EGFR protein).  This structure reveals a relatively hydrophobic cavity in the paratope of 
necitumumab that can accommodate the arginine at position S492/468 in the EGFR epitope.  
Further I find that other cetuximab and panitumumab resistance variants of EGFR are also 
permissive for necitumumab binding, suggesting significant plasticity in binding of necitumumab 
to EGFR.  A survey of structures of therapeutic antibodies bound to their targets suggests 
paratope shape may be an important property to consider in the selection of monoclonal 
antibodies in therapeutic strategies. 
Another mechanism of oncogenic dysregulation is the gene rearrangement  of EGFR that 
results in EGFR variant III (EGFRvIII), an important target of many classes of immunotherapies 
for glioblastoma multiforme (GBM).  I show in small angle X-ray scattering analyses of the 
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ectodomain of EGFRvIII some evidence of structural flexibility in domain II that may be important 
for its documented transactivation of other receptor tyrosine kinases.  I also report an X-ray 
crystal structure of the ectodomain of EGFRvIII in complex with the antigen binding or VHH 
domain of a camelid heavy-chain only antibody (HCAb), that has ~25-fold specificity for EGFRvIII 
compared to wild type EGFR.  The structure reveals that the VHH gains specificity for EGFRvIII 
by targeting an epitope on domain IV that is sterically occluded in wild type EGFR by the 
intramolecular ‘tether’. This structure provides the direct evidence of dynamic uncoupling of the 
‘tether’.  My work corroborates the utility of the ‘tether’ as a source of antibody specificity for 
oncogenic EGFR, and is the first structural view of specific antibody targeting of an oncogenic 
EGFR variant. 
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CHAPTER ONE 
Introduction 
	 2	
A longstanding question in signal transduction biology is how cell surface receptors 
propagate the message of ligand availability across the plasma membrane.  Regulation of 
growth factor receptors by their growth factor ligands is critical in control of cellular 
proliferation, tissue development, and angiogenesis, and contributes to many developmental 
processes (Cote, 2012; Maina, 1996; McDonell, 2015).  An important class of growth factor 
receptors contain intracellular tyrosine kinase domains, which function to mediate trans-
autophosphorylation of regulatory tyrosines (Lemmon and Schlessinger, 2010).  Whereas the 
catalytic kinase domains are structurally and functionally well conserved, these receptor 
tyrosine kinases (RTK’s) contain diverse extracellular domain architectures, with many 
combinations of different types of subdomains.  The structural diversity of the extracellular 
architectures of receptor tyrosine kinases suggests mechanistic diversity in how these 
receptors are regulated by their cognate growth factor ligands, and such diversity is now 
starting to be fully explored (Lemmon and Schlessinger, 2010; Lemmon, 2014). 
The epidermal growth factor receptor (EGFR) was the first receptor tyrosine kinase to 
be identified (Carpenter, 1978) and mechanistically investigated.  It was also the first growth 
factor receptor for which the concept of ligand-induced dimerization was shown as a relevant 
mechanism for extracellular regulation of its intracellular tyrosine kinase domain (Lemmon, 
1997; Yarden, 1987).  Epidermal growth factor (EGF) induces receptor-mediated dimerization 
of EGFR, which leads to activation of its cytoplasmic tyrosine kinase domains.  Subsequent 
autophosphorylation of regulatory tyrosines in a disordered cytoplasmic C-terminal regulatory 
region results in recruitment of adaptor proteins that contain Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains. This recruitment initiates cascades of downstream 
signaling events through multiple pathways, including MAP kinase/Erk, phosphatidylinositol 
3-kinase/Akt, and phospholipase C/Ca2+, culminating in a variety of cellular responses, 
including proliferation or differentiation (Lemmon and Schlessinger, 2010).    
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Ligand-induced activation of EGFR can be bypassed by genetic mutation or its 
overexpression.  The resulting elevated aberrant activity of the EGFR can lead to constitutive 
activation of proliferative signaling that causes oncogenic transformation.  Moreover, 
overexpression and mutation of EGFR have been implicated in and drive many human 
cancers, including tumors of the brain, head and neck, and epithelial tissues.  The most well 
characterized, and common, of EGFR-activating oncogenic mutations are found in its 
tyrosine kinase domain, and include hydrophobic residues in a helix that stabilize an 
activation loop that sterically locks the catalytic site in its inactive state.  This activating 
mechanism drives EGFR’s responsiveness to tyrosine kinase inhibitor gefitinib (Lynch, 2004; 
Paez, 2004).  The mechanistic basis for the mode of EGFR activation by these mutations is 
reasonably well established for many of the mutations that have been identified (Shan, 2012), 
though gaining predictive power of mutations that are activating and driver mutations remains 
an important avenue of investigation.  This dissertation focuses on structural mechanisms of 
extracellular oncogenic dysregulation and therapeutic antibody targeting of the epidermal 
growth factor receptor family. 
The structural basis for ligand-induced dimerization of the epidermal growth factor 
receptor family was pioneered by X-ray crystallographic studies in the early 2000’s, which 
revealed at atomic resolution how EGF binding to its receptor leads to receptor-mediated 
dimerization of its extracellular region (Garrett, 2002; Ogiso, 2002).  Ligand binding to EGFR 
induces dramatic conformational rearrangement in its extracellular region in which an 
intramolecular ‘tether’ between cysteine rich domains (CRD’s) II and IV is broken, bringing 
domains I and III closer together and exposing a critical β hairpin in cysteine rich domain II 
that mediates important dimerization contacts (Burgess, 2003; Ferguson, 2003). These X-ray 
crystal structures provided a structural model for ligand-induced homodimerization of EGFR 
(Figure 1.1) (Burgess, 2003) and a framework for study of relationships between ligand 
binding to ErbB receptors and receptor homo- or hetero-oligomerization (Ferguson, 2000; 
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Kumagai et al., 2001).  Structural studies of other members of the ErbB/HER family showed 
that similar intramolecular ‘tethers’ between domains II and IV also exist in ErbB3 (Cho, 
2002), and ErbB4 (Bouyain, 2005).  By contrast, the orphan receptor ErbB2/HER2, for which 
there is no known ligand, was found by crystallographic analysis to be constitutively 
‘extended’ as a monomer, revealing that it is structurally distinct from the other ErbB 
receptors (Cho, 2003).  This structural distinction can be harnessed by targeted antibody 
therapeutics to gain specificity for targeting ErbB2/HER2, such as trastuzumab/HerceptinTM 
(Cho, 2003) and pertuzumab/PerjetaTM (Franklin, 2004).  In Chapter Five, I discuss antibody 
targeting of an oncogenic EGFR variant that utilized a similar binding mechanism. 
Hypotheses regarding the precise biological role of this intramolecular ‘tether’ in ErbB 
receptors have evolved since these first structures were determined.  Though in 2003, it was 
proposed that the domain II/IV  intramolecular interaction may be responsible for receptor 
autoinhibition (Burgess, 2003; Ferguson, 2003; Walker, 2004), mutation of tethering residues 
is not activating (Mattoon, 2004) and the extracellular regions of both EGFR and ErbB4 retain 
a tethered-like conformation in the absence of these interactions (Dawson, 2007; Liu, 2012).  
Simple exposure of the β-hairpin in domain II by deletion of domain IV is not sufficient to drive 
ligand-independent dimerization of the EGFR extracellular region, suggesting that ligand-
induced conformational remodeling of domain II is critical for EGFR activation (Dawson, 
2005). In addition, the unliganded, inactive Drosophila melanogaster EGFR extracellular 
region lacks a domain II/IV tether and is instead an ‘extended’ monomer, suggesting that the 
presence of a ‘tether’ is not a sufficient autoinhibitory mechanism (Alvarado, 2009).  
In 2006, Mellinghoff and colleagues identified activating missense mutations in the 
extracellular region of the EGFR in glioblastoma multiforme (GBM) tumors or cell lines.  
Expression of these altered EGFR molecules induces cellular transformation of NIH3T3 cells 
and tumor growth in murine xenograft models (Lee et al., 2006).  In addition, these mutations 
are sufficient to induce IL-3 independent growth of the murine B cell line Ba/F3, which are 
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dependent on IL-3 for growth unless they express a constitutively active kinase (Warmuth, 
2007).  These mutations are largely located in critical ‘hinge’ points (Lee et al., 2006; Ymer, 
2011); clustering in a hydrophobic interface between domains I and II or at the interface 
between domains II and III – regions that had previously been ignored (Figure 1.2).  
Subsequent exome sequencing analysis of a panel of other epithelial cancers identified 
analogous mutations in ErbB3 in the same interface, suggesting possible mechanistic 
similarities in the modes of extracellular oncogenic dysregulation of ErbB receptors (Jaiswal 
et al., 2013).   In work published in 2014 (Bessman, 2014) and reproduced in Chapter Two, I 
found that these EGFR-activating mutations in the extracellular region of EGFR increase 
ligand binding affinities for the mutated EGF receptors without measurably altering the ligand-
induced EGFR homo-dimerization affinities.  As described in Bessman et al. (2014) and 
Chapter Two, these data suggest that the extracellular oncogenic mutations may alter the 
thermodynamic linkage of ligand binding and dimerization of EGFR rather than simply 
promoting ligand-independent dimerization (Bessman, 2014).  
Structural studies of the intracellular EGFR tyrosine kinase domain showed that, 
unlike some other tyrosine kinases that require phosphorylation of an activation loop to 
stabilize an active conformation (Hubbard, 2013; Lemmon, 2014), formation of an asymmetric 
kinase dimer is essential for EGFR tyrosine kinase activation (Figure 1.1).  In this asymmetric 
dimer, the C-lobe of one, inactive, monomer interacts with the N-lobe of the other and thereby 
allosterically stabilizes its catalytically competent conformation (Zhang, 2006).  The formation 
of this asymmetric dimer is required for tyrosine kinase activation as mutation of the 
crystallographic dimer interface abolishes kinase activity.  It is also clear that formation of this 
asymmetric dimer can be regulated by mechanisms involving interactions with the 
juxtamembrane regions of EGFR.  It has been shown through crystallographic analysis that 
the intracellular juxtamembrane region forms a ‘latch’ around this asymmetric dimer, 
stabilizing it through van der Waals interactions (Figure 1.1) (Jura, 2009; Red Brewer, 2009).  
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Despite these advances in our structural knowledge of isolated EGFR domains, the 
precise nature of the allosteric coupling of extracellular ligand-induced dimerization and 
intracellular dimerization of the tyrosine kinase domains remains unclear.  The extracellular 
region of EGFR was originally viewed as a module that served simply to drive ligand-induced 
dimerization of the intracellular tyrosine kinase domain.  However, it has been shown in 
recent years that inactive, EGFR dimers also exist that are altered by ligand binding (Chung, 
2010; Yu, 2002).  It is also unclear from structural studies how structural asymmetry could be 
communicated across the plasma membrane, as structures of ligated human EGFR in 
complex with EGF or TGFα are completely symmetric (Lu et al., 2012; Ogiso, 2002).  Ligand 
binding studies of intact EGFR on the cell surface argue that negative cooperativity of ligand 
binding underlies this coupling of asymmetry (MacDonald, 2008; Pike, 2012).  The implicit 
structural asymmetry associated with negative cooperativity was crystallographically 
observed in a ligated structure of the Spitz-bound EGFR ortholog from Drosophila 
melanogaster (Alvarado et al., 2010).  However, in the human counterpart, such negatively 
cooperative ligand binding is not recapitulated in studies of the isolated EGFR extracellular 
region, suggesting that additional interactions from the cytoplasmic domains and/or the 
plasma membrane are also important for such complex ligand binding equilibria. In addition, 
the extracellular regions of the Drosophila melanogaster and C. elegans orthologs of EGFR 
dimerize with high affinity in the absence of ligand (Freed, 2015), observations that suggest 
there may be autoinhibitory mechanisms within receptor dimers that are altered by ligand 
binding.   
Taken together, it is clear that EGFR is allosterically regulated in a manner similar to 
other allosterically regulated receptor tyrosine kinases, such as the insulin receptor (Lemmon, 
2014).  In Chapter Three, I describe advances towards application of structural techniques 
such as hydrogen/deuterium exchange coupled to mass spectrometry to understand this 
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allostery.  Future work that will build upon this may reveal how extracellular oncogenic 
mutations in EGFR dysregulate the coupling of extra- and intra-cellular communication. 
Another mode of extracellular oncogenic dysregulation of EGFR results from gene 
rearrangements of EGFR and expression of exon excluded forms of the receptors.  
Historically, one of the first oncogenes to be identified was v-ErbB, from avian 
erythroblastosis virus (from which the ErbB family derived its name).  v-ErbB is a mutated 
form of EGFR that results in a large deletion of its extracellular region and also harbors 
several intracellular region mutations.  The most common extracellular oncogenic form of 
EGFR produces a similar, N-terminally truncated form of the receptor, called variant III 
(EGFRvIII) (Sugawa, 1990; Wong, 1992).  EGFRvIII is constitutively active and 
phosphorylated and has been found to contribute cellular transformation and therapeutic 
resistance in glioblastoma (Gan, 2009), non-small cell lung cancer (Okamoto, 2003) and 
head and neck squamous cell carcinoma (Sok, 2006).  Because of its expression at high 
frequency in glioblastoma, EGFRvIII has emerged as an important target for several classes 
of cancer immunotherapies (Choi, 2013; Johnson, 2015).  In Chapter Five, I identify a novel 
mode of specific targeting of EGFRvIII by a nanobody that may have potential as an imaging 
and/or therapeutic agent. 
 Due to the important role of the epidermal growth factor receptor family in driving 
human cancers, the members of this family are the targets of several classes of cancer 
therapies.  These include therapeutic antibodies, such cetuximab that block ligand-induced 
activation of EGFR (Li, 2008; Li, 2005; Schmeidel, 2008; Schmitz, 2009), and small molecule 
tyrosine kinase inhibitors that block ATP binding and kinase activation (Gazdar, 2009).  In the 
context of both targeted therapeutic approaches, clinical resistance remains a formidable 
problem.  Resistance can result from gene amplification, missense mutations, or alteration of 
downstream signaling networks such that they are rendered less sensitive to the input signals 
from growth factor receptors.   
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In the case of the EGFR, there are three targeted anti-EGFR antibody therapies 
currently approved by the U.S. Food and Drug Administration for clinical use in cancer 
therapy.  These antibodies are cetuximab/ErbituxTM, panitumumab/VectibixTM, and 
necitumumab/PortrazzaTM.  Cetuximab/Erbitux, a mouse/human chimeric IgG1 antibody 
approved for head and neck and colorectal cancers, binds to EGFR domain III to an epitope 
that overlaps the binding site for EGF and other EGFR ligands (Li, 2005).  Cetuximab blocks 
ligand binding to EGF receptor.  It further sterically prevents the ligand-induced 
conformational changes required for EGFR dimerization.  Panitumumab is a humanized IgG2 
antibody that is also approved for head and neck and colorectal cancers.  The efficacies of 
these antibody therapies for treating metastatic colorectal cancers was recently compared in 
a phase III clinical trial called ASPECCT (Price, 2015).  Necitumumab, a humanized IgG1 
antibody that shares the same framework region as cetuximab, binds to a nearly identical 
epitope as cetuximab, though through completely different binding interactions with its 
paratope (Li, 2008).  Necitumumab/PortrazzaTM in combination with gemcitabine and cisplatin 
for treatment of squamous non-small cell lung cancer received approval by the U.S. Food 
and Drug Administration in November 2015. 
 Recent sequencing efforts of patients resistant to EGFR-directed antibody therapies 
has revealed that one of the major mechanisms of resistance to these targeted therapies are 
point mutations in the shared epitope of these three antibodies (Bertotti, 2015).   These 
missense mutations decrease the effectiveness of these antibody inhibitors of EGFR by 
substantially decreasing the binding affinities of the antibodies for the mutated receptor 
molecules.  Sixteen percent of patients in the cetuximab arm of the ASPECCT trial developed 
resistance through one particular mutation – S492R in pro-EGFR, or S468R using the mature 
amino acid numbering of EGFR (Bertotti, 2015; Montagut, 2012; Price, 2015). In Chapter 
Four, I present a collaborative study with Eli Lilly & Company to investigate the binding of 
necitumumab to EGFR harboring cetuximab resistance mutations.  My structural analysis 
suggests that paratope shape may be an important feature that dictates the susceptibility of a 
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targeted antibodies to development of resistance due to epitope mutation.  Surprisingly, the 
interfaces of cetuximab and necitumumab in complex with the EGFR are not significantly 
different in quantitative measures of shape complementarity, despite the latter containing a 
buried hydrophobic cavity that contributes to its structural plasticity (Lawrence, 1993).  
Comparison of the paratopes of cetuximab and necitumumab to those of other therapeutic 
antibodies for which complex structures have been determined reveals a structural class of 
therapeutic antibodies that contain similar buried cavities between their VL and VH domains.  
Further studies are required to establish whether antibodies this class of antibody paratope 
are less susceptible to development of resistance due to epitope mutations. This work has 
implications for therapeutic antibody design, and the clinical use of necitumumab for these 
cases of cetuximab resistance. 
 I focus on aspects of two areas in this dissertation: (1) the structural and mechanistic 
basis for extracellular oncogenic dysregulation of the epidermal growth factor receptor 
(EGFR), and (2) the structural basis of antibody targeting and/or inhibition of the EGFR, 
either in the context of oncogenic dysregulation, or resistance to existing monoclonal 
antibody therapies.  My studies highlight that our mechanistic understanding of the allosteric 
regulation of the epidermal growth factor receptor is still evolving, and the work presented in 
Chapters Two and Three present progress towards understanding modes of EGFR allosteric 
regulation that may have lessons important for understanding how cell surface receptors may 
be allosterically regulated, more broadly.  The second focus reveals mechanisms by which 
therapeutic antibodies can target oncogenic forms of the EGFR or variants that cause 
resistance to existing monotherapies.  My work in this area has implications for 
understanding mechanisms of specificity and plasticity of targeting antibodies to cell surface 
receptor molecules.  
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Figure 1.1.  Structural Model of Ligand-Regulation of the Epidermal Growth Factor 
receptor, from (Lemmon, 2014).  (A) X-ray structure based model of EGF receptor 
activation by EGF.  In the absence of EGF, the EGFR extracellular region forms an 
intramolecular ‘tether’ between two cysteine rich domains II and IV (shown in green).  In this 
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conformation, the ligand binding domains I and III and held too far apart to simultaneously 
bind ligand.  This autoinhibited ‘tethered’ conformation is presumably linked to an inactive 
conformation of the tyrosine kinase domain, shown on the bottom part of the left side of panel 
A.  EGF induces a dramatic conformational rearrangement that remodels the conformation of 
domain II and releases the intramolecular ‘tether,’ unshielding a β hairpin in domain II that is 
critical for and drives dimerization of the EGFR extracellular region.  Formation of this dimer 
is indispensable for EGFR activation, as mutation of this hairpin abrogates EGFR activation.  
This symmetric dimer is linked to an asymmetric dimer of the tyrosine kinase domain, shown 
on the bottom right side of panel A.  Kuriyan and colleagues showed in 2006 that formation of 
this asymmetric dimer is essential for EGFR activation (Zhang, et al. 2006) .  In this 
asymmetric complex, one kinase monomer in a catalytically inactive conformation 
allosterically activates the active conformation of the other through N-love/C-lobe interactions.  
(B) A cartoon representation of the process shown in A, highlighting the ‘tethered’ to 
‘extended’ conformational transition in driving EGFR dimerization. 
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Figure 1.2.  Extracellular transforming variants of the Epidermal Growth Factor 
receptor. 
 
(A) Structural location of identified extracellular point activating and transforming point 
mutations in EGFR, found in glioblastoma multiforme (GBM) patients or cell lines (Lee et al., 
2006). These mutations are largely located in a relatively hydrophobic interface between 
domains I and II, stabilizing this interface. (B)  Another common oncogenic variant of EGFR 
found in ~30-50% of GBM patients is EGFRvIII.  EGFRvIII is an gene rearrangement that 
results in exclusion of exons 2-7 of EGFR, leading to a deletion of mature amino acids 6-273, 
A265 
R84 
E60 
C227 
A265V/D/T 
T239P 
G574V ‘Dimerization arm’ 
R84K 
B A 
C 
I II III IV 
II III IV 
Wild-type EGFR extracellular region 
EGFRvIII extracellular region 
1 165 310 480 621 
310 480 621 
Novel glycine Free cysteine 
	 13	
and insertion of a unique glycine at its N-terminus, at the exon junction.  This mutation also 
leaves an unpaired cysteine residue in the extracellular region of EGFRvIII, at mature amino 
acid position 283 (C16 in EGFRvIII).  
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 CHAPTER TWO 
Complex relationship between ligand binding and 
dimerization in the Epidermal Growth Factor Receptor 
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SUMMARY 
The EGFR plays pivotal roles in development and is mutated or overexpressed in 
several cancers. Despite recent advances, the complex allosteric regulation of EGFR 
remains incompletely understood. In efforts to understand why the negative cooperativity 
observed for intact EGFR is lost when its isolated extracellular region (ECR) is studied, we 
uncovered unexpected relationships between ligand binding and receptor dimerization. The 
two processes appear to compete. Surprisingly, dimerization does not enhance ligand 
binding (although ligand binding promotes dimerization). We further show that simply forcing 
EGFR ECRs into pre-formed dimers in the absence of ligand yields ill-defined, 
heterogeneous structures. Finally, we demonstrate that extracellular EGFR-activating 
mutations in glioblastoma patients enhance ligand binding affinity without directly promoting 
EGFR dimerization – suggesting that these oncogenic mutations alter the allosteric linkage 
between dimerization and ligand binding. Our findings have important implications for 
understanding how EGFR and its relatives are activated by specific ligands and pathological 
mutations. 
 
Note:  This chapter is reproduced as published in  
Bessman, N.J., Bagchi, A., Ferguson, K.M., Lemmon, M.A. Complex relationship 
between ligand binding and dimerization in the Epidermal Growth Factor Receptor.  Cell 
Reports. 9, 1306-17. 
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INTRODUCTION 
 
X-ray crystal structures determined in 2002 and 2003 (Burgess, 2003) provided 
mechanistic pictures of how extracellular ligand binding induces EGFR dimerization. A single 
ligand binds simultaneously to both domains I and III in the extracellular region (ECR) of one 
EGFR molecule, driving it into an ‘extended’ conformation as shown in Figure 2.1. This 
conformational change exposes a dimerization interface in domain II, through which the ECR 
then self-associates with a dissociation constant (KD) in the micromolar range (Burgess, 
2003; Dawson, 2005; Dawson et al., 2007). The model depicted in Figure 2.1 satisfyingly 
explains ligand-induced EGFR dimerization. It fails, however, to capture the complex ligand-
binding characteristics seen for EGFR at the cell surface – with concave-up Scatchard plots 
interpreted either as negative cooperativity (De Meyts, 2008; MacDonald, 2008) or distinct 
affinity-classes of EGF-binding site (Schlessinger, 1986) with high-affinity sites responsible 
for EGFR signaling (Defize et al., 1989). This cooperativity or heterogeneity is lost when the 
ECR from EGFR is studied in isolation, as also observed for the insulin receptor (De Meyts 
and Whittaker, 2002). 
 Insight into structural origins of EGF/EGFR binding complexity was provided by 
studies of the D. melanogaster EGFR (dEGFR), which – unlike its human counterpart – 
retains its negative cooperativity when the soluble ECR is isolated (Alvarado et al., 2010). 
Crystal structures of the ECR from dEGFR revealed a relatively simple ‘half-of-the-sites’ 
reactivity in which occupying one binding site in an asymmetric dEGFR dimer restrains and 
reduces the ligand-binding affinity of the second site (Alvarado et al., 2010). Subsequent 
detailed comparisons of human and Drosophila receptor ECR dimer structures led Leahy and 
colleagues to perform experiments suggesting similar half-of-the-sites reactivity for human 
EGFR (Liu et al., 2012). Moreover, detailed studies of EGF binding to intact hEGFR in cells 
are consistent with this model (MacDonald, 2008). The observed (or inferred) negative 
cooperativity requires formation of a stable singly-liganded receptor dimer, a species that is 
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never seen for the isolated ECR from hEGFR (Lemmon, 1997) but forms readily for its 
Drosophila counterpart (Alvarado et al., 2010). The ECR of the Drosophila receptor even 
dimerizes significantly (KD ~ 40 µM) without bound ligand (Alvarado, 2009), reminiscent of the 
ligand-independent (pre-formed) dimers reported for intact, cell-surface, hEGFR in many 
studies (Lemmon, 2009). We therefore reasoned that artificially dimerizing the ECR from the 
human receptor might restore negative cooperativity and provide avenues for studying details 
of the complex ligand-binding characteristics of hEGFR. Indeed, engineered dimers of the 
hEGFR ECR were previously reported to have increased ligand-binding affinity and concave-
up Scatchard plots (Adams et al., 2009; Jones, 1999). Similarly, concave-up Scatchard plots 
(suggesting negative cooperativity) could be restored to the insulin receptor ECR by fusing it 
to a dimeric immunoglobulin Fc domain (Bass et al., 1996) or to a dimerizing leucine zipper 
(Hoyne et al., 2000). 
 Here, we describe studies of the ECR from human EGFR that has been artificially 
dimerized, or harbors oncogenic mutations found in glioblastoma patients (Lee et al., 2006). 
Our findings provide new insight into the heterogeneous nature of pre-formed ECR dimers 
and origins of negative cooperativity. The data also argue that the extracellular structures 
induced by ligand binding are not ‘optimized’ for dimerization and, conversely, that 
dimerization does not optimize the ligand-binding site. Moreover, glioblastoma mutations 
appear to affect the allosteric linkage between ligand binding and dimerization rather than 
simply stabilizing EGFR dimers as expected. These studies have important implications for 
understanding extracellular activating mutations found in ErbB receptors in glioblastoma and 
other cancers, and also for understanding specificity of ligand-induced ErbB receptor 
heterodimerization. 
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RESULTS and DISCUSSION 
 
Pre-dimerizing the EGFR extracellular region has a modest effect on EGF binding 
affinity 
To access pre-formed dimers of the hEGFR extracellular region (sEGFR) 
experimentally we used two approaches. In one, we fused a dimerizing Fc domain to the very 
C-terminus of sEGFR (residue 621 of the mature protein) to create sEGFR-Fc. In the second, 
we fused a dimeric leucine zipper – from the S. cerevisiae transcription factor GCN4 – to the 
sEGFR C-terminus to yield sEGFR-Zip. Both proteins were expressed using a baculovirus 
expression system and were purified using approaches similar to those used in our earlier 
studies of sEGFR (see Experimental Procedures). Size exclusion chromatography (SEC) 
and/or sedimentation equilibrium analytical ultracentrifugation (AUC) confirmed that the two 
sEGFR fusion proteins are dimeric (Figure 2.7). 
 To measure KD values for ligand binding to sEGFR-Fc and sEGFR-Zip, we labeled 
EGF with Alexa-488 and monitored its binding to sEGFR proteins by measuring fluorescence 
anisotropy (FA). As shown in Figure 2.2A, EGF binds approximately 10-fold more tightly to 
the dimeric sEGFR-Fc or sEGFR-Zip proteins than it does to monomeric sEGFR (Table 2.1). 
The curves obtained for EGF binding to sEGFR-Fc and sEGFR-Zip fit well to simple one-site 
binding functions, and did not show any sign of negative cooperativity. This suggests that 
both EGF-binding sites in the dimer are equivalent, or have KD values that are sufficiently 
similar to be indiscernible in this assay. Thus, our initial studies did not support the 
hypothesis that simply dimerizing human sEGFR restores the negatively cooperative ligand 
binding that is seen for the intact receptor in cells. 
 One surprise from these data was that forced sEGFR dimerization has only a small 
(≤10-fold) effect on EGF-binding affinity. Under the conditions of the FA experiments, isolated 
sEGFR (without zipper or Fc fusion) remains monomeric; the FA assay contains just 60 nM 
EGF, so the maximum concentration of EGF-bound sEGFR is also limited to 60 nM – which 
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is more than 20-fold lower than the KD for dimerization of the EGF/sEGFR complex (Dawson, 
2005; Lemmon, 1997). This ≤10-fold difference in affinity for dimeric and monomeric sEGFR 
seems modest in light of the strict dependence of sEGFR dimerization on ligand binding 
(Dawson, 2005; Lax et al., 1991; Lemmon, 1997); sEGFR does not dimerize detectably even 
at millimolar concentrations in the absence of ligand, but ligand binding promotes receptor 
self-association with a KD value in the 1 µM range (corresponding to a Gibbs free energy or 
ΔG for dimerization of -8 kcal/mol). Straightforward linkage of these equilibria should stabilize 
EGF binding to dimeric sEGFR by up to 8 kcal/mol compared with binding to monomeric 
sEGFR. This would translate into an approximately ~106-fold increase in affinity of ligand for 
the dimer. The small difference in EGF-binding affinity for dimeric and monomeric sEGFR is 
also significantly smaller than the 40-100 fold difference typically reported between high-
affinity and low-affinity EGF-binding on the cell surface when data are fit to two affinity-
classes of binding site (Burgess, 2003; Magun et al., 1980). 
 
Mutations that prevent sEGFR dimerization do not significantly reduce ligand-binding 
affinity 
The small (≤10-fold) increase in ligand-binding affinity caused by sEGFR pre-
dimerization led us to question the extent to which domain II-mediated sEGFR dimerization is 
linked to ligand binding. It is typically assumed that the domain II conformation stabilized 
upon forming the sEGFR dimer in Figure 2.1C optimizes the positions of domains I and III for 
EGF binding. To test this hypothesis, we introduced into sEGFR a well-characterized pair of 
domain II mutations that block dimerization: one at the tip of the dimerization arm (Y251A) 
and one at its ‘docking site’ on the adjacent molecule in a dimer (R285S). The resulting 
double (Y251A/R285S) mutation abolishes both sEGFR dimerization and EGFR signaling 
(Dawson, 2005; Ogiso, 2002). Importantly, we used isothermal titration calorimetry (ITC) for 
these studies, where all interacting components are all free in solution. Previous studies 
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employing surface plasmon resonance (SPR) have indicated that dimerization-defective 
sEGFR variants bind immobilized EGF with reduced affinity (Dawson, 2005), and we were 
concerned that this may reflect avidity artifacts – where dimerizing sEGFR binds more avidly 
than monomeric sEGFR to sensorchip surfaces bearing immobilized EGF. 
 Surprisingly, our ITC studies showed that the Y251A/R285S mutation has no 
significant effect on ligand-binding affinity for sEGFR in solution (Table 2.1). These 
experiments employed sEGFR (with no Fc fusion) at 10 µM – ten times greater than the KD 
value for dimerization of ligand-saturated wild-type sEGFR (KD ~1 µM). Dimerization of wild-
type sEGFR (sEGFRwild-type) should therefore be complete under these conditions, whereas 
the Y251A/R285S-mutated variant (sEGFRY251A/R285S) does not dimerize at all (Dawson, 
2005). The KD value measured for EGF binding to dimeric sEGFRwild-type was essentially the 
same (within 2-fold) as that for sEGFRY251A/R285S (Figure 2.2B,C and Table 2.1), arguing that 
the favorable ΔG of sEGFR dimerization (-8 kcal/mol) does not contribute significantly 
(< 0.4 kcal/mol) to enhanced ligand-binding. Similarly, affinities for TGFα binding to 
sEGFRwild-type or sEGFRY251A/R285S are indistinguishable at 80 nM and 82 nM respectively 
(Table 2.2). These ITC data lead to two important conclusions. First and most importantly, 
they show that (when avidity effects in SPR are avoided) domain II-mediated dimerization 
does not significantly enhance ligand binding – implying that there is no positive linkage 
between ligand binding and sEGFR dimerization. Second, the results force us to revise the 
interpretation of EGF/sEGFR ITC studies that we published in 1997 (Lemmon, 1997).  We 
previously ascribed the major entropy-driven event (with positive ΔH) to sEGFR dimerization, 
modeling EGF binding as an enthalpy-driven event based on ITC of EGF binding to isolated 
domain III (Figure 2.9).  The fact that the entropy-driven event is maintained in the absence of 
sEGFR dimerization refutes this and reveals that EGF binding to the intact ECR is entropy 
driven, consistent with the associated conformational changes (see	Figure 2.9).	
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 Thus, contrary to the ~104-106 fold enhancement in ligand-binding expected if the 
sEGFR dimerization and EGF binding equilibria were straightforwardly linked, our data 
(summarized in Table 1) reveal that blocking sEGFR dimerization has little influence on 
ligand-binding affinity. Although ΔG for ligand binding is therefore essentially unchanged by 
the Y251A/R285S mutation, the enthalpy change (ΔH) associated with EGF binding is more 
favorable (less positive) by 2.0 kcal/mol for sEGFRwild-type than for sEGFRY251A/R285S. 
Compensating for this, TΔS is less favorable by 1.6 kcal/mol for binding to sEGFRwild-type. Very 
similar results were obtained for TGFα (Figure 2.9A/B and Table 2.2). Moreover, direct 
comparison of ITC and FA experiments shows that EGF binds sEGFRwild-type with very similar 
affinities under conditions where it does (ITC) and does not (FA) dimerize (Table 2.1 and 
Figure 2.2A,B) – also arguing for an absence of positive linkage between ligand binding and 
dimerization. Dimerization of EGF-bound sEGFRwild-type is essentially complete in our ITC 
experiments ([EGF/sEGFR] reaches 10 µM) and is essentially absent in FA ([EGF/sEGFR] ≤ 
60 nM), yet both studies report similar EGF-binding KD values. Moreover, even for covalently-
dimerized sEGFR-Fc, mutation of the dimerization arm does not impair ligand binding. As 
shown in Figure 2.2D, surface plasmon resonance (SPR) analysis of EGF binding to wild-
type and Y251A/R285S-mutated sEGFR-Fc revealed that this mutation has a negligible effect 
on EGF-binding affinity in the Fc fusion. 
 
Thermodynamics of EGF binding to sEGFR-Fc 
If there is no discernible positive linkage between sEGFR dimerization and EGF 
binding, why is it that sEGFR-Fc and sEGFR-Zip bind EGF ~10-fold more strongly than wild-
type sEGFR in Figure 2.2A? To investigate this, we compared ITC titrations of EGF into 
sEGFR-Fc and sEGFR-Zip (Figure 2.3A and B) with those for EGF into non-fused, isolated 
sEGFR. As shown in Table 2.1, the positive ΔH for EGF binding to pre-dimerized sEGFR is 
greater (more unfavorable) than for binding to isolated (non-dimerized) sEGFRwild-type, 
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suggesting that enforced dimerization may actually impair ligand/receptor interactions such 
as hydrogen bonds and salt-bridges. This increased ΔH is more than compensated for, 
however, by a favorable increase in TΔS. We suggest that this favorable entropic effect might 
reflect an ‘ordering’ imposed upon unliganded sEGFR when it is pre-dimerized, such that it 
exhibits fewer degrees of freedom compared to monomeric sEGFR. In particular, since EGF 
binding does induce sEGFR dimerization it seems clear that pre-dimerization will reduce the 
entropic cost of bringing two sEGFR molecules into a dimer upon ligand binding. 
 
 
Possible heterogeneity of binding sites in sEGFR-Fc 
Closer inspection of titrations of EGF into sEGFR-Fc such as that shown in Figure 
2.3A suggested some heterogeneity of sites, as evidenced by the slope in the early part of 
the experiment. To investigate this possibility further, we repeated the titrations over a range 
of temperatures. We reasoned that, if there are in fact two different types of EGF-binding site 
in the sEGFR-Fc dimer, they might be characterized by different values for heat capacity 
change (ΔCp). If so, the small differences might become more evident at higher (or lower) 
temperatures. Indeed, ΔCp values have been correlated with the nonpolar surface area buried 
upon binding (Livingstone et al., 1991) – and we know that this differs for the two Spitz-
binding sites in the asymmetric Drosophila EGFR dimer (Alvarado et al., 2010). As shown in 
Figure 2.3C, the heterogeneity was more easily discernible at higher temperatures for 
sEGFR-Fc – especially at 25˚C and 30˚C – suggesting the possible presence of distinct 
classes of binding sites in the sEGFR-Fc dimer. We were not able to fit the two KD values (or 
ΔH values) uniquely with any precision, since the experiment does not have enough 
information for unique fitting to a model with 4 variables. Whereas binding to wild-type 
sEGFR could be fit confidently with a single-site binding model throughout the temperature 
range in Figure 2.3C, enforced sEGFR dimerization (by fusion to Fc) creates some apparent 
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heterogeneity in binding sites, which may reflect negative cooperativity of the sort seen with 
dEGFR. The different binding sites are too close in their KD values to be discerned in ITC or 
FA studies, and can only be distinguished based on different ΔH values at higher 
temperature. Nonetheless, these data do suggest that negative cooperativity may indeed be 
an intrinsic property of the hEGFR extracellular region as suggested (Liu et al., 2012), and as 
visualized for the Drosophila receptor (Alvarado et al., 2010). Presumably, interactions 
involving other parts of EGFR are responsible for the greater distinction in KD values seen for 
the intact receptor (Macdonald-Obermann and Pike, 2009). 
 
Ligand binding is required for well-defined dimerization of the EGFR extracellular 
region 
To investigate the structural nature of the pre-formed ECR dimer in sEGFR-Fc, we 
used negative stain electron microscopy (EM). We hypothesized that enforced dimerization in 
the Fc fusion might cause the ligand-free ECR from hEGFR to form the same type of loose 
domain II-mediated dimer that was seen in crystals of its unliganded Drosophila counterpart 
(Alvarado, 2009). As shown in Figure 2.4A, it was clear in the presence of saturating ligand 
that the ECRs in sEGFR-Fc form the characteristic heart-shape dimer seen 
crystallographically and in EM studies by Springer’s group (Lu et al., 2010; Mi et al., 2011). 
Figure 2.4B presents a structural model of the liganded sEGFR dimer fused to a dimeric Fc 
domain, and Figure 2.4C shows a calculated projection of this model at 12 Å resolution. The 
selection of class averages for sEGFR-Fc plus EGF in Figure 2.4A resemble this model very 
closely, confirming that the expected ECR dimer does indeed form. Class averaging of single 
particles yielded clear densities for all 4 receptor domains, arranged as expected for the 
EGF-induced domain II-mediated ‘back-to-back’ extracellular dimer shown in Figure 1 
(Garrett, 2002; Lu et al., 2010). In a subset of classes, the Fc-domain also appeared well 
resolved with good signal, indicating that these particular arrangements of the Fc domain 
relative to the ECR represent highly populated states – with the Fc domains occupying similar 
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positions to those of the kinase domain in detergent-solubilized intact receptors (Mi et al., 
2011). 
 By contrast, in the absence of EGF, EM studies of sEGFR-Fc failed to yield signal-
enhanced class averages with well-defined and interpretable inter-domain relationships 
(Figure S4) – despite significant effort with the same protein preparations and staining 
conditions that yielded the clear averages shown in Figure 2.4A. Thus, simply forcing the 
ECR from hEGFR into a dimer by fusing to an Fc domain does not cause it to form a well-
ordered domain II-mediated back-to-back dimer. Ligand binding is required for this type of 
dimer to form. 
 Whether the ECRs are tethered or extended in unliganded sEGFR-Fc (or sample 
both conformations) is not clear. Solution small angle X-ray scattering (SAXS) studies 
showed that sEGFR-Fc becomes more significantly compact upon EGF binding, with the 
radius of gyration (Rg) falling from 65.0 Å to 56.4 Å (Figure 2.4D) and the maximum 
interatomic distance (Dmax) within the molecule falling from 198 Å to 175 Å (Figure 2.4E). 
Values for Rg and Dmax for ligand-bound sEGFR-Fc agree reasonably well (within 8%) with 
those calculated for a model with the Fc domain dimer appended to an extended sEGFR 
dimer resembling that seen in crystal structures of EGF/EGFR complexes (Figure 2.4B and 
2.4F, model i) – although flexibility in the relative orientations of the ECR and Fc regions 
make direct comparison difficult. The relatively large Rg and Dmax values for sEGFR-Fc in the 
absence of ligand (Figure 2.4D and 2.4E) are more consistent with a model in which the 
ECRs are splayed apart, possibly while remaining tethered. Indeed, a model in which two 
tethered EGFR ECRs are attached to the Fc dimer and maximally splayed apart (Figure 2.4F, 
model ii) yields an Rg of 69 Å (compared with 65 Å for unliganded sEGFR-Fc) and a Dmax 
value of 212 Å (compared with 198 Å for unliganded sEGFR-Fc). An Fc-fused dimer in which 
the tethered sEGFR moieties are adjacent (Figure 4F, model iii) is more compact, suggesting 
that unliganded sEGFR-Fc may lie (on average) between models ii and iii. Thus, in 
agreement with the EM results, our SAXS data also argue that ligand binding is necessary for 
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formation of the well-defined domain II-mediated dimerization interface. Simply forcing the 
receptor molecules into close proximity is not sufficient – as Springer and colleagues also 
concluded in related studies (Lu et al., 2012). 
 Our results, and those of Lu et al (2012), argue that pre-formed dimers of the human 
EGFR extracellular region do not contain a well-defined domain II-mediated interface. Rather, 
the ECRs in these dimers are likely to sample a broad array of positions (and possibly 
conformations). This conclusion argues against recently published suggestions that stable 
unliganded extracellular dimers “disfavor activation in pre-formed dimers by assuming 
conformations inconsistent with” productive dimerization of the rest of the receptor (Arkhipov 
et al., 2013). The ligand-free inactive dimeric ECR species modeled by Arkhipov et al., 2013 
are simply not stable. Indeed, it has been known for some time that the isolated ECR from 
EGFR has a very low propensity for self-association without ligand, with a KD value in 
millimolar range (Lemmon, 1997). The data presented here further show that sEGFR does 
not form a defined structure even when forced to dimerize in an Fc fusion. It is therefore 
difficult to envision how the ECR could disfavor activation in pre-formed dimers by assuming 
any particular conformation. It has also been argued that the unliganded extracellular region 
somehow impedes dimerization driven by the intracellular region (Endres et al., 2013). The 
orientational flexibility of the ECR indicated by our EM and SAXS studies of sEGFR-Fc and 
by studies from the Springer laboratory (Lu et al., 2010; Lu et al., 2012; Mi et al., 2011) 
makes it very difficult to imagine how the ECR could sterically constrain dimerization 
mediated by the other parts of EGFR. Moreover, if ligand binding activates EGFR simply by 
removing steric constraints imposed by the ECR it is difficult to understand why specific 
mutations of even single residues in the dimerization interface should block activation 
(Dawson, 2005; Ogiso, 2002), and conversely why mutations that destabilize the tethered 
configuration are not activating (Mattoon et al., 2004; Walker et al., 2004). 
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Structural implications of weak linkage between ligand binding and dimerization 
It has typically been assumed that binding of a single ligand molecule between 
domains I and III of an sEGFR molecule stabilizes a structure resembling one half of the 2:2 
receptor dimer in Figure 2.1C. Indeed, this is the assumption in Figure 2.1B. In addition, the 
domain II conformation in a ligand-bound sEGFR monomer is thought to be ideally suited (or 
poised) for dimerization (Dawson, 2005; Dawson et al., 2007). This assumption predicts (and 
presumes) that ligand binding and dimerization are strongly positively linked for EGFR and 
sEGFR. The almost complete lack of such linkage in our studies suggests that the domain II 
conformation stabilized by EGF binding may not be optimal for dimerization. Indeed, the 
precise conformation of domain II in a liganded sEGFR monomer is not known, even though 
SAXS studies of a non-dimerizing sEGFR variant clearly showed that it becomes extended 
upon EGF binding, with the dimerization arm exposed (Dawson et al., 2007). Our studies of 
the Drosophila EGFR (Alvarado et al., 2010) also showed clearly that restraining the domain 
II conformation through interactions at the dimerization interface can significantly impair 
ligand binding affinity (this is the origin of negative cooperativity). With this precedent in mind, 
we suggest that domain II-mediated sEGFR dimerization may distort the domain II 
conformation in a way that compromises ligand binding to domains I and III. Conversely, we 
suggest that the domain II conformation stabilized by ligand binding is suboptimal for 
dimerization. In this scenario, ligand-binding and dimerization contacts would exert opposite 
influences on domain II – effectively competing with one another. This competition could 
effectively nullify the expected positive linkage between ligand binding and dimerization. If 
this view is correct, the ligand-bound sEGFR dimer visualized by crystallography would 
reflect a ‘compromise’ in which domain II adopts a structure that is intermediate between the 
ideal conformation for ligand binding and the ideal conformation for domain II-mediated 
dimerization. 
 The precise role played by the extracellular region (ECR) in EGFR activation has 
been a subject of debate in recent years. The ECR was initially viewed as a module that 
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serves simply to drive ligand-induced receptor dimerization (Burgess, 2003). Some more 
recent data also support this view (Lu et al., 2010; Mi et al., 2011), and this is the simple view 
that predicts positive linkage between ligand binding and dimerization. Alternatively, the ECR 
has been argued to function as a steric impediment to ligand-independent receptor 
dimerization, relieved only when the ECR binds ligand (Chantry, 1995; Endres et al., 2013; 
Jura, 2009) – as mentioned above. In a third possibility it has been proposed that the ligand-
bound ECR dimer must achieve a particular conformation in order for the receptor to be 
active (Alvarado et al., 2010; Arkhipov et al., 2013; Lemmon, 2009; Liu et al., 2012; Wilson et 
al., 2009). Although ligand binding promotes ECR dimerization – presumably by exposing the 
dimerization arm as in Figure 2.1 – the compromise between optimal ligand binding and 
optimal dimerization will result in a particular conformation, which in turn may be required for 
productive signaling. Different discrete structures (stabilized by different ligands) may even 
signal differently (Wilson et al., 2009). A similar compromise between dimerization and ligand 
binding is also seen in our studies with TGFα (Figure 2.9 and Table 2.2), bolstering the view 
that this conformational ‘competition’ may be functionally important. There is nothing in our 
data, however, to support a role for ligand binding in reversing a pre-existing steric hindrance 
to dimerization. 
 
Extracellular oncogenic mutations observed in glioblastoma alter linkage between 
ligand binding and sEGFR dimerization 
Missense mutations in the extracellular region of hEGFR were discovered in several human 
glioblastoma multiforme samples or cell lines, and occur in 10-15% of glioblastoma cases 
(Brennan et al., 2013; Lee et al., 2006). Several were shown to elevate basal receptor 
phosphorylation and to cause EGFR to transform NIH-3T3 cells in the absence of EGF (Lee 
et al., 2006). Thus, these are oncogenic mutations that constitutively activate EGFR, although 
the mutated receptors can be further activated by ligand (Lee et al., 2006; Vivanco et al., 
2012). Two of the most commonly mutated sites in glioblastoma, R84 and A265 (R108 and 
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A289 in pro-EGFR) are in domains I and II of the ECR respectively, and contribute directly to 
intramolecular interactions between these domains in inactive sEGFR that are thought to be 
autoinhibitory (Figure 2.5). Domains I and II become separated from one another in this 
region upon ligand binding to EGFR (Alvarado, 2009), as illustrated in the lower part of Figure 
2.5. Interestingly, analogous mutations in the EGFR relative ErbB3 have also been reported 
in colon and gastric cancers (Jaiswal et al., 2013). 
 We hypothesized that mutations in the domain I/II interface might activate EGFR by 
disrupting autoinhibitory interactions between these two domains – possibly promoting a 
domain II conformation capable of driving dimerization even in the absence of ligand. We 
used sedimentation equilibrium AUC to test this hypothesis, but found that sEGFR variants 
harboring R84K, A265D or A265V mutations all remained completely monomeric in the 
absence of ligand (Figure 2.6A) at a concentration of 10 µM, which is similar to that 
experienced at the cell surface (Lemmon, 1997). As with wild-type sEGFR, however, adding 
ligand promoted dimerization of each mutated sEGFR variant – with KD values that were 
indistinguishable from that measured for wild-type. Thus, the extracellular EGFR mutations 
seen in glioblastoma do not simply promote ligand-independent dimerization of the 
receptor’s ECR – consistent with our finding that even dimerized sEGFR-Fc requires ligand 
binding in order to form the characteristic ‘heart-shaped’ dimer observed in crystallographic 
studies. 
 Interestingly, the ligand-binding affinity of sEGFR was significantly increased by all of 
the glioblastoma-derived mutations studied here (Figure 2.6B). The effects ranged from a 5-
fold increase for A265D to an almost 20-fold increase for R84K. Similar affinity increases 
were also seen for TGFα binding (Figure 2.11). ITC studies of EGF binding (Figure 2.6C) 
further revealed that the 5-20 fold increase in ligand-binding affinity (a 1-2 kcal/mole reduction 
in ΔG) for R84K and A265V variants can be accounted for by ΔH values that are more 
favorable (less positive) by around 3 kcal/mole when compared to the values for wild-type 
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sEGFR (Table 2.1). The A265D variant differs (with a less favorable ΔH), possibly because it 
introduces a charged group into a relatively hydrophobic region of the protein. These data are 
consistent with a model in which the glioblastoma mutations in the domain I/II interface “free 
up” domains I and II to occupy positions that permit more optimal interactions with bound 
ligand. For example, replacement of R84 with a lysine – seemingly a rather conservative 
substitution – may destabilize the domain I/II interface by disrupting its hydrogen bond 
network. 
 We suggest that domain I is normally restrained by domain I/II interactions so that its 
orientation with respect to the ligand is compromised. When the domain I/II interface is 
weakened with mutations, this effect is reversed. If this results simply in increased ligand-
binding affinity of the monomeric receptor, the biological consequence might be to sensitize 
cells to lower concentrations of EGF or TGFα (or other agonists). However, cellular studies of 
EGFR harboring glioblastoma-derived mutations (Lee et al., 2006; Vivanco et al., 2012) 
suggest ligand-independent activation, arguing that this is not the key mechanism. Instead, 
the domain I/II interface mutations may also reduce restraints on domain II so as to permit 
dimerization of a small proportion of intact receptor driven by the documented interactions 
that promote self-association of the transmembrane, juxtamembrane, and intracellular 
regions or EGFR (Endres et al., 2013; Lemmon et al., 2014; Red Brewer et al., 2009). 
 One particularly interesting possibility is that the elevated ligand-binding affinity 
caused by the R84K, A265V and A265D mutations does not reflect enhanced binding to 
monomeric sEGFR, but instead reflects some ‘rescue’ of the expected linkage between 
ligand binding and dimerization – so that that ligand does bind significantly more strongly to 
dimers than monomers for these variants. In this model, the domain I/II interface mutations 
would reduce communication between the dimerization and ligand-binding sites so that 
optimal domain II-mediated dimerization has less of a restraining influence on the ligand-
binding site. The importance of influences on domain II conformation in activation of EGFR by 
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the glioblastoma mutations is also supported by studies of tether mutations in EGFR that alter 
ligand binding in almost exactly the same way, but do not activate the receptor (and do not 
impact domain II). Mutations that disrupt the intramolecular tether seen in Figure 2.1A 
enhance ligand binding to sEGFR to the same degree as the glioblastoma mutations 
(Elleman et al., 2001; Ferguson et al., 2003). Moreover, four different types of tether-
disrupting mutation all have essentially the same effect on ligand-binding thermodynamics 
(Figure 2.12) as seen for R84K or A265V (ΔH becomes more favorable by ~4 kcal/mole). 
None of these tether-disrupting mutations constitutively activates EGFR, however (Mattoon et 
al., 2004; Walker et al., 2004). The key difference between the (non-activating) tether 
mutations and the (activating) glioblastoma mutations is that only the latter directly influence 
domain II conformation, arguing that this is the key to the oncogenicity of R84K and A265V/D 
mutations. 
 
CONCLUSIONS 
 
Setting out to test the hypothesis that simply dimerizing the EGFR extracellular 
region is sufficient to recover the negative cooperativity lost when it is removed from the 
intact receptor, we were led to revisit several central assumptions about this receptor. Our 
findings suggest three main conclusions. First, we find that enforcing dimerization of the 
hEGFR extracellular region does not drive formation of a well-defined domain II-mediated 
dimer that resembles ligand-bound ECRs or the unliganded ECR from Drosophila EGFR. Our 
EM and SAXS data show that ligand binding is necessary for formation of well-defined ‘heart-
shaped’ domain II-mediated dimers. This result argues that the unliganded extracellular 
dimers modeled by Arkhipov et al. (2012) are not stable, and that it is therefore highly 
improbable that stable conformations of pre-formed extracellular dimers disfavor receptor 
activation by assuming conformations inconsistent with productive dimerization of the rest of 
the receptor (Arkhipov et al., 2013). Recent work from the Springer laboratory employing 
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kinase inhibitors to drive dimerization of hEGFR (Lu et al., 2012) has also shown that EGF 
binding is required to form the ‘heart-shaped’ ECR dimer shown in Figure 2.1C. These 
findings leave open the question of the nature of the ECR in pre-formed EGFR dimers, but 
certainly argue that it is unlikely to resemble the crystallographic dimer seen in the case of 
unliganded Drosophila EGFR (Alvarado, 2009) or what has been suggested by computational 
studies (Arkhipov et al., 2013). 
 Second, our ITC results suggest that enforcing dimerization of the ECR from hEGFR 
may restore some of the complexity in ligand binding that is seen for intact hEGFR, but is lost 
when the soluble ECR is studied in isolation. Some apparent heterogeneity in EGF-binding 
sites was restored in our ITC studies of the dimeric sEGFR-Fc fusion. However, since the 
difference in KD values was too small to be quantitated with confidence, it is clear that simple 
dimerization cannot fully recapitulate the apparent negative cooperativity seen for the intact 
receptor. This finding supports arguments that the transmembrane and/or intracellular 
regions of the receptor also play an important role in defining negative cooperativity in 
hEGFR (Adak et al., 2011; Macdonald-Obermann and Pike, 2009), and underlines the need 
to consider cooperation of interactions mediated by all domains within the intact or nearly-
intact receptor (Bessman and Lemmon, 2012). It is interesting that the relative contributions 
of intra- and extra-cellular regions to the allosteric properties of the receptor appear to differ 
greatly between mammals and insects – where negative cooperativity is recapitulated in the 
isolated ECR (Alvarado et al., 2010). Similar differences can also be seen between human 
receptors within a family. For example, whereas the characteristic concave-up Scatchard 
plots seen for the intact insulin receptor can only be recapitulated for the isolated ECR of that 
receptor by fusion to a dimerization domain (Bass et al., 1996; Hoyne et al., 2000), the 
related IGF1 receptor ECR retains negative cooperativity without such modifications (Surinya 
et al., 2008). Differences in the relative contributions of intra- and extra-cellular regions to 
precise receptor regulation may have important signaling relevance. 
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 Third, our calorimetric studies of the ECR from hEGFR show that ligand does not 
bind with substantially higher affinity to dimers than to monomers – despite the fact that 
ligand binding is required for ECR dimerization. This result argues that ligand binding is 
required to permit dimerization but that domain II-mediated dimerization compromises, rather 
than enhances, ligand binding. Assuming flexibility in domain II, we suggest that it serves to 
link dimerization and ligand binding allosterically. Optimal ligand binding may stabilize one 
conformation of domain II in the scheme shown in Figure 1 that is then distorted upon 
dimerization of the ECR – in turn reducing the strength of interactions with the ligand. Such a 
mechanism would give the appearance of a lack of positive linkage between ligand binding 
and ECR dimerization, and a good test of this model would be to determine the structure of a 
liganded sEGFR monomer (which we expect to differ from a half-dimer). This model also 
suggests a mechanism for selective hetero- over homo- dimerization of certain ErbB 
receptors. If a ligand-bound EGFR monomer has a domain II conformation that forms 
heterodimers with the ErbB2 ECR in preference to EGFR homodimers, this could explain 
several important observations. It could explain reports that ErbB2 is a preferred 
heterodimerization partner (Graus-Porta et al., 1997), and might also explain why EGF binds 
more tightly to EGFR in cells where it can form heterodimers with ErbB2 than in cells that 
lack ErbB2, where only EGFR homodimers can form (Li et al., 2012). Moreover, if different 
EGFR agonists stabilize slightly different domain II conformations, this view of a flexible 
domain II as an allosteric link between ligand binding and dimerization suggests hypotheses 
for how individual ligands might induce subtly different receptor states or select for specific 
heterodimer signaling complexes (Sweeney and Carraway, 2000; Wilson et al., 2009). 
Interestingly – as our data with glioblastoma mutations suggest – alterations in the allosteric 
communication between domain II and the adjacent ligand-binding domain I can also be 
oncogenic. 
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EXPERIMENTAL PROCEDURES 
 
sEGFR constructs 
Construction of sEGFR variants with mutations in the domain II/IV tether or the 
dimerization arm was described previously (Dawson, 2005). Glioblastoma-derived mutations 
were introduced by standard PCR methods. To generate the sEGFR-Fc fusion, the coding 
sequence for sEGFRwild-type in pFb was first mutated to introduce an Fse I restriction site close 
to its 3’ end. The cDNA encoding the Fc domain from human IgG1 (IMAGE clone 4575935) 
was purchased from Open Biosystems, and was used as a PCR template to create a 
fragment containing the Fc domain coding region flanked by Fse I and Not I sites at the 5’ 
and 3’ ends, respectively. This fragment was then cloned into the pFb-sEGFRwild-type plasmid 
containing an Fse I site, yielding a plasmid encoding residues 1-645 of the pro-EGFR protein, 
followed by an alanine-glycine linker (introduced by the Fse I site), and then by the 231 
residue Fc domain and a C-terminal hexa-histidine tag. The sEGFR-Zip pFb plasmid was 
constructed by first amplifying a fragment encoding the 33-residue coiled-coil domain from 
yeast GCN4 by a series of four PCR reactions, each extending the length of the fragment at 
the 3’ end. This fragment also contained 20 nucleotides at the 5’ end that were 
complementary to the C-terminus of sEGFR, as well as a hexa-histidine tag and Not I site at 
the 3’ end. This fragment was used as a primer to PCR-amplify (from a pFb-sEGFRwild-type 
template) a fragment encoding sEGFR followed by the 33-residue coiled-coil domain and a 
C-terminal hexahistidine tag, which was then ligated into the pFb plasmid. All constructs were 
verified by DNA sequencing. 
 
 
Reagents and proteins 
EGF and TGFα were purchased from Millipore Inc. Wild-type and mutated sEGFR 
variants were expressed in Sf9 cells employing a baculovirus system using the pFastbac 
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(pFb) plasmid (Invitrogen) as described previously (Ferguson, 2000). Details of constructs 
and of purification procedures are described below. 
 
Binding and dimerization analyses 
Binding of ligand to sEGFR proteins and/or sEGFR dimerization was performed using 
isothermal titration calorimetry (ITC); fluorescence anisotropy (FA); surface plasmon 
resonance (SPR) or sedimentation equilibrium analytical ultracentrifugation (AUC), as 
summarized below.  
 
Protein purification 
All sEGFR proteins were purified from the conditioned medium of baculovirus-
infected Sf9 cells following the same procedure. Briefly, 4 days post-infection, clarified 
conditioned media was concentrated to ~1 l and diafiltered against 4 l of 25 mM Tris-HCl, 
pH 8.0, containing 150 mM NaCl (binding buffer). Diafiltered media was applied to a Ni-NTA 
agarose column (Qiagen), and sEGFR protein was eluted with increasing concentrations of 
imidazole in binding buffer. Fractions containing sEGFR were dialyzed, buffer-exchanged, or 
diluted into 25 mM MES, pH 6.0, containing 30 mM NaCl and sEGFR was purified by cation-
exchange chromatography using a Source S column (GE Healthcare) with a gradient of 5% - 
50% of 25 mM MES, pH 6.0, containing 500 mM NaCl (over 15 column volumes). The 
sEGFR-containing fractions were concentrated and protein was further purified by size-
exclusion chromatography on a Superose 6 column (GE Healthcare) pre-equilibrated in 
25 mM HEPES, pH 8.0, containing 150 mM NaCl. Typical yields were 0.2-1 mg/l of Sf9 cells 
(depending on the sEGFR variant) and protein was >90% pure by Coomassie stained SDS-
PAGE. 
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Isothermal titration calorimetry (ITC) 
All ITC experiments were performed at 25˚C (unless specifically stated otherwise) 
using a MicroCal ITC200 instrument. Ligand and sEGFR proteins were dialyzed overnight 
into 20 mM HEPES, pH 8.0, containing 150 mM NaCl, and 3.4 mM EDTA. The sEGFR 
concentration in the calorimeter cell ranged from 8 to 25 µM, and the concentration of ligand 
in the syringe ranged from 60 to 280 µM. All protein concentrations were determined by 
measuring absorbance of purified protein at 280 nm and using the extinction coefficient 
predicted from primary amino acid sequence. A total of 39 µl of ligand (in 2-3 µl aliquots) was 
injected over the course of each titration. Data from the first (small) injection were discarded 
to eliminate syringe leakage artifacts. Ligand titrations into receptor-free ITC buffer were 
performed to determine the heat of ligand dilution, and these heats were subtracted from the 
ligand-into-receptor titration data. Data were fit to a single-site binding model in the Origin 
software package. All titrations were performed independently at least three times, and 
representative titrations are shown, with values for ΔH and other parameters quoted as mean 
± standard deviation. 
 
Fluorescence anisotropy (FA)-based binding assays 
EGF was labeled with Alexa-488 utilizing a tetrafluorophenyl ester to label primary 
amines, according to the protocol provided with the Alexa Fluor 488 Protein Labeling Kit from 
Molecular Probes (Eugene, OR). Labeled EGF (EGF488) was purified away from free label by 
size-exclusion chromatography on a Superdex Peptide (GE Healthcare) column equilibrated 
in 20 mM HEPES, pH 8.0, containing 150 mM NaCl. Labeling efficiency was calculated by 
determining the concentration of purified, labeled EGF from its absorbance at 280 nm, using 
an extinction coefficient of 18,825 cm-1M-1 (as predicted from the primary sequence of EGF) 
and at 490 nm, using the extinction coefficient of the Alexa-488 label (71,000 cm-1M-1). 
EGF488 at 10 nM (for sEGFR-Fc and sEGFR-Zip) or 60 nM (for sEGFRwild-type) was incubated 
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with varying amounts of sEGFR protein for 30 minutes at room temperature in 20 mM 
HEPES, pH 8.0, containing 150 mM NaCl. Fluorescence polarization (FP) measurements for 
each sample were taken on a Beacon instrument at 20˚C. FP values were converted to 
anisotropy, and binding curves were derived by assuming that the maximal anisotropy 
response corresponded to [EGFfree]=0, and that the anisotropy in the absence of receptor 
corresponded to [EGFfree]=[EGFtotal]. The resulting curves were fit to binding models using the 
GraphPad Prism software. sEGFR-Fc and sEGFRwild-type binding data were fit to simple 
single-site binding models, whereas sEGFR-Zip binding data were fit to a model with a Hill 
coefficient of ~1.9, presumably reflecting the presence of sEGFR-Zip monomers at very low 
receptor concentrations. Three independent titrations were performed for each receptor 
variant. 
 
Surface plasmon resonance (SPR) 
SPR binding experiments were performed using a Biacore 3000 instrument at 25˚C. 
EGF and TGFα were immobilized as described (Dawson, 2005), immobilizing 100-150 
response units (RUs). sEGFR variants at various concentrations in 25 mM HEPES, pH 8.0, 
containing 150 mM NaCl, 3 mM EDTA, and 0.005% Nonidet-p20 were injected at a flow rate 
of 10 µl/min for 10 minutes, which was sufficient to reach equilibrium even at the lowest 
concentrations. KD values for binding of sEGFR variants to these surfaces were determined 
by fitting the equilibrium responses over a range of concentrations to a single-site Langmuir 
binding equation using GraphPad PRISM 6.0. Surfaces were regenerated using 1 min 
injections of 10 mM sodium acetate, pH 5.0, containing 1 M sodium chloride. Multiple rounds 
of regeneration did not impair sEGFR binding. All experiments were repeated independently 
at least three times. 
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Analytical ultracentrifugation (AUC) 
Samples of sEGFR wild-type and the glioblastoma-derived variants at concentrations 
of 10 µM, 5 µM, and 2 µM were loaded into 6-hole sample cells in 25 mM HEPES, pH 8.0, 
containing 150 mM NaCl for sedimentation equilibrium AUC using a Beckman XL-A 
instrument and an An-Ti 60 analytical rotor at speeds of 6,000, 9,000 and 12,000 r.p.m. at 
room temperature. For experiments including TGFα, the ligand was present in a 1.2-fold 
molar excess over sEGFR protein concentration. Data were analyzed using a single species 
fit in Sedfit (Schuck et al., 2002) and Sedphat (Schuck, 2003), and were also fit to a 
monomer-dimer association model as described (Dawson, 2005), using the program 
HeteroAnalysis (UConn Biotechnology Bioservices Center). 
 
Electron microscopy (EM) 
For the EGF/sEGFR-Fc complex, 755 individual particles, manually picked from 150 
images using the EMAN2 software package (Tang et al., 2007), were grouped into 10 
classes by a reference-free alignment procedure in the program Spider (Shaikh et al., 2008). 
For the sEGFR-Fc protein alone, 2,566 particles from 673 images were grouped into 20 
classes by the same reference-free alignment procedure. For Figure 4C, a model for the 
sEGFR-Fc fusion protein bound to EGF (shown in Figure 4B) was created by manually 
superposing PDB entries 3NJP (Lu et al., 2010) and the Fc portion of PDB entry 1HZH 
(Saphire et al., 2001). A 12 Å resolution map was calculated from this model using the 
molmap command in the UCSF Chimera software package (Pettersen et al., 2004). This low-
resolution map was then used to create 2D projections from multiple angles using the 
makeboxref command in the EMAN2 software suite. The projection angle that best matched 
our experimental class averaging results is displayed. 
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Small-angle X-ray scattering (SAXS) 
Protein samples were prepared for SAXS at concentrations of 10-20 µM in 25 mM 
Tris-HCl, pH 8.0, containing 150 mM NaCl, and 40 minute exposures at 4˚C were performed 
on a Rigaku S-MAX3000 pinhole camera system, with a Rigaku 007HF rotating anode source 
and a Rigaku 300 mm wire grid ASM DTR 200 detector. 
Scattering data were radially-averaged and reduced to two-dimensional plots using 
the SAXSgui software, and intensity data from buffer exposures were then subtracted out. 
Radius of gyration (Rg) values were determined from Guinier plots using the Primus software 
package (Konarev et al., 2003). The maximum interatomic distance (Dmax) was obtained by 
examining P(r) curves generated by the Gnom software package (Svergun, 1992). Briefly, for 
each scattering dataset, P(r) curves were calculated for a range of Dmax from 100 to 250 Å, in 
5 Å increments. Dmax was determined by identifying the value that gave the best fit to the 
experimental scattering data. 
 
Electron microscopy (EM) 
Receptor samples at a concentration of 2 µg/ml in 25 mM Tris-HCl, pH 8.0, 
containing 150 mM NaCl were applied to glow-discharged carbon grids and stained with 
0.75% uranyl formate. Images were collected on a Tecnai T12 microscope at 67,000x 
magnification and operating at 120 keV, and were analyzed as described in Methods. 
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CHAPTER TWO FIGURES 
 
Figure 2.1. Structural view of ligand-induced dimerization of the hEGFR extracellular 
region (ECR). 
(A) Surface-representation of tethered, unliganded, sEGFR is shown from PDB entry 1NQL 
(Ferguson et al., 2003). Ligand-binding domains I and III are colored green, and cysteine-rich 
domains II and IV are colored cyan. The intramolecular domain II/IV tether is circled in red 
and labeled.  (B) Surface representation of a hypothetical model for an extended EGF-bound 
sEGFR monomer based on SAXS studies showing an extended conformation for an EGF-
bound sEGFR variant with a dimerization arm mutation (Dawson et al., 2007). The model 
was extracted from the extended dimer in PDB entry 3NJP (Lu et al., 2012), but it should be 
stressed that no details are known for the precise domain II conformation in the extended 
monomer. The model is colored as in A. In addition, EGF is colored blue, the exposed 
domain II dimerization arm is labeled, and the red boundary represents the primary 
dimerization interface. (C)  Surface representation of a 2:2 (EGF/sEGFR) dimer, taken from 
PDB entry 3NJP (Lu et al., 2012), colored as in B. Primary dimerization contacts, mediated 
by the domain II dimerization arm, are circled in red and labeled. Figure generated by 
Nicholas Bessman and Mark Lemmon. 
+EGF
+EGF/EGFR
I
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III
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INACTIVE ACTIVEINACTIVE
	 45	
 
Figure 2.2. Dimerization of the ECR has little effect on its affinity for EGF. 
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(A) Data from fluorescence anisotropy (FA) experiments for binding of Alexa-488-labeled 
EGF (EGF488) to monomeric sEGFRwild-type (black triangles), dimeric sEGFR-Fc (orange 
diamonds) and dimeric sEGFR-Zip (blue circles). Ligand concentrations were 60 nM (for 
sEGFRwild-type experiments) or 10 nM (for sEGFR-Fc and sEGFR-Zip). sEGFR-Fc and 
sEGFR-Zip are both dimeric (see Figure S1), whereas sEGFRwild-type remains monomeric in 
this assay. Data shown are representative of three independent experiments. Mean values (± 
standard deviation) for KD and other thermodynamic parameters are listed in Table 1.  (B) 
Representative ITC analysis of EGF binding to sEGFRwild-type at 25˚C. EGF (80 µM) was 
injected into sEGFRwild-type protein (10 µM) in the ITC cell. Mean KD and ΔH values (± 
standard deviation) from three independent experiments are listed (see Table 1).  (C) ITC 
analysis of EGF binding to the non-dimerizing sEGFRY251A/R285S variant. Details are the same 
for B. Equivalent experiments for TGFα binding in Figure S3A and B.  (D) SPR analysis of 
EGF binding to constitutively-dimeric sEGFR-Fc, with (solid orange diamond) or without 
(orange/black diamonds) dimerization-disrupting mutations (Y251A/R285S) in domain II. 
sEGFR-Fc protein (with wild-type or Y251A/R285S-mutated dimerization interface), was 
flowed over a sensorchip surface bearing EGF. The equilibrium SPR response for each 
indicated sEGFR-Fc concentration was measured, and data were fit to a simple single-site 
binding model. Data are representative of three independent repeats, with best fit KD values 
(± standard deviation) noted. Equivalent studies for TGFα are shown in Figure S3C.  This 
figure is the work of Nicholas Bessman. Atrish Bagchi provided some purified proteins used 
to perform the experiments. 
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Figure 2.3. Evidence for heterogeneity of sites in forced sEGFR dimers. 
(A) Representative ITC data for EGF binding to sEGFR-Fc at 25˚C, with EGF at 130 µM in 
the syringe and sEGFR-Fc in the cell at 8.4 µM. The mean ΔH value from three independent 
experiments (± standard deviation) is listed.  (B) ITC data for EGF binding to sEGFR-Zip at 
25˚C, with EGF in the syringe at 105 µM and sEGFR-Fc in the cell at 11.3 µM. ΔH is listed as 
in A, reflecting three independent repeats.  (C) ITC was performed for EGF binding to 
sEGFR-Fc (upper graphs) and sEGFRwild-type (lower graphs) at the different temperatures 
marked, to resolve potential heterogeneity in ligand binding sites within the dimer. The 
concentration of EGF in the calorimeter syringe was 80 µM, and the sEGFR protein was 
present in the cell at 9 µM. For sEGFR-Fc, which showed evidence for more than one binding 
event, data are shown for an additional titration at 25˚C that used 25 µM sEGFR-Fc in the cell 
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and 280 µM EGF in the syringe – the improved signal-to-noise confirming existence of a 
second binding event, potentially reflecting asymmetry in the sEGFR-Fc dimer. This 
experiment was conceived by Atrish Bagchi and performed by Nicholas Bessman, with 
protein reagents from Atrish Bagchi.  Both authors analyzed data. 
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Figure 2.4. Ligand-binding is required for formation of the domain II-mediated ‘back-to-
back’ dimer. 
(A) Selection of reference-free class averages from single-particle EM images of negatively 
stained EGF/sEGFR-Fc complexes. Figure S4 shows an example of a field with- and without 
EGF.  (B) Structural model for an EGF/sEGFR-Fc complex derived by appending the Fc 
portion from PDB entry 1HZH (Saphire et al., 2001) to the EGF-bound sEGFR dimer from 
PDB entry 3NJP (Lu et al., 2012). EGF is colored blue (space filling), the ligand-binding 
domains I and III in sEGFR are green, cysteine-rich domains II and IV are cyan, and the Fc 
portion is orange.  (C) Two-dimensional projection from a calculated 12 Å resolution map 
based on the EGF/sEGFR-Fc model shown in B, generated as described in Supplemental 
Experimental Procedures. This projection strongly resembles the experimentally-determined 
class averages for EGF-bound sEGFR-Fc.  (D) Rg values derived from Guinier analysis of 
SAXS data for samples containing 10-20 µM sEGFR-Fc in the absence (open bar) or 
presence (black bar) of a 1.3-fold molar excess of EGF. Experimental data represent the 
mean of four independent experiments (± standard deviation). Rg values calculated from the 
three models (i – iii) shown in F are also plotted.  (E) SAXS-derived values for maximum 
interatomic distance (Dmax) for sEGFR-Fc alone (open bar) and the EGF/sEGFR-Fc complex 
(black bar). Data represent means (± standard deviation) from 4 independent repeats. 
Calculated Dmax values for the three models shown in F are also plotted for comparison.  (F) 
Three distinct structural models (i, ii, and iii) were constructed for unliganded sEGFR-Fc. In 
model i, the sEGFR moiety forms the back-to-back dimer seen in the presence of ligand (or 
for the unliganded ECR from Drosophila EGFR). In models ii and iii, sEGFR retains its 
tethered conformation, but the two sEGFR moieties in the dimer are either maximally splayed 
apart (model ii) or adjacent to one another (model iii). Rg and Dmax values were calculated for 
each model, for comparison to experimentally-determined parameters.  This work was 
conceived by Mark Lemmon and Nicholas Bessman, and performed by Nicholas Bessman.   
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Figure 2.5. Location of EGFR domain I/domain II interface mutations in glioblastoma. 
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Cartoon representations of sEGFR crystal structures in liganded (red) and unliganded (cyan) 
states are shown, from PDB entries 1MOX (Garrett, 2002) and 1YY9 (Li et al., 2005) 
respectively. The two structure are aligned using domain I (residues 1-184) as reference. The 
side-chains of R84 and A265 are shown, where the majority of mutations have been seen in 
glioblastoma (Lee et al., 2006; Vivanco et al., 2012). These side-chains are buried in a 
relatively hydrophobic interface between domains I and II in the unliganded structure. This 
region of the structure is expanded in the lower part of the figure to show how ligand binding 
forces domain II away from domain I, disrupting the domain I/II interface. Mutations at R84 
and A265 may activate the receptor by mimicking this effect.  
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Figure 2.6. Effects of glioblastoma mutations on sEGFR properties. 
(A) Sedimentation equilibrium AUC analysis of sEGFR variants harboring mutations found in 
glioblastoma, performed with each sEGFR variant either alone at 10 µM (open symbols) or at 
5 µM in the presence of a 1.2-fold molar excess of TGFα (closed symbols). Data are plotted 
as the natural logarithm of absorbance at 280 nm (A280, monitoring protein concentration) 
against a function of the radius squared [(r2-r02)/2] for AUC data obtained at 9000 r.p.m. at 
room temperature, where r is the radial position in the sample and r0 is the radial position of 
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the meniscus. For an ideal single species, data transformed in this way yield a straight line 
with slope proportional to molecular mass (Cantor and Schimmel, 1980). TGFα was used 
instead of EGF since it contains only one tyrosine (and no tryptophans), so contributes 
negligibly to A280. In the absence of ligand, best-fit molecular masses were 75 kDa (wild-
type); 80 kDa (R84K and A265V); and 89 kDa (A265D). The slight elevation for A265D may 
reflect some aggregation, but these data argue that the mutations do not cause constitutive 
dimerization. In the presence of TGFα, single-species fits yielded molecular masses of 
157 kDa (wild-type); 141 kDa (R84K); 143 kDa (A265V); and 175 kDa (A265D). Estimated KD 
values for sEGFR dimerization in the presence of TGFα, fit as described (Dawson, 2005), 
were 1.5 µM (R84K); 1.0 µM (A265V); and 4.8 µM (A265D) – compared with 1.2 µM for wild-
type sEGFR  (B) Ligand binding by each mutated sEGFR variant was analyzed using SPR, 
flowing the protein at a range of concentrations over EGF immobilized on a sensorchip. Best 
fit KD values for EGF binding were 83 ± 2.6 nM (wild-type); 4.3 ± 0.9 nM (R84K); 16 ± 2.6 nM 
(A265V); and 8.6 ± 3.0 nM (A265D). Similar data for TGFα are shown in Figure S5.  (C) ITC 
analysis of EGF binding to sEGFR variant harboring mutations found in glioblastoma 
patients. Titrations were performed with 80 µM EGF aliquots injected into 10 µM sEGFR 
protein.  This figure is the work of Atrish Bagchi. 
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Figure 2.7 Analysis of molecular mass of EGFR-Fc and sEGFR-Zip. 
(A)  Sedimentation equilibrium AUC data, showing single-species fits for data obtained with 
sEGFR-Fc alone at 10 µM at a speed of 10000 r.p.m. Data were fit using Sedphat (Schuck, 
2003) and yielded an excellent fit – with small random residuals – to a single species of 
223 kDa. This compares will with the expected mass of an sEGFR-Fc dimer (190 kDa plus 
~20% w/w carbohydrate).  (B)  An equivalent experiment to that shown in A for sEGFR-Fc, 
but with the addition of a 1.2-fold molar excess of TGFα. The best-fit molecular mass is 
unchanged (at 225 kDa), showing that the dimeric sEGFR-Fc is not further oligomerized upon 
ligand binding.  (C)  Size exclusion chromatography analysis of sEGFRwild-type (black curve), s-
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EGFR-Zip (blue curve), and sEGFR-Fc (orange curve), injected onto a Superose 6 column at 
a concentration of 10 µM. The receptor elution volumes reveal that sEGFR-Fc and sEGFR-
Zip are both dimers, while sEGFRwild-type is monomeric as expected.  This was performed by 
Nicholas Bessman. 
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Table 2.1.  ITC data for EGF binding to sEGFR variants. 
Values are the mean ± standard deviation of at least three independent experiments. ΔG 
values are calculated from the mean KD, and TΔS values are obtained by subtracting ΔG from 
the mean value for ΔH. These data were generated and analyzed by Nicholas Bessman. 
 
 
 
 
 
sEGFR variant KD 
(nM) 
∆H 
(kcal/mol) 
ΔG 
(kcal/mol) 
T∆S 
(kcal/mol) 
sEGFRwild-type 78 ± 14/39 ± 4 +6.9 ± 0.5 -9.7 (ITC) 
/10.1 (FA) 
16.6 
(ITC)/17.0 
(FA) 
sEGFRY251A/R285S 74 ± 10 +8.9 ± 1.0 -9.7 18.6 
sEGFR-Fcwild-type 7.8 ± 3 +10.3 ± 0.5 -11.1 21.4 
sEGFR-Zipper 8.9 ± 1.1 +12.3 ± 0.6 -11.0 23.3 
 
 
Table 2.2, related to Table 2.1.  ITC data for TGFα  binding to sEGFR variants. 
Values are the mean ± standard deviation of at least three independent experiments. ΔG 
values are calculated from the mean KD, and TΔS values are obtained by subtracting ΔG from 
the mean value for ΔH. These data were generated and analyzed by Nicholas Bessman. 
 
 
 
 
sEGFR variant KD 
(nM) 
∆H 
(kcal/mol) 
ΔG 
(kcal/mol) 
T∆S 
(kcal/mol) 
sEGFRwild-type 80 ± 16 +8.2 ± 0.8 -9.7 17.9 
sEGFRY251A/R285S 82 ± 10 +10.1 ± 1.2 -9.7 19.8 
sEGFR-Fcwild-type nd +11.0 ± 0.7 nd nd 
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Figure 2.8, ITC of EGF binding to domain III, and EGF/sEGFR dimer dissociation. 
(A)  EGF was titrated into 10 µM sEGFR domain III purified as described (Lemmon, 1997). 
Fitting to a single binding-site model yielded a KD value of 3.1 ± 1.9 µM, and a ∆H for EGF 
binding of -4.5 ± 0.6 kcal/mol.  (B)  To assess the enthalpy associated with dimerization of 
liganded sEGFR, a dilution experiment was performed in which 17.5 µM sEGFRwild-type to 
which a 1.3-fold molar excess of EGF had been added was diluted by injection into an ITC 
cell containing only buffer. 13 injections of 3 µl each were made, allowing measurement of 
dissociation heats in the ITC cell over an equilibrium concentration range of ~0.2 – 2.4 µM for 
the EGF/sEGFRwild-type complex. Importantly, EGF dissociation from sEGFRwild-type will be 
negligible over this concentration range. Because the heat of injection does not change 
systematically from the first injection to the last, and because the integrated heat of each 
injection is so low (and can not be distinguished from instrumental noise), we conclude that 
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the ΔH for dimerization of EGF-bound sEGFRwild-type must be <<|2| kcal/mol.  This work was 
performed by Nicholas Bessman, 
 The titrations in Figures 2.2B and 2.2C fit very well to a single entropy-driven 
(positive ΔH) ligand binding event. In our 1997 studies (Lemmon, 1997), which pre-dated 
structures of sEGFR, we inferred that this entropy-driven event reflects sEGFR dimerization, 
and that ligand binding has a small negative ΔH (based on studies of EGF binding to isolated 
domain III, repeated in A). Our new finding that the major entropy-driven event is unaffected 
by mutations that abolish sEGFR dimerization proves this wrong. Moreover, based on 
calorimetric dissociation experiments (B) we find that dimerization of ligand-bound sEGFRwild-
type has a negligible ΔH. Thus, EGF binding is entropy driven, consistent with another recent 
report (Alvarenga et al., 2012). 
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Figure 2.9, related to Figure 2.2.  TGFα  binding to sEGFR and sEGFR-Fc variants. 
(A)  Representative ITC analysis of TGFα binding to sEGFRwild-type at 25˚C. TGFα was 
present in the syringe at 70 µM, and sEGFRwild-type was present in the calorimeter cell at a 
concentration of 8 µM. Mean values (± standard deviation) for KD and ΔH for TGFα binding 
from three independent experiments are listed in the figure.  (B)  Equivalent experiment to 
that shown in A for sEGFRY251A/R285S.  (C)  SPR analysis of TGFα binding to sEGFR-Fc with 
wild-type domain II or with the Y251A/R285S mutations in the domain II dimerization 
interface. Note that, whereas these mutations had no effect on EGF binding to sEGFR-Fc, 
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they appear to reduce TGFα binding by ~6-fold, possibly suggesting a slightly different 
dependence on dimerization for binding of the two ligands – consistent with the observed 
structural differences in EGF/sEGFR and TGFα/sEGFR complexes (Liu et al., 2012; Wilson 
et al., 2009).  (D)  ITC analysis of TGFα binding to sEGFR-Fc. TGFα was present in the 
syringe at 70 µM, and sEGFR-Fc was present in the calorimeter cell at 9 µM. As with EGF 
binding, TGFα binding to sEGFR-Fc has a higher (positive or unfavorable) enthalpy than 
binding to sEGFRwild-type – by 2.8 kcal/mol (compared with 3.4 kcal/mol in the EGF case) – 
affinity is increased due to entropic effects.  This work was performed by Nicholas Bessman. 
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Figure 2.10.  Example raw EM images for sEGFR-Fc plus and minus ligand.  
Examples of raw image files are shown, from EM studies of negatively stained samples, for 
sEGFR-Fc plus EGF (left panel) and without ligand (right panel). 150 images such as these 
were used for single-particle analysis as described in Methods. Example particles are 
enclosed in green boxes in each representative image.  This work was performed and 
analyzed by Nicholas Bessman. 
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Figure 2.11, related to Figure 2.6.  TGFα  binding to sEGFR variants harboring 
glioblastoma mutations. 
Binding of each glioblastoma-mutated sEGFR variant to TGFα was analyzed by SPR, using 
the same approach described for EGF binding in Figure 6B, but with immobilized TGFα 
instead of EGF. Best fit KD values for TGFα binding (from three independent experiments) 
were 532 ± 23 nM (sEGFRwild-type); 8.6 ± 0.9 nM (sEGFRR84K); 90 ± 6 nM (sEGFRA265V); and 
55 ± 4 nM (sEGFRA265D). Glioblastoma mutations in EGFR thus enhance TGFα binding to the 
isolated ECR by 6-62 fold.  This work was performed and analyzed by Atrish Bagchi. 
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Figure 2.12, related to Figure 2.6.  ITC studies of EGF binding to sEGFR with tether-
disrupting mutations. 
(A)  EGF was titrated at 25˚ C into a cell containing 10 µM sEGFR(501), a variant of sEGFR 
that lacks essentially all of domain IV (Elleman et al., 2001), so cannot make the 
intramolecular tether. KD for EGF binding to this variant is 7.8 nM (Dawson, 2005), and ΔH is 
2.2 ± 0.2 kcal/mol.  (B)  The Δ575-584 mutation deletes a prominent loop from the fifth 
disulfide-bonded module of domain IV in sEGFR, removing a loop that interacts with the 
dimerization arm in the tethered sEGFR structure – and thus weakening the tether (Dawson, 
2005). KD for EGF binding to this variant is 32 nM (Dawson, 2005), and ΔH is 
2.7 ± 0.1 kcal/mol.  (C)  The 246-253* mutation was initially described by Garrett et al. (2002), 
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and includes the following 6 mutations, designed to break dimerization arm contacts: Y246E, 
N247A, T249D, Y251E, Q252A, and M253D. These mutations disrupt the intramolecular 
tether shown in Figure 1A and the dimerization contacts in Figure 1C. KD for EGF binding to 
this variant is 260 nM by SPR (Dawson, 2005), and ΔH is 3.3 ± 0.1 kcal/mol.  (D)  The 246-
253*/∆575-584/D563A/H566A/K585A-mutated variant includes all of the changes in the other 
tether mutations described here, and also includes mutations of D563, H566, and K585 in 
domain IV to alanine. These residues contribute directly to the domain II/IV tether. Thus, this 
variant has all tether contacts as well as the dimerization site mutated. ΔH for EGF binding to 
this variant is 2.5 ± 0.1 kcal/mol.  This was performed by Nicholas Bessman and Atrish 
Bagchi.  
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CHAPTER THREE 	
  Towards understanding allosteric regulation of intact 
EGFR using hydrogen/deuterium exchange coupled 
to mass spectrometry 
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SUMMARY 
 The epidermal growth factor receptor (EGFR) was the first growth factor receptor for 
which ligand-induced dimerization was shown to be a relevant mechanism for receptor 
activation.  Recent studies, however, have shown that ligand-independent inactive dimers 
also exist at the cell surface in both human EGFR and EGFR orthologues in Drosophila 
melanogaster and Caenorhabditis elegans (Freed, 2015).  In chapter two, we discovered that 
ligand binding and dimerization are competitive processes, and alterations in the 
thermodynamic linkage of these processes can contribute to EGFR oncogenic dysregulation 
(Bessman, 2014).  We hypothesized that allosteric regulation of EGFR by the GBM mutations 
studied in Chapter Two may alter the relative energetic contributions of extra and intra-
cellular interactions to EGFR dimerization, and proposed to study the nature of this 
dysregulation by hydrogen/deuterium exchange coupled to mass spectrometry analysis of 
intact EGFR in detergent micelles and unilamellar proteoliposomes.  In this chapter, I discuss 
progress towards application of this approach to study allosteric regulation of EGFR. 
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INTRODUCTION 
In Chapter Two, we identified the EGFR domain I/II interface as a novel site of 
autoinhibitory interactions (Bessman, 2014).  We also showed that glioblastoma-linked 
mutations in this interface do not simply promote ligand-independent EGFR activation by 
enhancing domain II-mediated dimerization in the absence of contributions from EGFR 
intracellular domains and the plasma membrane.  Surprisingly, these activating glioblastoma 
mutations in the extracellular region of EGFR sensitize the receptor to inhibition by lapatinib 
(Vivanco, 2012), a kinase inhibitor that, based upon crystallographic data, binds preferentially 
to the kinase inactive conformation and also has a relatively slow off-rate (Wood, 2004).  
Taken together with the observations that there are inactive, preformed dimers at the cell 
surface (Yu, 2002) and the extracellular regions of the Drosophila melanogaster (Alvarado, 
2009) and C. elegans orthologs of EGFR dimerize in the absence of ligand (Freed, 2015), we  
hypothesized that EGFR is regulated by long-range, allosteric conformational changes.  
Taken together, it is increasingly clear that the role of the EGFR extracellular region in 
mediating receptor activation may involve long range allosteric effects in response to ligand 
binding in addition to its role in mediating receptor dimerization, and that there are 
autoinhibitory mechanisms within receptor dimers.  
Although there are extensive structural and biochemical data on isolated individual 
domains of the EGF receptor (Dawson, 2005; Dawson, 2007; Ferguson, 2003; Red Brewer, 
2009; Zhang, 2006), there are only a handful of studies that have biophysically assessed the 
coupling of extracellular and intracellular conformations (Lu, 2010; Lu, 2012; Mi, 2011; Wang, 
2011).  Some of these studies directly point to an interdependence between extracellular and 
intracellular conformations.  For example, kinase inhibitors that preferentially bind to the 
active kinase configuration also may enhance extracellular dimerization (Lu, 2012).  In 
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addition, there has been a suggestion that modulation of the intracellular juxtamembrane 
region affects affinity (Macdonald-Obermann, 2009) and cooperativity (Adak, 2011) of ligand 
binding.   The hypothesis of conformational ‘cross talk’ and ‘inside-out’ signaling mechanisms 
across the membrane and its importance in EGF receptor activation has also been 
challenged by a study that argued that conformational linkage of the extracellular and 
intracellular domains is weak (Lu, 2010). 
These analyses demonstrate that we do not yet understand the relationship between 
extracellular and intracellular conformation of EGFR.   I proposed to study the relationship 
between ligand-induced extracellular conformational changes and intracellular tyrosine using 
hydrogen/deuterium exchange coupled to mass spectrometry (HDX/MS).  Backbone amide 
hydrogens exchange with solvent hydrogens at rates that are sensitive to both secondary 
structure and internal motions.  As amide hydrogens can only exchange with solvent 
hydrogens (or deuteriums) when backbone hydrogen bonding in secondary structures are 
transiently broken, the rates of amide hydrogen exchange are sensitive to backbone 
dynamics and structural fluctuations (Skinner, 2012).  The kinetics of amide hydrogen 
exchange can be followed on a residue level by NMR or on a peptide level by mass 
spectrometry (Skinner, 2012), although residue resolution can now be achieved by analysis 
of overlapping peptides and isotopic envelope shape information (Kan, 2013).  These data 
can give valuable information about changes in secondary structure and dynamics given a 
perturbation, and therefore it may serve as a useful structural tool to analyze the oncogenic 
EGFR mutations discussed in Chapter 2. 
In this chapter, I discuss preliminary efforts to assess the long range conformational 
effects of ligand binding to the extracellular region in full-length receptors by 
hydrogen/deuterium exchange coupled to mass spectrometry.  I report EGF-dependent 
protection factors in the EGFR extracellular region.  I also made substantial progress toward 
application of this technique to studying full-length EGFR in detergent micelles.  Future 
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studies focused on such analyses of EGFR reconstituted in a physiologically relevant setting 
may gain insight into the mechanisms underlying receptor oncogenic dysregulation and lipid-
mediated autoinhibition.   
 
RESULTS AND DISCUSSION 
Hydrogen/Deuterium exchange analysis of the isolated EGFR extracellular region in 
the presence and absence of EGF 
We performed hydrogen/deuterium exchange coupled to mass spectrometry 
experiments on the recombinantly produced and purified EGFR extracellular region (mature 
amino acids 1-618, sEGFR) in the presence and absence of saturating concentrations of 
EGF.  We observed EGF-driven hydrogen exchange protection in regions of sEGFR known 
to be involved in direct contacts with EGF, and dimerization (Figure 3.1).   Briefly, peptides 
spanning the N-terminal region of domain I, and the β strands in domain III that make direct 
contacts with EGF undergo HDX protection.  The magnitude of HDX protection in EGF driven 
protection ranges from ~10,000 fold in some peptides in a random coil part of domain I to 
between ~10-100 fold in peptides in the β helix solenoid of EGFR domain III and the 
dimerization interface in domain II.  In addition, we observed ~100-fold allosteric HDX 
protection in the C-terminal region of domain III, at the domain III/IV interface.  This protection 
could be a result of the stabilization of the domain III/IV boundary in a ligated EGFR dimer.  
There is also a very small (<10-fold) deprotection effect on a loop in domain III (aa. 370-380).  
For instance, peptide 369-381 +3 exhibits a 4 % increase in HX at the 24,000 second 
timepoint with excellent statistical significance (p=0.0005) by an unpaired t-test.  Other 
peptides in this region require more independent replicates for measure of statistical 
significance. 
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This HDX protection likely results from the secondary structure stabilization at 
protein/protein interfaces, and, in the context of ligand-binding peptides in domain I, from 
structure acquisition.  The relative magnitude of these changes shown in Figure 3.1 suggest 
an energetic distribution of the relative contributions of stabilization that result from high 
affinity EGF binding to domains I and III (Kd ~150 nM) and dimerization (Kd ~1 µM).  These 
results corroborate the extant view that HDX protection factors can be useful tools to directly 
quantitatively analyze the relative stabilization of secondary structure at protein/protein 
interfaces (Skinner, 2012).  The deprotection effect on the aa. 370-380 loop may result from 
the loss of interactions with domain II in this region of domain III.  In principle, one could 
conceivably use this approach to also analyze receptor/detergent micelle, receptor/lipid, and 
receptor/downstream effector interactions and secondary structure and dynamics, as has 
been reported recently for G-protein coupled receptors (Chung, 2011; Duc, 2015; Shukla, 
2014).   
My preliminary HDX analysis of the EGFR extracellular region is an important step 
towards eventual application of this technique and other complementary structural mass-
spectrometry based techniques, like fast photochemical oxidation coupled to mass 
spectrometry (FPOP), which measures changes in solvent accessibility (Chen, 2010), to 
studying the allosteric regulation of full-length EGFR.  These mass spectrometry-based 
structural techniques can be applied to systems that are not currently amenable to X-ray 
crystallography, such as large complexes or membrane proteins.   
In performing these experiments, I encountered two main technical challenges 
imposed by both of the types of subdomains in the EGFR extracellular region.  Domains II 
and IV in the EGFR extracellular region are cysteine rich domains, and both are structurally 
stabilized by the presence of the vast majority of EGFR’s disulfide bonds.  Domains I and III 
are the ligand binding domains, and each contain a β helix solenoid structure. 
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The first technical challenge was MS/MS coverage of peptides in the cysteine rich 
domains.  Under the conditions (pH~ 2.5-3) that minimize back exchange for the HDX 
experiment, the reduction potential of common reducing agents such as tris(2-
carboxyethyl)phosphine (TCEP) is mitigated, effectively reducing the efficiency of disulfide 
reduction, and thereby lowering the intensities of both MS1 and MS2 spectra of the reduced 
species. Because the acid proteases commonly used for HDX (such as pepsin) are relatively 
nonspecific, computational identification of disulfide crosslinked peptides remains 
challenging.  We attempted to use empirically observed cut sites from MS/MS analysis as a 
restraint to identify disulfide-linked peptides, but this approach did not significantly improve 
coverage in EGFR domains II and IV (Z.-Y. Kan, S. W. Englander, personal communication). 
As an alternate approach, four iterative rounds of MS/MS using exclusion lists and inclusion 
lists were used to identify a comprehensive list of identified peptides in non-deuterated 
samples of the EGFR extracellular region.   This approach yielded a library of 392 peptides of 
sEGFR, with ~85% coverage of the extracellular region (example coverage of one of these 
MS/MS runs is shown in Figure 3.2).   
While MS/MS coverage of nondeuterated sEGFR in its cysteine rich domains was 
significantly improved through use of a rapid dilution approach (detailed in Methods), 
significant loss of coverage in low abundant species in cysteine rich domains II and IV 
occurred in analysis of MS1 spectra of deuterated samples.   Similar loss of coverage has 
been previously reported (Bobst, 2014; Burke, 2008), and could result from both reverse 
phase chromatographic broading of the deuterated peptides (we used a rather large retention 
time window for this reason, but this did not help).  In addition, statistical validation of the 
isotopic envelopes implemented in ExMS relies on high spectral resolution and signal to 
noise (Kan, 2011).  Such data quality may be lost for low abundance peptides in the cysteine 
rich domains of EGFR.   We did manage to observe HDX protection for some peptides with 
cysteines in domain II, such as one in the ‘buttressing’ interaction in domain II (Dawson, 
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2005) (aa. 275-283, Fig. 3.1), suggesting the optimized rapid dilution approach is useful.  
However, this approach comes with a greater cost in back exchange, averaging ~25%, than 
can potentially be achieved in the cooled box reverse phase HPLC setup I used (Walters, 
2012).    Even greater back exchange has been previously observed for offline protease 
digestion approaches developed to mitigate the MS/MS coverage problem in disulfide rich 
regions of proteins (Burke, 2008), highlighting the importance of developing alternate 
approaches to simultaneously minimize back exchange while maximizing reduction efficiency 
of disulfides for mass spectrometry identification. 
An alternative approach that has been recently described uses electron transfer or 
capture dissociation (ETD/ECD) based fragmentation to directly cleave the thiol-thiol bond in 
the gas phase (Bobst, 2014).  While hydrogen/deuterium scrambling has previously been 
observed with this type of fragmentation, gaining interpretable information about EGFR and 
other receptors with HDX analysis does not necessarily require single residue resolution as 
has recently been described for smaller globular systems (Kan, 2013).   ETD/ECD 
fragmentation has shown dramatic improvement in coverage for another disulfide-rich 
glycoprotein transferrin, which is about the same size as the EGFR extracellular region 
(Bobst, 2014), and is therefore a promising future direction for HDX/MS analysis of disulfide 
rich proteins like EGFR. 
The second technical challenge was to prepare a fully deuterated control sample to 
calculate peptide-resolved back exchange correction factors.  Through screening many 
conditions, the closest conditions for full deuteration of sEGFR were incubation of sEGFR in 
0.08% FA 150 mM NaCl pH 2.4 at room temperature for 65 hours and at 70 degrees for 5 
minutes.  The distribution of fractional deuteration of peptides in sEGFR under these 
conditions is compared to a positive control (cytochrome C, for which full deuteration 
conditions are widely established), in Figure 3.3 (Hu, 2016).  The midpoint of the two 
distributions are about the same, suggesting that the majority of the peptides are indeed fully 
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deuterated.  However, sEGFR contains a ‘tail’ of peptides that are still not fully deuterated 
under these conditions (as shown in Figure 3.3A).  These peptides are located within the β 
helix solenoid structures of domains I and III.  In addition, aggregation of sEGFR under these 
conditions decreases the effective concentration injected into the mass spectrometer and 
reduces coverage in domains II and IV.  While the scale factors for peptide specific back 
exchange are not necessary for comparative HDX analyses of the same peptides, they do 
limit the analyses to exclude quantitative comparison of distinct peptides, and therefore the 
raw amide hydrogen exchange rates.  This would preclude any analysis of sEGFR dynamics, 
and would limit any analysis to changes in sEGFR dynamics by a perturbation (i.e. mutations 
and ligand binding). 
 
Progress towards purification and application of HDX to analysis of full length EGFR 
I collaborated with the laboratory of Daniel Leahy (Johns Hopkins), which has 
previously described an approach to reconstitute detergent solubilized EGFR lacking the C-
terminal tail that is phosphorylated upon EGF-induced activation (amino acids 1-998), or 
tEGFR (Qiu, 2009; Wang, 2011; Wang, 2013), to analyze MS/MS coverage of near-full length 
tEGFR construct.  The tEGFR receptor was purified with an EGF-competitive mAb and eluted 
with EGF, and supplied in a dodecylmaltoside-containing buffer.  We performed preliminary 
MS/MS coverage analysis of this receptor construct, using a similar dilution approach 
described above for sEGFR (Figure 3.2B).  We were able to identify peptides spanning the 
entire receptor construct, in both extra- and intra-cellular regions of tEGFR (Figure 3.2B).  We 
did observe many more peptides in disulfide rich regions in the extracellular region of EGFR 
than coverage experiments for sEGFR (Figure 3.2A), presumably due to the contribution of 
the reducing agent DTT in the buffer and incubation at room temperature for 10 minutes.  We 
did not obtain peptides in the first ten residues of the intracellular juxtamembrane region, 
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perhaps due to inaccessibility of the transmembrane (TM) domains to pepsin, producing long 
peptides too hydrophobic to be eluted from a C18 column under these conditions. 
 As the analysis possible with tEGFR is inherenty limited by the mAb-based 
purification approach (it can only be purified in complex with an Fab of an EGF-competitive 
antibody, such as cetuximab or EGF), we decided to design an alternate approach to purify 
full-length EGFR.  The baculovirus expression system was used to produce recombinant 
EGFR in Sf9, HiFive, and TnI insect cells.  Full length EGFR expressed the best in Sf9 cells, 
with an optimal harvest time of 48-55 hours post infection.  Receptor proteins with a C-
terminal hexahistidine tag were purified from the isolated membranes of Sf9 cells by TALON 
purification followed by anion exchange and size exclusion chromatography. Full-length 
EGFR (FL-EGFR) solubilized in CHAPS eluted primarily as a presumably monomeric peak 
by size exclusion chromatography (MW ~170 kDa), with a ‘shoulder’ indicating possible 
aggregation.  These purifications were done within 30 hours of lysis to limit time-dependent 
loss of tyrosine kinase activity of the detergent-solubilized receptors, with a yield of ~20 µg/L 
Sf9 cells.  I also made Flag- and Strep-tagged version of full-length EGFR, and the 
purification efficiency of EGFR containing either of these tags is higher than that of a 
hexahistidine tagged EGFR. 
 Preliminary autophosphorylation assays were also performed with CHAPS-
solubilized full-length EGFR (detailed in Methods).  EGFR autophosphorylation experiments 
were performed with protein after ion exchange purification (prior to size exclusion 
chromatography) to evaluate if the tyrosine kinase module would be catalytically active once 
subject to purification and to mitigate concerns regarding time-dependent loss of kinase 
activity.  Protein >70% pure by Coomassie staining (not shown) at this stage of purification, 
and was concentrated to an OD280 of 0.3 (~2 µM) for autophosphorylation experiments.  
Autophosphorylation was initiated by addition of 1 mM ATP (pH 7) and 10 mM MgCl2 at room 
temperature for 10 minutes with or without 40 µM EGF (detailed in Methods).  Reactions 
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were quenched by addition of reducing 3x Laemmli sample buffer, and analyzed by 
immunoblotting using anti-PY20 and a phosphospecific anti-pY1068 antibody (Santa Cruz) 
and anti-EGFR murine antibody cocktail Ab-12 (Thermo Scientific) as shown in Figure 3.6. 
There is some spectral overlap between the anti-pY1068 and anti-EGFR antibodies in the 
immunoblot shown in Figure 3.6A (evident by the yellow color in lanes 5 and 8, but analysis 
of other lanes shows approximate equal loading of EGFR).  Nevertheless, as shown in figure 
3.6A, EGFR autophosphorylation is dependent on addition of both ATP and MgCl2, 
suggesting that the tyrosine kinase module is active under these conditions.   However, 
addition of EGF under these conditions does not measurably increase the tyrosine 
autophosphorylation of EGFR in CHAPS.  These results are consistent with the first 
detergent-solubilized preparations of EGFR which had noted an absence of EGF-dependent 
increase in autophosphorylation unless a preincubation step was included (Cohen, 1980), 
which I speculate could be due to an increase in the kinetic activation barrier of dimerization 
imposed by detergent micelles.  An alternate possibility is that the protein is in aggregates, 
consistent with the subsequent size exclusion analysis of these preparations showing an 
‘aggregated’ shoulder (Figure 3.5A), and aggregation causes an increase in ligand-
independent tyrosine kinase domain activation (Yarden, 1987).  A third possibility is that there 
is a loss of autoinhibition due to loss of interactions with lipids, and because of the CHAPS 
micelle (although EGF stimulation has been previously observed of tEGFR in 
dodecylmaltoside micelles) (Wang, 2011; Wang, 2013).  Protein is >80% pure by Coomassie 
staining after size exclusion chromatography (Figure 3.5B). 
 Overall, my progress towards application of HDX/MS to evaluating long-range 
allosteric regulation in EGFR is still at a very preliminary stage.  However, HDX/MS, coupled 
to other MS-based structural techniques, has the potential to reveal modes of oncogenic 
allosteric dysregulation of EGFR, which may rationalize the differences in lapatinib sensitivity 
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of the extracellular GBM mutations studied in Chapter 2 (Bessman, 2014), as well as 
structural mechanisms for ligand discrimination in EGFR (Ronan, 2016). 
 
METHODS 
Protein purification and constructs. 
 
sEGFR constructs were purified as described previously (Ferguson, 2000).  EGF was 
purchased from Chemicon, inc.  Full length EGFR constructs for purification were made by 
amplifying EGFR with a 5’ KpnI site and a 3’ Xho site, double digesting the amplified DNA, 
and ligating a gel purified amplified product into a digested pfastBac vector.  The expression 
tag was inserted at the amplification step.   All constructs were verified by DNA sequencing. 
Full-length EGFR was purified from Sf9 cells using a baculovirus system.  Sf9 cells 
were infected with 10 ml/L of P2 baculovirus, and harvested after 50 hours.  Cell pellets were 
washed in ice-cold PBS, and lysed in an isotonic buffer conditions – 25 mM HEPES pH 7.5 
200 mM NaCl, 15 % glycerol, 1x mammalian protease inhibitors (Roche, Palo Alto, CA) 1 mM 
PMSF, using sonication (though a pressure-based French press system would likely be 
preferable) on ice.  Cell debris was removed by centrifugation at 10000g (a range between 
500g and 30000g was tried and 10000g gave the best purification with least loss, data not 
shown) for 10 minutes at 4 degrees.  Membranes were isolated from the supernatant by 
ultracentrifugation of the resulting lysate at 150,000g for 1.5 hours. Membranes were 
resuspended in 25 mM HEPES pH 8 200 mM NaCl, 15 % glycerol, 1x mammalian protease 
inhibitors (Roche, Palo Alto, CA) 1 mM PMSF with a dounce homogenizer. Detergent 
extraction was performed by direct addition of the shown concentrations of the relevant 
detergents and nutating at 4 degrees for 1.5 hours (Figure 3.4).  CHAPS and DDM were 
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taken forward, as a previous purifications for EGFR and tEGFR have been described using 
these detergents (Coskun, 2011; Qiu, 2009). Unsolubilized material was removed by 
ultracentrifugation at 100,000g for 1 hour.  The resulting supernatant was incubated by batch 
binding to 0.25 ml of Talon (Co2+ affinity) resin/L Sf9 cells (pre-equilbrated with 2 column 
volumes of the same conditions as the lysate) for 1 hour, and washed with four column 
volumes of 25 mM HEPES 5 mM imidazole 1% CHAPS 1x mammalian protease inhibitor 
cocktail (Roche, Palo Alto, CA), 15% glycerol, 1 mM PMSF, 200 mM NaCl, pH 8, and eluted 
in the same buffer containing 50 mM imidazole.  Protein was further purified by anion 
exchange chromatography using a resource Q column (GE Healthcare).  Purified EGFR 
fractions in CHAPS were pooled and further purified by size exclusion chromatography with a 
Superose 6 column (GE Healthcare).  Full length-EGFR in CHAPS eluted by size exclusion 
chromatography predominantly as two species – the major of which is likely monomeric with 
an aggregated or oligomeric ‘shoulder’.  The identitiy of this protein was further confirmed by 
tandem MS/MS analysis (Wistar Proteomic Facility, data not shown).  Similar purification 
results were also observed for full-length EGFR purified in dodecylmaltosize (DDM), and 
purified receptor in 25 mM HEPES 150 mM NaCl 0.05% DDM 1x mammalian protease 
inhibitor cocktail (Roche, Palo Alto, CA) 15 % glycerol 1 mM PMSF pH 8.  This protein was 
confirmed to bind to immobilized EGF in a Biacore binding assay under these conditions 
(data not shown). 
Near full length EGFR (truncated at amino acid 998), or tEGFR, bound to EGF was 
purified from HEK293 GnTi- cells as previously described (Qiu, 2009; Wang, 2011; Wang, 
2013), and was generously provided by Lily Raines and Daniel Leahy of Johns Hopkins 
University School of Medicine.   
 
 
	 85	
Autophosphorylation reactions.   
The autophosphorylation activity of CHAPS-solubilized full-length EGFR was performed after 
resource Q fraction.  Protein was in 25 mM HEPES ~200 mM NaCl 1% CHAPS 15% 
glycerol 1x mammalian protease inhibitor cocktail pH 8.0 (Roche, Palo Alto, CA) 1 mM 
PMSF and was concentrated to a buffer reference subtracted Abs280 of 0.3 using a 100 kDa 
cutoff concentrator at 500g (at 4 degrees).  EGFR Buffer for the experiment was 25 mM 
HEPES 150 mM NaCl 1% CHAPS 15% glycerol 1x mammalian protease inhibitor cocktail 
pH 8.0 (Roche, Palo Alto, CA) 1 mM PMSF.  Stocks were 0.5 M MgCl2, 50 mM ATP (pH 7), 
and 400 µM EGF (in 50 mM HEPES 150 mM NaCl pH 8.0) – all sterile-filtered.  Reactions 
were initiated by mixing 7.6 µl EGFR in indicated conditions with 2.4 µl EGFR buffer, or 1.6 
µl EGFR buffer with 0.8 µl of ATP alone, MgCl2 alone, or EGF alone, or 0.8 µl EGFR buffer 
with combinations of the other two, or 0.8 µl of ATP with 0.8 µl MgCl2 and 0.8 µl EGF.   
 
H/DX reactions 
Deuterium on-exchange for EGFR extracellular region was carried out at room 
temperature by adding 1.2 µl of sEGFR stock (125 µM) in 50 mM HEPES pH 8 150 mM NaCl 
to 0.3 µl of this same buffer or EGF resuspended in this buffer (at a stock concentration of 
625 µM).  Reactions were initiated by addition of 6 µl of deuterium on-exchange buffer (150 
mM NaCl in D2O) so that the final reaction conditions 80% D2O 10 mM HEPES pH 8 (pD~8.4) 
150 mM NaCl.  Reactions were quenched with addition of 20 µl of pre-chilled QB (0.1 % FA 
pH 2.8 6.2 M Guanidine 500 mM TCEP) for 30 sec. then diluted with 34.5 µl FB (0.8% FA 
10% glycerol) to make final 180 mM TCEP 2 M Gndn-HCl and final volume for each reaction 
60 µl.  These samples were then immediately frozen in liquid nitrogen. The samples were 
stored at −80°C until analysis by MS. 
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For tEGFR, purified receptor was supplied in a buffer containing 0.03% 
dodecylmaltoside and 0.5 mM DTT at a concentration of ~10 µM (as determined by the 
Leahy lab by SDS-PAGE and comparison to BSA standards).  To gain insight into the upper 
limit of coverage in the extracellular coverage of tEGFR, a 6 µl aliquot quenched with 20 µl 
QB (0.1 % FA pH 2.8 6.2 M Guanidine 500 mM TCEP) for ten minutes at room temperature 
then diluted with FB (0.8% FA 10% glycerol) to make final 180 mM TCEP 2 M Gndn-HCl and 
final volume for each reaction 60 µl. 
 
Protein digestion, peptide fragmentation and MS 
H/DX samples were individually thawed at 0°C for 2 min, then injected (50 µl) and 
pumped through an immobilized pepsin (Sigma) column at al flow rate of 100 µl/min for 3 
minutes. Pepsin (Sigma) was immobilized by amine coupling to POROS 20 AL support 
(Applied Biosystems) and packed into column housings of 2 mm × 2 cm (64 µl) (Upchurch). 
Protease-generated fragments were collected onto a C18 HPLC trap column (800 µm × 2 
mm, Dionex). Peptides were eluted into and through an analytical C18 HPLC column (0.3 × 
75 mm, Agilent) by a nonlinear 10–50% buffer B gradient over 15 minutes at 9 µl/min (Buffer 
A: 0.1% formic acid; Buffer B: 0.1% formic acid, 99.9% acetonitrile) followed by a 10 minute 
wash cycle that increased the % Buffer B to 95%.  Each injection was also followed 
immediately by an additional 30 minute wash protocol that cycled from 10% Buffer B to 80% 
Buffer B four times using a flow rate of 9 µl/min.  The effluent was electrosprayed into the 
mass spectrometer (LTQ Orbitrap XL, Thermo Fisher Scientific).  The SEQUEST (Bioworks 
v3.3.1) software program (Thermo Fisher Scientific) was used to identify the likely sequence 
of the parent peptides using non-deuterated samples via tandem MS using a database that 
contained EGFR as well as several other systems being studied by the Englander group. A 
comprehensive peptide pool for wild-type sEGFR was developed by four iterative rounds of 
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MS/MS using rejection and inclusion lists of previously identified peptides, and the same 
peptide pool was used for all subsequent analyses of wild-type sEGFR with and without EGF. 
The mass spectrometer used was a ThermoScientific LTQ Orbitrap XL (Thermo 
Fisher Scientific, Waltham, MA, USA) operated at a 60,000 resolution (~1 s/scan). Data were 
collected in profile mode with an AGC target of 106. The mass calibration was checked daily 
and recalibrated when necessary (G2 ppm rms deviation over 9 masses/100 scans in the 
calibration mix). Source parameters were: spray voltage 3.5 kV; capillary voltage 40 V; tube 
lens 170 V; capillary temperature 150 °C. MS/MS CID fragment ions were usually detected in 
the LTQ stage of the instrument in centroid mode at normal scan rate with an AGC target 
value of 104. CID fragmentation was at 35% energy for 30 ms at Q of 0.25. 
 
H/DX data analysis 
MATLAB-based MS data analysis tool—ExMS—was used for data processing, using 
a retention time window of 3 minutes (Kan, 2011). Briefly, the ExMS program searches raw 
MS data, identifies individual isotopic peaks/envelopes from a list of MS/MS peptides 
obtained from SEQUEST search and calculates centroid values of these envelopes. The 
program is used to first identify the isotopic envelope centroid and chromatographic elution 
time of each parental non-deuterated peptide, and then this information is subsequently used 
to identify deuterated peptides. 
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CHAPTER THREE FIGURES 
 
Figure 3.1  Preliminary HDX/MS analysis of the extracellular region of EGFR.  (A) Data 
for representative peptides in the ligand binding and dimerization interfaces in the EGFR 
extracellular region.  Amide hydrogen/deuterium exchange rates calculated by normalizing 
the centroid shift of the isotopic envelope compared to the monoisotopic mass by the 
maximum number of exchangeable amides for a given peptide.  Plots are plotted over a 
timecourse (in seconds), on a log scale, with standard deviations of independent replicates of 
each timepoint indicated by the error bars. The first two peptides on the left are in domains I 
and III, respectively, and are peptides that are involved in direct interactions with EGF.  The 
two peptides on the right are in the dimerization interface. 245-253 is the β hairpin that forms 
the direct ‘tether’ interaction, while 275-283 forms the ‘buttressing’ interaction.  (B) % change 
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from the 100 sec timepoint (unless indicated) plotted as binned on the structure of the EGF 
(shown in green) bound sEGFR dimer (PDB ID 3NJP). The only exception to this (to highlight 
the small deprotection at longer timescales) is the % deprotection (shown in cyan) of the aa. 
370-380 loop.  The % deprotection here is calculated from the longest timepoint (t ~105 s). 
 
Figure 3.2  Preliminary MS/MS coverage of EGFR extracellular region and tEGFR (full 
length EGFR aa. 1-998) in dodecylmaltoside micelles. (A) MS/MS coverage of the 
extracellular region of EGFR compared to the domain architector of sEGFR.  Coverage is 
limited in the cysteine rich domains shown in green.  Each blue bar represented one peptide 
mapped onto the amino acid residue number for the sEGFR construct, for which a domain 
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architecture is shown in the top part of the panel. (B)  MS/MS coverage of intact tEGFR in 
dodecylmaltoside micelles.   
 
 
Figure 3.3 Distribution of fractional deuteration of ‘all-D’ sample of sEGFR compared to 
cytochrome C. (A) Distribution of fractional deuteration of peptides in the optimal ‘all D’ 
sample of sEGFR under the conditions described in the Methods.  The fractional deuteration 
is a result from both experimental deuteration as well as back exchange and is compared to a 
positive control (cytochrome C).  The half-maximal fractional deuteration across all peptides 
is indicated by the dashed line.  There is a long tail to the left of this line that are peptides in 
the domain I and III solenoid structures that are difficult to unfold under these conditions. (B) 
A positive control (cytochrome C) for evaluation of the distribution with the same quench 
protocol used for analysis of sEGFR.  
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Figure 3.4 Assessment of FL-EGFR detergent extraction efficiency.  FL-EGFR was 
purified as described in the Methods section from Sf9 cells.  Whole cell lysate (WCL), 
prepared by direct lysis of Sf9 cells in reducing Laemmli buffer, was compared quantitatively 
to assess protein loss at early stages of the purification and detergent extraction efficiency. 
1U-in represents the input to the 1st ultracentrifugation step, and 1U-sup is the supernatant.  
As can be seen, a large fraction of the protein is lost at this step, suggesting this step may 
need more optimization.  Det-in. is the input to the detergent extraction step, and compared 
quantitatively to six different detergents indicated.  As can be seen, the detergent extraction 
efficiency is quite high, and does not vary significantly across detergents. 
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Figure 3.5 Progress towards purification of full length EGFR.  The CHAPS-solubilized 
full-length EGFR, purified as described in the Methods, was examined by size-exclusion 
chromatography using a Superose 6 column (GE Healthcare).  As can be seen, the ~170 kDa 
protein elutes mostly as a monomer by SEC, although the stokes radius may be slightly lower 
than would be predicted for a monomer, suggesting it may be compact in the context of a 
CHAPS micelle.  There is also an aggregated ‘shoulder’ at lower elution volumes.  (B) 
Fractions containing the peaks shown in the aborbance trace shown in panel A were 
concentrated 10-fold by TCA precipitation and visualized by SDS-PAGE and Coomassie 
staining.  As shown, the full length EGFR is >80% pure. 
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Figure 3.6 Preliminary autophosphorylation analysis of full-length EGFR in CHAPS.  
Autophosphorylation reactions on Talon and ion exchange purified FL-EGFR were done as 
stated in the Methods, and analyzed by SDS-PAGE and immunoblotting using antibodies 
specified in Methods.  Lane order: (order of 10 mM MgCl2, 1 mM ATP, 40 µM EGF).  1. - - - 2. 
+ - - 3. - - + 4. - + - 5. + + - 5. + - + 7. - + + 8. + + +  
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CHAPTER FOUR 
Molecular basis of Necitumumab/PortrazzaTM 
inhibition of EGFR variants associated with acquired 
cetuximab resistance. 
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SUMMARY 
 
 The epidermal growth factor receptor (EGFR) family is implicated in a number of 
cancers and members of the family are the targets of monoclonal antibody therapies.  
Cetuximab/ErbituxTM is an EGFR antibody that is approved for head and neck and colorectal 
cancers.  Unfortunately, resistance to this targeted therapy limits its therapeutic benefit.  Our 
collaborators at Eli Lilly show that Necitumumab/PortrazzaTM, recently approved by the U.S. 
Food and Drug Administration for squamous non small cell lung cancer, inhibits EGFR with 
cetuximab and panitumumab resistance mutations.  To understand how necitumumab can 
bind to resistance mutations despite sharing a nearly identical epitope, I determined a 2.8 Å 
X-ray crystal structure of the necitumumab Fab fragment in complex with isolated EGFR 
domain III bearing the S492R (S468R in mature numbering) cetuximab resistance mutation.  
Comparison of the paratopes of cetuximab and necitumumab to those of other therapeutic 
antibodies reveals a structural class of antibodies that contain buried cavities between their 
VH and VL domains. My structural analysis reveals that plasticity and hydration of the 
necitumumab paratope may make it a useful therapeutic agent for these cases of cetuximab 
resistance and for future combination therapies.  We also identify paratope shape as a 
potential feature of antibodies that may be utilized in synergistic modes in combinatorial 
therapeutics. 
 
SIGNIFICANCE 
 
Resistance to anti-epidermal growth factor receptor monoclonal antibody therapies, including 
cetuximab/ErbituxTM is often driven by epitope mutations.  Necitumumab/PortrazzaTM binds 
and inhibits EGFR mutants that cause cetuximab resistance despite sharing a common 
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epitope, through structural plasticity of its paratope, which I observe in an X-ray crystal 
structure of EGFR domain III S492R (S468R in mature numbering) in complex with the Fab 
fragment from necitumumab.  Necitumumab therefore may be a useful agent in future 
combination therapies. 
 
INTRODUCTION 
The Epidermal Growth Factor (EGF) receptor or ErbB/HER family of receptor 
tyrosine kinases (RTKs) have been implicated in and drive many human cancers.  It is well 
established that antibodies to the extracellular region of the EGF receptor (EGFR) that 
prevent ligand binding and conformational changes required for receptor activation can inhibit 
tumor growth in vivo.  Therapeutic antibodies in current clinical use that target the ErbB family 
include cetuximab/ErbituxTM, panitumumab/VectibixTM – both of which target EGFR/HER1 
itself—and trastuzumab/HerceptinTM, which targets ErbB2/HER2.  In addition, there are 
several antibodies that target ErbB3/HER3 in clinical trials, including KTN3379 (Kolltan 
Pharmaceuticals, New Haven, CT) (Lee, 2015).   
Cetuximab/Erbitux™ is in active clinical use to treat colorectal, and head and neck 
squamous cell cancers.  As with all targeted cancer therapies, acquired resistance to 
cetuximab limits the duration of effective treatment.  In some cases resistance to cetuximab 
has been attributed to mutations in intracellular signaling molecules, such as KRAS and 
BRAF.  In 2012, a mutation in extracellular region of EGFR itself was identified in metastatic 
KRAS wild-type colorectal cancer (mCRC) tumors that had acquired resistance to cetuximab 
treatment (Montagut et al., 2012).  These alterations gives rise to a single amino acid 
substitution in the cetuximab epitope (S492R in pro-EGFR or S468R, using the numbering 
system that starts from the mature protein).  In that study it was reported that another EGFR 
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targeted monoclonal antibody drug, panitumumab, is an effective inhibitor of the S468R 
mutant and therefore would be the therapy of choice for cetuximab resistant patients.  
Recent exome sequencing analysis of KRAS wild-type colorectal cancer tumors has 
systematically identified genomic alterations in response to EGFR cetuximab therapy 
associated with resistance to cetuximab (Arena et al., 2015; Bertotti, 2015; Medico, 2015; 
Morelli, 2013; Siravegna, 2015) which include genetic alterations in EGFR, ERBB2, PDGFR, 
and amplification of FGFR1, MET, and ERBB2 (Bardelli, 2013; Yonesaka, 2011).  Additional 
EGFR extracellular region mutations  - K443T, G441E, G441R, and I467M (in mature amino 
acid numbering) – were also identified following treatment with cetuximab, and with 
panitumumab, in patient samples and in cell lines (Table 1) (Bertotti, 2015; Briag, 2015; 
Siravegna, 2015).  Whereas panitumumab was shown to bind and inhibit K443T and S468R, 
it has greatly diminished binding for I467M and G441E/R.  G441R is also associated with 
resistance to both cetuximab and panitumumab in gastrointestinal cancer (Briag, 2015).  The 
G441E EGFR mutant, when ectopically expressed in cetuximab-sensitive cell line NCI-H508 
cells, reduces cetuximab EGFR inhibition and increases activation of downstream signals in a 
manner that is dependent on expression of the downstream adaptor IRS2, consistent with 
previous observations that these mutations are sufficient in inducing resistance to cetuximab 
therapy (Bertotti, 2015).   
Overall, EGFR mutations within the shared epitope of cetuximab and panitumumab 
represent a major mechanism of clinical resistance to cetuximab; 16 % of mCRC patients in 
the cetuximab arm of the ASPECCT trial developed the S468R mutation, where only 1 % of 
patients did so in the panitumumab arm (Newhall, 2014; Price, 2015), suggesting that that 
this resistance mutation occurs more selectively after EGFR inhibition by cetuximab. 
Necitumumab/PortrazzaTM (IMC-11F8), an anti-EGFR IgG1 antibody therapy recently 
approved in combination with gemcitabine and cisplatin for squamous non small cell lung 
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carcinoma, shares a very similar epitope to that of cetuximab (IMC-225) and panitumumab, 
though the paratopes are quite different (Li, 2008; Li et al., 2005).  Like cetuximab, its epitope 
overlaps with the EGF binding site, and therefore binding of necitumumab interferes with 
binding of EGF to EGFR (Li, 2008). 
The X-ray crystal structures of the necitumumab Fab fragment bound to isolated EGFR 
domain III (sEGFR-d3) and the full length EGFR extracellular region (sEGFR) were 
previously determined and show that necitumumab has completely different binding 
interactions from cetuximab despite sharing a nearly identical epitope (Li, 2008).  Previous 
analysis also identified a similar shape complementarity parameter in the necitumumab 
paratopic interface compared to that of cetuximab, despite having a buried hydrophobic 
cavity between its light and heavy chains, where it interacts with EGFR domain III (Li, 2008) .  
In this chapter I report that necitumumab retains high affinity for four described EGFR 
epitope mutations that cause cetuximab resistance.  Whereas these EGFR mutations greatly 
diminish the binding affinities of cetuximab, their effects are drastically smaller on binding of 
necitumumab.  Our collaborators at Ely Lilly show that necitumumab effectively inhibits EGFR 
bearing the most commonly observed of these mutations – the S468R mutation – and that 
necitumumab causes dose-dependent EGFR-S468R internalization and degradation. 
I also report the X-ray crystal structure to 2.8 Å resolution of the Fab fragment from 
necitumumab (Fab11F8) in complex with isolated domain III from EGFR (sEGFRd3) with the 
serine at position 468 substituted with arginine (sEGFRd3-S468R).  I was able to resolve 
clearly the side chain of the arginine at position 468 and to visualize how it is accommodated 
in this cavity in the interface between EGFR domain III and the Fab, and additional 
interactions that stabilize it, including a water-mediated hydrogen bond and several cation-pi 
interactions.   
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My structural analysis reveals that the packing between the light and heavy chains and 
consequent flatness of cetuximab paratope leave it susceptible to alterations by genetic 
mutation.  By contrast necitumumab contains a hydrophobic and hydrated cavity capable of 
exhibiting structural plasticity.  I also observe minor conformational changes within the 
necitumumab paratope, which may contribute to such plasticity.  Moreover, I suggest that the 
distinct modes of binding of cetuximab and necitumumab, despite sharing a common epitope, 
can potentially be exploited in the context of combinatorial therapies.  
 
RESULTS 
Necitumumab binds with high affinity and inhibits EGFR bearing cetuximab resistance 
mutations. 
To ask if necitumumab is able to bind with high affinity to EGFR mutants that cause 
cetuximab resistance, we collaborated with Eli Lilly and Company (New York, NY; 
Indianapolis, IN) to analyze antibody binding to HEK293T expressing EGFR bearing 
cetuximab resistance mutation S468R by immunostaining with Alexa-647 labeled antibodies.  
We find that necitumumab and panitumumab can retain binding and inhibition to cells that 
overexpress EGFR harboring the S468R (EGFR-S468R) mutation whereas cetuximab does 
not (Eli Lilly and Company, data, not shown).  Treatment of cells with necitumumab leads to 
inhibition and dose dependent downregulation and degradation of both wild type and EGFR-
S468R, whereas the EGFR-S468R is not effectively inhibited by cetuximab, with an 
associated decrease in receptor downregulation (Eli Lilly and Company, data, not shown).   
The arginine side chain at position 468 (S468R) in cetuximab resistant patients would 
clash with the cetuximab paratope.  The serine at position 468, however, projects towards a 
buried hydrophobic cavity (Figure 4.2) in the necitumumab paratope, which led us to 
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hypothesize that necitumumab would retain EGFR binding affinity.   The presence of this 
cavity makes no significant difference between measures of shape complementarity between 
cetuximab and necitumumab (Table 4.4).  Increasing the packing density in this cavity by 
replacing this serine with an isoleucine (S468I) enhances necitumumab affinity while not 
altering cetuximab affinity (Li, 2008). 
The presence of this hydrophobic cavity (Figure 4.2) in this central location in the 
EGFR/necitumumab interface prompted us to hypothesize that it may bind to other EGFR 
mutants that cause cetuximab resistance in this region of the cetuximab epitope on EGFR.  
We find that necitumumab retains high affinity to four cetuximab resistance EGFR mutations.   
Two of these mutations directly project into this cavity (S468R/I467M), one is adjacent 
(S440L), and one is peripheral to the paratopic interface (K443T), suggesting additional 
structural considerations underlie the ability of necitumumab to bind, and therefore inhibit, 
these EGFR mutants (Figure 1). 
 
 
 
Binding of sEGFR harboring cetuximab resistance mutations to the Fab fragments of 
cetuximab and necitumumab. 
 
To evaluate the extent of diminished binding to cetuximab of the soluble extracellular 
region of EGFR (sEGFR) harboring mutations that have been linked to cetuximab resistance 
we used surface plasmon resonance (SPR/Biacore), exactly as we have done in the past 
(Ferguson et al., 2003; Li et al., 2005).   
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We generated sEGFR variants with the patient derived cetuximab resistance 
mutations S468R and K443T and with the cell line derived mutations S440L and I467M.  
Proteins with alterations at G441 could not be generated.  As shown in Figure 4.3B and Table 
4.2, sEGFR-S468R shows very weak binding (KD value >> 4 µM) to immobilized FabC225, 
and alteration at the adjacent amino acids (sEGFR-I467M) reduces binding by more than 50-
fold.   Substitution of leucine at position S440, which is located close to S468 on the adjacent 
β-strand of domain III, also dramatically reduced binding to FabC225 (KD value >> 4 µM), and 
substitution of K443 with threonine reduced binding more than 100-fold (Figure 4.3A).  Of 
note, we had previously observed that substitution of K443 with alanine, did not affect 
measurably cetuximab binding (Li, 2008).  These same sEGFR variants bind to immobilized 
EGF with very similar affinities to those observed for wild type sEGFR, indicating that the loss 
of binding affinity for cetuximab is not due to a general destabilization of domain III of the 
protein but to the local effect of these particular amino acid substitutions. 
We next quantified the binding energetics of EGFR bearing cetuximab resistance 
mutations by surface plasmon resonance of recombinantly expressed and purified mutants of 
the EGFR extracellular region.  We engineered all of these mutations in the recombinant 
baculovirus expressed extracellular region of EGFR (sEGFR). sEGFR binds to the Fab 
fragment of necitumumab (Fab11F8) and cetuximab (FabC225) with high nanomolar affinity 
(Table 4.2).  We find that binding of sEGFR-S468R to immobilized Fab11F8 is just 2-fold 
weaker than binding of wild type sEGFR, in stark contrast to the dramatic loss of binding of 
this protein to FabC225 (Figure 4.3C).  A variant of sEGFR harboring the other patient 
derived mutation (sEGFR-K443T) shows similar high affinity binding to immobilized Fab11F8, 
whereas the two cell line derived variants, sEGFR-I467M and sEGFR-S440L, show slightly 
weaker binding with KD values of 27 and 53 nM respectively.  For these cetuximab resistance 
sEGFR variants, binding of necitumumab is predicted to be 10 to ~ 500 fold stronger than 
binding of cetuximab (Table 4.2). 
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X-ray crystal structure of sEGFRd3-S468R/Fab11F8. 
To gain molecular insight into the ability of necitumumab to bind with high affinity and 
inhibit these sEGFR variants we determined the 2.8 Å resolution X-ray crystal structure of the 
necitumumab Fab fragment bound to domain III of EGFR harboring the S468R cetuximab 
resistance mutation (sEGFRd3-S468R/Fab11F8).  X ray diffraction data collection and 
refinement statistics are shown in Table 4.3. 
 Clear electron density could be seen for the arginine side chain at amino acid 
position 468 in initial molecular replacement solutions.  Following refinement, clear density 
can be seen for the side chain in each of the four molecules in the asymmetric unit (Figure 
4.4), as well as an ordered coordinated water molecule in three of the four complexes.  
Electron density for both the arginine side chain and coordinated water molecule can be seen 
when both are omitted from the model (Figure 4.4) and in simulated annealing composite 
omit maps (data not shown).  The structure reveals that necitumumab is able to 
accommodate R468 in a buried hydrophobic cavity between the light and heavy chains that is 
hydrated.    
In addition to being sterically accommodated, R468 makes several important 
interactions that contribute to stabilizing the introduction of a basic residue in a hydrophobic 
environment.  The guanidinium moiety in the arginine side chain engages in hydrogen bonds 
with the main chain carbonyl of G100A in CDR H3 and a water mediated hydrogen bond with 
the side chain of S35 in CDR H1 (using Chothia numbering for the VH amino acids).  
Hydration of this cavity is essential for stabilizing R468 in a relatively hydrophobic 
environment.  In addition to a water mediated interaction, R468 engages in cation-pi 
interactions with F100C, Y33, and Y50.  The Y50 sidechain rotates ~15 degrees towards the 
R468 to contribute to this interaction (Figure 4.1B). Views of electrostatic potential of the 
	 106	
necitumumab paratope alone (Figure 4.2) reveals that F100C contributes to a region of 
electronegative potential within the hydrophobic cavity, consistent with it being able to 
contribute to a cation-pi interaction.   
The structures of EGFR domain III wildtype and domain III S468R are very similar -- 
domain III overlays with an pairwise root mean square displacement (RMSD) of 0.458 Å, 
while overlaying the entire structure of the complex including Fab11f8 overlay with an RMSD 
of 0.569 Å, indicating that the EGFR S468R mutation does not dramatically alter the 
conformation of either EGFR or the Fab fragment from necitumumab.  The mean buried 
interface area in the domain III S468R complex is very similar –  896 Å2, as compared to 875 
Å2 in the wild-type structure, consistent with the view that the mutation fills a small cavity that 
is otherwise unoccupied.   
One notable difference in the mutated structure is that the binding of the 
necitumumab Fab to this mutated EGFR domain III is less rigid than in the wild-type 
structure, as evidenced by a structural ‘wobble.’  Upon overlaying domain III (aa 311-480) of 
EGFR in each of the four complexes in the asymmetric unit, we noticed a ‘wobble’ in the 
necitumumab light chain conformation.  The conformation of the VL domain are more 
different in the four complexes in the asymmetric unit in the domain III S468R structure than 
they are the eight complexes in the asymmetric unit in the domain III wild-type structure.  
Analysis of these different conformations reveals a screw motion of the antibody complex, 
with a small translation away from the site of mutation and rotation around the two-fold 
symmetry axis within the Fab (Figure 4.5).   
Comparison of the necitumumab and cetuximab paratopes to those of other 
therapeutic antibodies.  
As mentioned previously the R468 side chain in sEGFRd3-S468R is accommodated 
in a hydrophobic cavity between the VL and VH chains in this Fab.  Overlaying the 
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sEGFRd3S468R from our structure with the domain III from the structure of sEGFR bound to 
FabC225 immediately shows that there is insufficient space to accommodate the arginine 
due to a steric clash with the side chain of Y100A (in Chothia numbering) in CDR H3 (Fig. 
4.2) of cetuximab.  A surface view comparison of the cetuximab paratope reveals that it is 
relatively flat, where the necitumumab paratope has a buried cavity between its VH and VL 
domains.   Comparison of the necitumumab and cetuximab paratopes further reveals that this 
difference in paratope shape is due to CDR H3 conformation.  In cetuximab, the conformation 
of CDR H3 sterically blocks the ability of this antibody to accommodate amino acid 
substitutions in EGFR located at the apex of domain III that the antibody paratopes target 
(Figure 4.1).  This sterically ‘locked’ conformation is stabilized by bivalent polar interactions 
between D100 in the VH domain and N91 and Y50 in the VL domain (Figure 4.2). 
The presence of the hydrophobic cavity in necitumumab makes no significant 
difference in quantitative measures of shape complementarity (Lawrence, 1993) (Table 4.4). 
Identifying this cavity in necitumumab capable accommodation of alterations in its target 
prompted us to compare the paratopes of cetuximab and necitumumab to those of other 
fourteen other therapeutic antibodies for which complex structures have been determined 
(Table 4.4).  Analysis of sixteen different antibody paratopes revealed a structural class of 
antibodies that contain buried cavities similar to the one found in necitumumab.  My analysis 
did not reveal a significant correlation between the shape complementarity (Sc) and the 
presence of a buried cavity between the light and heavy chains, nor between the antibody 
origin and shape complementarity.  However, there is a greater ratio of mean interface area 
to shape complementarity in antibodies that contain buried cavities in their paratopes, 
presumably because the antibody must bury more surface area in order to form a cavity.  
Other examples of this trend include MORO9825, KTN3379, and RG7116, all anti-ErbB3 
antibodies that have an Sc statistic of 0.62-0.65.  Comparison of the ratio of buried surface 
area to Sc of KTN3379 to the ratios of MORO9825, and RG7116 reveals that antibodies with 
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higher ratios tend to have larger buried cavities akin to the one found in necitumumab.  While 
there is no physical meaning to this ratio, in combination with contact analysis (MacCallum, 
1996), it may serve as a potentially useful benchmark for evaluating new antibody paratopes 
in terms of the presence of similar buried cavities akin to that of necitumumab and other 
therapeutic antibodies.  Further studies are needed to evaluate whether other such cavities in 
this structural class of antibodies would be less susceptible to resistance through epitope 
mutations such as the ones studied here. 
 
DISCUSSION 
 
Resistance to targeted cancer therapeutics remains a formidable challenge that has 
increased the necessity for the development of combination therapies, and sequential 
therapeutic rechallenge approaches.  Epitope mutations, a major mechanism of cetuximab 
resistance in KRAS wild-type colorectal cancer, induce resistance by decreasing the affinity 
of cetuximab for EGFR.  High affinity cetuximab binding to EGFR is necessary for its ability to 
block ligand binding and conformational changes and therefore EGFR activation.  In the case 
of cetuximab, high affinity EGFR binding is driven through relatively high shape 
complementarity and the presence of a high abundance of bulky aromatic residues in the 
CDR regions.  Presence of bulky aromatic amino acid sidechains in complementarity 
determining regions (CDR’s) and high shape complementarity is often thought necessary to 
promote high affinity binding (Chatellier, 1996; Ohno, 1985), and there have been several 
efforts to increase the prevalence of such bulky residues in therapeutic antibody CDR’s 
(Fisher, 2010).   
I find here that necitumumab is an effective inhibitor of EGFR mutants that cause 
resistance to cetuximab, despite sharing a common epitope.  My structural analysis reveals 
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that hydration of a hydrophobic cavity in the necitumumab paratope is critical for its 
effectiveness in accommodating genetic changes to its epitope.  The presence of this cavity 
is driven by the conformation of CDR H3, which is known to be hypervariable and ‘kinked’ 
(Weitzner, 2015; Xu, 2015) (Figure 4.2).  CDR H3 may be a marker for presence of such a 
buried cavity more generally.  Necitumumab also exhibits structural plasticity in binding less 
rigidly to a genetically altered epitope (Figure 4.5). We find through biochemical analysis that 
it is less sensitive to genetic alterations in its epitope on the EGFR than cetuximab, and may 
be an effective therapeutic agent in the context of cetuximab resistance through epitope 
mutations (Figure 4.3). 
I observe in an X-ray crystal structure of the S468R mutation in domain III of EGFR 
bound to the Fab fragment of necitumumab that hydration of this cavity, as well as several 
cation-pi interactions in the necitumumab paratope may help to stabilize the S468R mutation 
in this hydrophobic pocket.  It is well established that solvation and desolvation of 
antibody/antigen interfaces can play important roles in both enthalpic and entropic 
contributions to antibody/antigen interaction energetics (Acchione, 2009; Bhat, 1994).   
Buried water molecules at antibody/antigen interfaces, in order to contribute favorably to the 
thermodynamics of antibody/antigen binding, must mitigate the inherent entropic penalty 
associated with limiting the degrees of freedom of the water molecules through enthalpic 
contributions through hydrogen bonding networks.   
In the context of the necitumumab interaction with EGFR-S468R, the energetic penalty 
associated with burial of a positively charged residue in a region of low dielectric constant 
would likely be higher than the 2-fold decrease in binding we observed for necitumumab 
binding to sEGFR S468R, supporting the thermodynamic importance of the buried water 
molecule in providing a hydrogen-bond acceptor for the buried guanidinium of the arginine 
sidechain, which is an important enthalpic contribution that stabilizes the buried positive 
charge in this cavity.  Such a trapped water molecule may still, however, lead to an entropic 
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penalty in the thermodynamics of antibody binding to EGFR, and therefore necitumumab 
binding to the S468R mutation could potentially be engineered to be even greater if a direct 
hydrogen bond with R468 were engineered.  The presence of this hydrophobic cavity 
facilitates accommodation of genetic mutations that can cause resistance to antibodies that 
target the same epitope in the EGFR, such as cetuximab and panitumumab.   
While cetuximab and necitumumab are no different in quantitative measures of shape 
complementarity, the method of Colman and Lawrence to quantitate protein/protein interface 
shape complementarity relies on a subset selection of vector normals to surfaces calculates 
in GRASP (Lawrence, 1993).  This calculation, while excellent for evaluating general shape 
complementarity and has been adopted as the most common tool to do so, may not be the 
appropriate calculation for evaluating the presence of a cavity at a protein/protein interface 
due to its exclusion of longer vectors that would penetrate into a buried cavity.   However, 
Thornton and colleagues have developed a computational approach to measure relative 
‘concavity’ of antibody paratopes by contact analysis, which may be a more useful measure 
for distinguishing between antibodies that are capable of exhibiting a similar mode of 
structural plasticity and those that cannot (MacCallum, 1996).  
Although it has been previously reported that panitumumab is also an effective 
inhibitor of the S468R EGFR mutant, there are some differences between cetuximab and 
panitumumab in terms of their mechanism of action.  Cetuximab (IgG1) and panitumumab 
(IgG2) both compete with binding of EGF and other EGFR ligands to EGFR domain III, 
therefore inhibiting receptor activation and signaling.   It is also clear through the case of 
trastuzumab/Herceptin, an ErbB2-directed antibody, that ErbB-targeted antibodies have an 
important role in mediating antibody-dependent cellular toxicity through engaging Fc 
receptors (Arteaga, 2012; Baselga, 2001; Molina, 2001; Spector, 2009).  It is also clear that 
cetuximab and panitumumab both also have an ADCC component that is important to their 
therapeutic effects, and the precise consequences of ADCC are different for IgG1 vs. IgG2 
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antibodies (Schneider-Merck, 2010).  In addition, some of the resistance mutations also 
cause a decrease in binding affinity for panitumumab, like I467M (Arena et al., 2015).  There 
is no X ray crystal structure of panitumumab bound to EGF receptor, but it is possible that 
this loss of affinity is due to a similar steric clash seen in cetuximab. 
There are several developing approaches to overcome mechanisms of resistance to 
anti-EGFR antibodies involving mutations in the antibody epitopes, most commonly antibody 
mixtures of distinct epitopes, of which there are several in clinical trials.  One such mixture 
called Sym-004, is a cocktail of two anti-EGFR monoclonal antibodies with non-overlapping 
epitopes on EGFR domain III (Pedersen, 2010)  This antibody mixture can overcome 
resistance to cetuximab in a cell line derived from non-small cell lung cancer NCI-H226 with 
induced cetuximab resistance, leading to EGFR inhibition and degradation (Iida, 2013).  Data 
from a phase I trial of Sym-004 suggest potent activity in mCRC patients.  However, this 
study did also find that the presence of the S468R mutation in one patient diminished activity 
of Sym-004, which could suggest one of  antibodies may also be susceptible to this mutation 
like cetuximab.  Another similar combination therapy, called Pan-HER, is a combination of six 
synergistic antibodies that simultaneously target epitopes on EGFR, HER2, and HER3 
(Jacobsen, 2015). This antibody combination is effective at inducing growth inhibition of 
several cancer cell lines and xenograft models, including ones with acquired resistance to 
cetuximab, suggesting that simultaneous targeting of several ErbB/HER family members may 
be an effective approach to overcome therapeutic resistance (Jacobsen, 2015).   
Both approaches illustrate the value and effectiveness of evolving combinatorial 
therapeutics, and evaluation of the appropriate synergistic combinations of antibodies for 
such strategies remains an important avenue of investigation.  They also illustrate that most 
commonly exploited functional property of therapeutic antibodies in the context of 
combination therapies is the epitope.  Our analysis shows for the first time that concavity and 
shape of an antibody paratope is another such property that can be exploited as a functional 
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synergism.   We find through comparison of sixteen antibody complex structures that the ratio 
of buried surface area to shape complementarity may be a useful approximate predictor of 
such a cavity to complement existing contact analysis algorithms (MacCallum, 1996).  These 
tools may serve as useful descriptive measures for antibody paratope shape for identification 
of synergistic pairs of antibody paratopes for combination therapies in the context of 
resistance to just one therapeutic.  
 
METHODS 
 
Protein production. 
The secreted full length extracellular region of EGFR (sEGFR; amino acids [aa] 1-
618 of mature EGFR), and of isolated domain III of EGFR (sEGFRd3; aa 1-4 followed by 
311-514) were produced in a baculovirus system from Sf9 cells as described previously 
(Ferguson et al., 2000; Li et al., 2005).  Cetuximab resistance variants were created using 
standard PCR methods and produced exactly as for wild type proteins.  The sEGFR and 
variants were purified by Ni-NTA chromatography, followed by size-exclusion 
chromatography (SEC) as previously described (Ferguson et al., 2000).  For sEGFRd3, an 
additional cation exchange purification step was included prior to SEC.  Cetuximab Fab 
fragment (FabC225) and necitumumab IgG were provided by Imclone Systems Corporation 
(New York, NY).  The necitumumab Fab (Fab11F8) was generated by papain digestion using 
a Pierce Fab Preparation Kit.  Following removal of the Fc on a protein A column, the Fab 
was further purified on a Superose 12 size exclusion chromatography column (GE 
Healthcare) equilibrated in 25 mM HEPES, 100 mM NaCl (pH 7.5). 
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Surface Plasmon Resonance binding studies 
Surface Plasmon Resonance (SPR) experiments were carried out on a Biacore 3000 
instrument at 25°C in buffer containing 25 mM HEPES, pH 8.0, 150 mM NaCl, 3 mM EDTA, 
and 0.005% nonidet-p20 (HBS-EP8) exactly as previously described (Li et al., 2005).  
FabC225 and Fab11F8, at 50 µg/ml in 10 mM sodium acetate, pH 5.5, were separately 
amine coupled to activated CM5 sensor surfaces by 5 minutes exposure at 10 µl/minute.  
EGF (Intergen Inc.) was immobilized at 200 µg/ml in 10 mM sodium acetate, pH 4.0.  A series 
of samples of the relevant sEGFR or sEGFRd3 at different concentrations in HBS-EP 8 buffer 
were injected over these surfaces and the equilibrium SPR response relative to a blank 
control surface (blocked with ethanolamine) was measured.  Injections with contact times of 
25 minutes at 10 µl/min for Fab surfaces and 15 minutes at 5 µl/min for EGF surface were 
used to ensure complete equilibration at all protein concentrations.  Regeneration between 
samples was used to restore baseline SPR response: 1 minute of 10 mM glycine-HCl, 1 M 
NaCl, pH 2.5 for Fab surfaces and 1 minute of 10 mM sodium acetate, 1 M NaCl, pH 4.5 for 
EGF surface.  For wild type sEGFR the equilibrium SPR response for each sample was 
plotted against protein concentration, and the curve fit to a one-site Langmuir binding model 
using Prism 6 (GraphPad Software, Inc.).  The Bmax value from these fits for wild type sEGFR 
binding to each ligand were then used to normalize the equilibrium SPR responses for 
binding of sEGFR variants.  These fraction maximal SPR binding values were plotted against 
concentration and fit to simple one-site Langmuir binding model with the Bmax fixed to 1.0.  
Experiments were conducted at least three times and the mean KD value determined from the 
fits to each independent, normalized binding curve (Table 4.2). 
Crystallization, data collection and structure determination 
For crystallization, samples containing a 1:2 molar ratio of sEGFRd3-S468R and 
Fab11F8 preequilibrated at room temperature for one hour were applied to a Superose 6 size 
exclusion column (GE Healthcare) that had been equilibrated in 25 mM HEPES, 200 mM 
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NaCl, pH 7.5.  Fractions containing the sEGFRd3-S468R/Fab11F8 complex were pooled, 
concentrated to 5-8 mg/ml and crystallized using the hanging drop vapor diffusion method at 
20° C.  Initial needle-like crystals of sEGFRd3-S468R/Fab11F8 were obtained from drops 
comprising 0.5 µl complex in 25 mM HEPES, 100 mM NaCl, pH 7.5 plus 0.5 µl of reservoir 
solution containing 50 mM sodium acetate, 250 mM ammonium sulfate, 15-20% PEG3350, 
pH 5.0.  Crystals appeared within one month.  Diffraction to 3 Å resolution was obtained from 
clusters of such needles but single crystals suitable for data collection could not be obtained.  
Large hexagonal plate crystals were grown using streak seeding with the needle clusters into 
drops containing 0.5 µl complex at 5-7 mg/ml in 25 mM HEPES 200 mM NaCl, pH 7.5 and 
0.5 µl reservoir solution containing 50 mM sodium acetate, 200 mM potassium citrate, 15-
20% PEG3350, pH 6-6.3. Crystals appeared within 2-3 weeks, and continued to grow for 
several months.  These crystals were flash frozen in liquid nitrogen following brief exposure 
to a cryoprotectant of reservoir solution supplemented with 12 % ethylene glycol.  Crystals 
were of space group P21.  Data were collected at the GM/CA APS beamline 23-ID-D using a 
Pilatus 6M detector.  The data were processed in HKL2000 (Otwinowski and Minor, 1997). 
Data collection statistics are summarized in Table 3. 
 The structure of sEGFRd3-S468R/Fab11F8 was solved by the method of molecular 
replacement (MR) using the program PHASER (McCoy, 2007).  Domain III (aa 311-502) and 
Fab11F8 (aa 1-210 from light chain and 1-221 heavy chain) from PDB ID 3B2U were used as 
independent search models to identify the four sEGFRd3-S468R/Fab11F8 complexes in the 
asymmetric unit. Clear electron density for the arginine side chain at position 468 could be 
seen in initial molecular replacement maps.  Initial stages of refinement used rigid body 
groups to refine the positions of the Fab variable domains.  Further manual refinement 
proceeded with iterative rounds of manual model rebuilding in COOT (Emsley, 2010) and 
refinement in PHENIX (Adams et al., 2010).  Later stages of refinement included TLS 
refinement using each chain as a TLS group.  To check for possible model bias, simulated 
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annealing composite omit maps were calculated in PHENIX and CNS (Brunger et al., 1998) 
using torsion angle dynamics at 2500 K. 
Structure Analysis. 
Structures were overlaid and RMSD values were calculated using the programs PYMOL 
(Delano Scientific, Palo Alto, CA), or COOT (Emsley, 2010), and reflect main chain atoms 
only.  Shape complementarity values were calculated using the Sc module in CCP4 
(Lawrence, 1993), excluding saccharide, ligand, and solvent molecules. Buried interface 
surface area was calculated using the PISA server.  Most of the X ray diffraction and 
structural analyses were completed using software compiled on SBGrid (Morin, 2013). 
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CHAPTER FOUR TABLES 
Table 4.1. 
 
Mutation Alternate 
numbering 
Cetuximab treated 
patients 
Panitumumab 
treated patients 
Cetuximab 
exposed cell line 
S440L S464L   X 
G441R G465R X X X 
G441E G465E X X  
K443T K467T X   
I467M I491M   X 
S468R S492R X  X 
 
Table 4.1.  Acquired antibody resistance mutations in the cetuximab/panitumumab 
epitope of EGFR (Arena et al., 2015; Bertotti et al., 2015; Montagut et al., 2012; 
Siravegna, 2015). 
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Table 4.2. 
 
 
Immobilized 
Ligand 
KD Values for binding to sEGFR (nM) 
WT S440L I467M K443T S468R 
FabC225 5.7 ± 0.5 >> 4000 296 ± 50 670 ± 103 >> 4000 
Fab11F8 6.4 ± 0.9 53.7± 7.3 27.4 ± 1.5 13.8 ± 0.4 12.4 ± 1.4 
EGF 147 ± 16 93.7± 10  175.9 ± 10.9 256 ± 25 107 ± 12 
 
Table 4.2. Mean KD values for binding of sEGFR wild type and cetuximab resistance 
mutations to immobilized Fab fragments of cetuximab (FabC225) and necitumumab 
(Fab11F8) and to EGF.   
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Table 4.3. 
	 Table 4.3. X-ray diffraction data collection and refinement statistics  
 
 sEGFRd3-S468R/Fab11F8 
Data collection  
Space group P21 
Cell dimensions    
    a, b, c (Å) 151.9, 80.8, 172.9 
    α, β, γ  (°)  90, 91.5, 90 
Resolution (Å) 2.8 (2.9-2.79)   
Rmerge 0.18 (0.72) 
I / σI 8.4 (1.2) 
Completeness (%) 96.4 (94.3) 
Redundancy 4.1 (2.8) 
  
Refinement  
Resolution (Å) (dmin) 50-2.8 (2.83-2.79) 
No. unique reflections 99,558 
Rwork / Rfree 0.236/0.256 (0.352/0.367) 
No. atoms  
    Protein 19,545 
    Ligand/ion 28 
    Waters 142 
B-factors  
    Protein 68.06 
    Ligand/ion  
    Water  
R.m.s. deviations  
    Bond lengths (Å) 0.002 
    Bond angles (°) 
Ramachandran favored (%) 
Ramachandran outliers (%) 
Rotamer outliers (%) 
0.677 
95.6 
0.4 
0.4 
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Table 4.4.  Structural features of selected therapeutic antibody/antigen interfaces. 
 
Therapeutic 
antibody 
(target 
antigen) 
PDB ID Source A.S.U. Sc statistic 
 
(Lawrence, 
1993) 
Interface 
area (Å2) 
Mean ratio 
of interface 
area to Sc 
(Å2) 
Cavity 
Necitumu-
mab/IMC-
11F8 (EGFR 
domain III 
wild-type) 
3B2U Humanized 
from 
chimeric 
library 
8 0.68± 0.03 878.1± 
29.3 
1292.5 Y 
Necitumu-
mab/IMC-
11F8 (EGFR 
domain III 
S468R) 
T.B.D
. 
Humanized 
from 
chimeric 
library 
4 0.69± 0.02 895.9± 
54.8 
1300.3 
 
Y 
Cetuximab/ 
IMC-225 
(EGFR) 
1YY9 Chimeric 1 0.703 875 1244.7 
 
N 
Sifalimumab 
(IFN-α2A) 
4YP
G 
Undisclosed 2 0.676± 
0.004 
1260.3± 
0.03 
1864.3 Y 
Fab 3379 
(ErbB3) 
5CU
S 
Undisclosed 4 0.654± 0.03 835.9± 
12.7 
1279.1 I 
MORO9825 
(ErbB3) 
4P59 Phage 
display 
selected 
from human 
combinatorial 
antibody 
library 
(HuCAL 
GOLD) 
1 0.626 1140.3 1821.6 Y 
(aP2) 5C0N Cloned and 
purified from 
rabbits 
2 0.612± 0.05 456.8± 
12.8 
746.9 
 
N 
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immunized 
with 
recombinant 
human and 
mouse aP2  
(aP2) 5D8J Cloned and 
purified from 
rabbits 
immunized 
with 
recombinant 
human and 
mouse aP2 
1 0.722 721.7 999.6 N 
(Jag1) 5Bo1 Phage 
display 
selected with 
recombinant 
human JAG1 
and JAG2 
from mouse 
and human 
from an 
undisclosed 
library 
2 0.75± 0.02 992± 15 1323.7 Y 
Onartuzumab 
(c-MET) 
4K3J Hybridomas 
from mice 
immunized 
with 
recombinant 
Met IgG and 
subsequently 
humanized 
and affinity 
matured 
1 0.772 831.1 1076.6 
 
Y 
Fab 39.29 
(Influenza 
hemaglutin A) 
4KV
N 
Cloned and 
selected 
from mice 
immunized 
with 
influenza 
strain 
combination  
1 0.761 1058.2 1390.5 
 
I 
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RG7116 
(ErbB3) 
4LEO Cloned from 
mice 
immunized 
with 
recombinant 
ErbB3, and 
subsequently 
humanized 
and 
glycoenginee
red 
1 0.64 927 1448.4 
 
Y 
Infliximab 
(TNFα) 
4G3Y Undisclosed 1 0.629 941.1 1496.2 I 
Canakinumab 
(IL-1β) 
4G6J human IgGκ 
monoclonal 
antibody of 
undisclosed 
origin 
1 0.726 950.6 1309.3 
 
I 
Basiliximab 
(IL-2Rα) 
3IU3 Chimeric 
mouse-
human 
antibody 
3 0.561± 0.01 1023.4±67
.3 
1825.4 Y 
(Notch1 NRR) 3L95 Phage 
display 
selected 
from human 
antibody 
library 
2 0.715± 0.02 871.2±20.
6 
1219.3 
 
N 
Daclixumab 
(IL-2Rα) 
3NFP Undisclosed 2 0.586± 
0.001 
916.6±78.
2 
1564.2 
 
I 
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CHAPTER FOUR FIGURES 
	
	
Figure 4.1  Structural basis for Necitumumab inhibition of EGFR-S468R. 
Necitumumab accommodates the S468R cetuximab resistance mutation in a buried 
hydrophobic cavity between its VH and VL domains that is hydrated in the structure of 
sEGFRd3-S468R bound to the Fab fragment of necitumumab (Fab11f8).  This buried water 
molecule, coordinated by S35 (in Chothia numbering), in addition to a hydrogen bond with the 
backbone carbonyl from G100A in the VL domain, and several cation-pi interactions due to 
the proximity of R468 to F100C, Y33 and Y50 in the VH domain, serve to stabilize the basic 
guanidinium moiety of R468 in this region of low dielectric constant.  
 
Fab11f8 
sEGFR 
S468R 
VL 
VH 
S468R Y50 
Y33 Y91 
V100 G100A 
L3 
H2 
H1 H3 
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Figure 4.2. EGFR-S468R interacts with a hydrophobic cavity in necitumumab with high 
electronegativity. (A) & (B) Electrostatic potential calculated in APBS (Baker, 2001) and 
mapped onto the surfaces of the respective antibody paratope surfaces show that cetuximab 
and necitumumab have similar electrostatic potential properties of their paratopes.  In both 
antibodies, there is a region of relatively high electronegative potential close to the region of 
the EGFR-S468R mutation. (C) & (D) Comparison of the paratopes of necitumumab and 
cetuximab reveals that the presence of the hydrophobic cavity in necitumumab is a 
consequence of CDR H3 conformation.  In cetuximab, the CDR H3 conformation may be 
stabilized by several polar interactions, and a salt bridge between D100 and N91, as a 
consequence poising the sidechain of Y100A to clash with the site of mutations associated 
with acquired cetuximab resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
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Figure 4.3.  Necitumumab binds with high affinity to EGFR mutations that cause 
cetuxumab resistance.  Samples of the indicated concentrations of sEGFR and variants 
were passed over Biacore surfaces to which (A) Fab11f8 (Necitumumab), (B) FabC225 
(Cetuximab) and (C) EGF had been immobilized.  Fabs and EGF were immobilized on 
Biacore CM5 chips using amine coupling.  Binding assay and data processing were 
conducted as described in the experimental procedures.  Representative, normalized binding 
curves are show and mean KD values are reported in Table 2.  
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Figure 4.4.  Electron density around one example of R468 in sEGFRd3-S468R/Fab11F8 
structure. 
(A)  MR model is shown with domain III in green, VH in orange and VL in yellow.  Main chain 
ribbon is shown and side chains are shown as lines. S468 is shown as in stick 
representation.  A 2mFo-DFc map from this PHASER model is shown contoured at 1.0 σ.  (B)  
Current model is shown, displayed as in A with the corresponding 2mFo-DFc map. 
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Figure 4.5.  Necitumumab exhibits a structural ‘wobble’ in binding to EGFR-S468R.  
(A) Comparison of the necitumumab complexes of wildtype sEGFRd3 and sEGFRd3-S468R, 
using only the coordinates of domain III to overlay the structures. Domain III is shown in grey 
with the side chain at position 468 shown in stick representation; S468 in yellow and R468 in 
cyan. The Fab is in yellow (VL) and pale orange (VH) when bound to wild type sEGFRd3 and 
in brown (VL) and orange (VH) when bound to sEGFRd3-S468R. Minor differences can be 
discerned in the relative positions of the VH and VL chains and in the positions of several 
side chains. (B) A similar domain III superposition of the 4 examples of the sEGFRd3-
S468R/Fab11F8 complexes in the asymmetric unit show that there are significant differences 
in the positions of the Fab with respect to domain III in each copy of the complex. For the 
complex show in A VH in orange and VL in yellow. The other 3 complexes are show in grey. 
(C) A similar overlay of all 8 complexes of sEGFRd3/Fab11F8 from PDB ID 3B2U shows that 
the 8 structures are much more similar.  
 
 
 
 
 
 5 
SUPPLEMENTARY FIGURE S3. 
Necitumumab exhibits structural plasticity in binding to sEGFRd3-S468R. 
 
 
A.  Comparison of the necitumumab complexes of wildtype sEGFRd3 and sEGFRd3-S468R, using only the coordinates of domain III 
to overlay the structures.  Domain III is shown in grey with the side chain at position 468 shown in stick representation; S468 in 
yellow and R468 in cyan.  The Fab is in yellow (VL) and pale orange (VH) when bound to wild type sEGFRd3 and in brown (VL) and 
orange (VH) when bound to sEGFRd3-S468R.  Minor differences can be discerned in the relative positions of the VH and VL chains 
and in the positions of several side chains.  B.  A similar domain III superposition of the 4 examples of the sEGFRd3-S468R/Fab11F8 
complexes in the asymmetric unit show that there are significant differences in the positions of the Fab with respect to domain III in 
each copy of the complex.  For the complex show in A VH in orange and VL in yellow.  The other 3 complexes are show in grey.  C. A 
similar overlay of all 8 complexes of sEGFRd3/Fab11F8 from PDB ID 3B2U shows that the 8 structures are much more similar. 
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CHAPTER FIVE 
Structural basis of specific targeting of oncogenic 
EGFRvIII by a camelid antibody/VHH domain. 
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SUMMARY 
 
Despite its clinical significance, it is not understood how oncogenic EGFR variant III, 
an aberrant EGFR gene rearrangement, found in ~30-50% of glioblastoma multiforme (GBM) 
cases, causes documented constitutive transactivation of EGFR and MET tyrosine kinases.  
Because the EGFRvIII ectodomain mutation renders a unique tumor-specific antigen, it has 
been an attractive target antigen for several types of immunotherapies.  Consequently, there 
has been significant interest in raising antibodies with specificity for EGFRvIII over wild-type 
EGFR.  I present a 2.9 angstrom X-ray crystal structure of the extracellular region of the 
EGFR mutant vIII (sEGFRvIII) with an unpaired cysteine mutated to serine (C16S) in complex 
with a camelid antibody.  This VHH domain, the variable domain from a heavy chain only 
camelid antibody, was generated by Paul van Bergen en Henegouwen (Utrecht University) by 
selection from a library for VHH domains that selectively bind EGFRvIII and not EGFR.  I 
show that this VHH domain has a 25-fold specificity for sEGFRvIII over wildtype sEGFR.  My 
X-ray crystal structure of the VHH in complex with the extracellular region of EGFRvIII 
reveals that this heavy chain only camelid antibody targets a novel epitope on EGFR domain 
IV that is occluded by the intramolecular ‘tether’ in wild-type EGFR.  The structural basis for 
EGFRvIII targeting by this VHH domain is the first structural view of specific antibody 
targeting of EGFRvIII and supports further analysis of this VHH domain as a potential tool for 
specifically targeting this important oncogenic EGFR variant.  As previously observed by 
others in the Ferguson laboratory, domain II of EGFRvIII in the sEGFRvIII/VHH structure is 
poorly ordered.  Small angle X-ray scattering analysis suggest that domain II of sEGFRvIII 
adopts multiple conformations, I suggest may play a role in the ability of EGFRvIII to 
transactivate other receptor tyrosine kinases, such as MET.  
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INTRODUCTION 
 
Mutation and overexpression of receptor tyrosine kinases (RTKs) is often associated 
with cellular transformation and is found in many human cancers. EGFR amplification and 
subsequent overexpression is a common molecular feature of glioblastoma multiforme 
(GBM), occurring at a frequency of 34-63% (Ekstrand, 1991; Heimberger, 2005; Libermann, 
1985; Shinojima, 2003).  Historically, one of the first viral oncogenes to be discovered from 
avian erythroblastosis virus was v-ErbB, which encodes a large extracellular truncation of the 
epidermal growth factor receptor (EGFR), and results in its elevated, constitutive tyrosine 
kinase activity and thereby cellular transformation (Downward, 1984).  The most common 
EGFR mutation found in glioblastoma multiforme (GBM) is a similar extracellular truncation of 
EGFR called EGFR variant III (EGFRvIII) (Wong, 1992).  EGFRvIII is reported to be present 
in ~30-50 % of glioblastoma cases and also less commonly in other cancers, such as lung, 
head and neck, and colorectal carcinomas (Gan, 2013).  
EGFRvIII is a transforming, oncogenic alternative splice variant of EGFR that results 
in an exclusion of its exons 2-7 (it is also referred to as del2-7), which encodes a receptor 
missing a large portion of its ectodomain (mature amino acid residues 6-273) that includes all 
of domain I and much of domain II.  The deletion includes both the domain I contribution to 
the ligand binding site and the part of domain II indispensable for wild-type EGFR 
dimerization (Dawson, 2005).  EGFRvIII retains low-level, constitutive kinase activity and is 
classified as an oncogene (Gan, 2013).  In this way it is reminiscent of v-erbB, which also has 
a large ectodomain deletion that includes the ligand-binding domains, leaving only a short 
portion of domain IV.  The expression of EGFRvIII has also been recently reported to 
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regulated by epigenetic mechanisms, as inhibition of histone deacetylation can decrease 
expression of EGFRvIII in glioma cell lines by 50-80% (Del Vecchio, 2013).  
Recent phosphoproteomic analysis of the glioblastoma cell lines U87MG and 
U373MG by White and colleagues has revealed EGFRvIII signaling networks that are quite 
distinct from wild-type EGFR, and involve transactivation the receptor tyrosine kinase MET 
(Huang, 2007; Johnson, 2012).  Indeed, dual inhibition of EGFR and MET increases 
cytotoxicity of EGFRvIII-expressing glioma cell lines and greater survival in an intracranial 
mouse model of glioma (Greenall, 2015b; Huang, 2007).  Moreover, transactivation of MET 
by EGFRvIII leads to resistance to the antibody rilotumumab, which binds to and neutralizes 
the MET ligand HGF (Pillay, 2009).  It has also been found that ErbB2 can inhibit 
phosphorylation of EGFRvIII through possible heterodimerization with EGFRvIII (O'Rourke, 
1998).  In recent years it has also been suggested that constitutive phosphorylation of 
EGFRvIII and downstream signaling may require coexpression of EGFRvIII with wild-type 
EGFR (Fan, 2013), which would support the notion that hetero-oligomerization with other 
receptors is likely relevant for EGFRvIII-mediated signaling (Greenall, 2015b).  It is not 
understood mechanistically how this cooperation of EGFRvIII and EGFR leads to 
transactivation of EGFR and MET tyrosine kinases and subsequent activation of STAT3/5, 
and thereby cellular transformation.   
The wild-type EGFR extracellular region contains two-cysteine-rich domains, 
domains II and IV. The 50 ectodomain cysteine residues are organized into 25 disulfide 
bonds (Ferguson et al., 2003). The EGFRvIII deletion reduces the number of cysteine 
residues to 29 and leaves an unpaired cysteine in domain II (Cys283 in mature numbering for 
wild-type sEGFR). It is clear from other receptor tyrosine kinase mutations that the presence 
of an unpaired ectodomain cysteine residue often produce significant changes in receptor 
activation mechanisms and has the potential to alter receptor trafficking, signaling, and 
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proliferative capacity (Greenall, 2015a).   For EGFRvIII, the presence of this unpaired 
cysteine was shown previously to contribute to disulfide mediated dimerization, and that 
mutation of the unpaired cysteine to a serine reduces dimerization and activation of EGFRvIII 
(Ymer, 2011).  In addition, a xenograft model of EGFRvIII C16S showed reduced 
tumorigenicity compared to ‘wild-type’ EGFRvIII (Ymer, 2011).  However, EGFRvIII 
transactivation of MET does not require covalent disulfide mediated dimerization, suggesting 
that intrinsic structural properties of EGFRvIII contributes to its hetero-oligomerization with 
other RTK’s and its oncogenic signaling properties (Greenall, 2015b).   
Previous unpublished work in the Ferguson laboratory suggests that a secreted 
protein with the unique N-terminal cysteine substituted with serine does not aggregate and is 
a good model protein to study the solution properties of sEGFRvIII.  Furthermore, this 
previous work in collaboration with Graham Carpenter at Vanderbilt University structurally 
and biochemically examined EGFRvIII to determine how the unpaired cysteine residue in 
domain II contributes to intracellular trafficking of EGFRvIII.   This work found that the 
unpaired cysteine of EGFRvIII contributes to disulfide-mediated crosslinking of EGFRvIII, 
which sequesters a population of EGFRvIII in the endoplasmic reticulum, consistent with a 
recent study (Greenall, 2015b).  Mutation of this cysteine to serine permits trafficking of 
EGFRvIII to the cell surface and increases survival of an intracranial murine .  Furthermore, in 
an X-ray crystal structure of the extracellular region of EGFRvIII (sEGFRvIII) C16S alone (K. 
R. Schmitz, K. M. Ferguson, unpublished data), the portion of domain II that remains in 
EGFRvIII is poorly ordered.   
I observe by small-angle X-ray scattering that there is an increase in the radius of 
gyration for sEGFRvIIIC16S compared to ‘tethered’ EGFRvIII models.  I speculate that this 
may be due to disorder in domain II and that this dynamic molecular feature may have 
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implications for understanding the structural basis of EGFRvIII-mediated hetero-
oligomerization and oncogenic signaling.   
Because EGFRvIII is a tumor specific antigen, there has been a lot of interest over 
the last two decades in raising antibodies that specifically target EGFRvIII over wild-type 
EGFR (Johns, 2002; Luwor, 2001; Wikstrand, 1995) for clinical applications.  Many such 
antibodies are either in clinical development, such as mAb806 (Johns, 2002; Reilly, 2015), or 
used in the context of chimeric antigen receptor-T cell therapies for glioblastoma multiforme, 
such as 3C10 (Johnson, 2015; Takasu, 2003).  I determined a 2.9 Å X ray crystal structure of 
the EGFRvIII C16S ectodomain in complex with VHH domain 34E5, that was selected on the 
basis of its ability to bind to EGFRvIII and not to wild type EGFR (P. van Bergen en 
Henegouwen, personal communication). I show that this VHH also has ~25-fold specificity for 
sEGFRvIII over wild-type sEGFR in a Biacore binding assay (Figure 5.5).  VHH domains are 
increasingly emerging as potential tools for several therapeutic and imaging applications, and 
we previously reported X-ray crystal structures of three inhibitory nanobodies/VHH domains 
in complex with sEGFR (Schmitz, 2013).  I discovered in the X-ray crystal structure of 34E5 
bound to the extracellular region of EGFRvIII that the VHH domain targets a novel epitope on 
EGFR domain IV that in wild-type EGFR is sterically occluded by the intramolecular ‘tether’ 
between domains II and IV.  Therefore, the VHH functionally mimics the intramolecular 
‘tether’ between cysteine rich domains II and IV.  Our structural analysis of nanobody/VHH 
targeting of a sterically occluded epitope in EGFR reveals a mechanism by which antibody 
specificity for oncogenic EGFRvIII can be achieved, and provides direct evidence of dynamic 
uncoupling of the intramolecular ‘tether’ in wild-type EGFR. 
 
In the next sections I will describe unpublished data from others in the Ferguson lab that set 
the stage for my studies on sEGFRvIII.  
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Role of Cys16 in EGFRvIII Dimerization.  
A soluble recombinant form of the extracellular region of EGFRvIII (sEGFRvIII) was 
previously produced using baculovirus infected Sf9 cells and purified exactly as described 
(Ferguson et al., 2000; Ferguson et al., 2003).  It was shown that the protein secreted from 
the Sf9 cells existed in two distinct populations that could be partially separated during 
purification.  One population was largely monomeric, as assessed by size exclusion 
chromatography. This population eluted from the initial Ni-NTA affinity purification column 
with low imidazole concentrations (50 - 75 mM).  The second population eluted predominantly 
at higher imidazole concentrations (> 100mM) and showed clear evidence of aggregation by 
size exclusion chromatography (data not shown).  Non-reducing SDS-PAGE suggested that 
this population contains multiple species of disulfide-linked oligomers.  These two populations 
do not interconvert, further supporting that the aggregation is through covalent interactions. 
It was reasoned that this aggregation could be due to the presence of an unpaired 
cysteine in the N-terminal region of sEGFRvIII.  In contrast to the wild type EGFR, the 
ectodomain of the vIII mutations has an odd number of cysteines.  The obvious choice for the 
unpaired cysteine is Cys16 in EGFRvIII (equivalent to Cys283 in mature EGFR, Fig. 5.1A. An 
sEGFRvIII variant with a serine at position 16 (C16S) was secreted from Sf9 cells as a largely 
monomeric and monodisperse protein.  The majority of this protein behaved as a single 
monomeric species, although there remains a small (< 1%) population of disulfide-linked 
aggregates (Ferguson laboratory unpublished data, not shown). 
To assess the influence of C16 in the oligomerization of EGFRvIII in cells, the 
Ferguson laboratory collaborated with Graham Carpenter’s lab to express the full length wild-
type EGFRvIII or EGFRvIII C16S mutant in HEK 293T cells and analyzed the expressed 
protein on non-reducing SDS gels. The Carpenter lab showed that EGFRvIII formed an 
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equivalent level of monomers and dimers, while the EGFRvIII C16S mutant formed only 
monomers. 
 
Influence of C16S on EGFRvIII Intracellular Trafficking.   
Previous reports have shown that the EGFRvIII is not trafficked efficiently to the cell 
surface, but it is not understood what molecular mechanisms contribute to this inefficient 
processing through the secretory pathway. A population of EGFRvIII receptors are 
sequestered in the secretory pathway (Wikstrand, 1997), and the population of EGFRvIII that 
does reach the cell surface are not internalized rapidly (Grandal, 2007).  A previous Ferguson 
laboratory collaboration with Graham Carpenter’s laboratory found a direct role of the C16S 
mutation on EGFRvIII trafficking. The Carpenter lab showed in these experiments that the 
vast majority of wild-type EGFR is present at the cell surface with a small intracellular pool 
detectable.  In contrast, the results show that EGFRvIII is predominantly present in 
intracellular pools on a reticular lattice that resembles the distribution of ER.  Similar 
experiments of EGFRvIII with the unpaired cysteine residue mutated to serine suggest that 
the intracellular pool of EGFRvIII C16S is diminished relative to EGFRvIII (G. Carpenter, 
personal communication, data not shown). These data in addition show that in HEK293T 
cells, EGFRvIII exists as a mixture of monomers and dimers.  The ER localization of 
EGFRvIII is consistent with the slow conversion of monomers to dimer species due to the 
delayed formation of intermolecular compared to intramolecular disulfides, as observed with 
secreted immunoglobulins (Nag, 2015). 
If EGFRvIII is predominately located in the endoplasmic reticulum, then its 
glycosylation would be of the immature or high-mannose type.  In contrast, the EGFRvIII 
C16S mutant, if more efficiently processed to the cell surface, should have complex 
oligosaccharide chains.  The types of oligosaccharide present on these molecules can be 
distinguished by sensitivity to endoglycosidase H, which selectively cleaves high-mannose 
oligosaccharides (Maley, 1989; Tarentino, 1974).  The Carpenter lab demonstrated that the 
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while EGFRvIII is sensitive to Endo H digestion, the C16S is mutant is relatively resistant. 
The results of Endo H digestion of EGFRvIII compared to the completely non-glycosylated 
form of EGFRvIII produced in the presence of tunicamycin (Oslowski, 2011) further support 
the conclusion that the cysteine mutant contains complex glycans where the ‘wild-type’ 
EGFRvIII contains predominantly high mannose glycans (G. Carpenter, personal 
communication, data not shown).  Therefore, while EGFRvIII is characterized by the 
presence of high-mannose oligosaccharides typical of ER localized proteins, the EGFRvIII 
C16S mutant contains complex chains typical of cell surface proteins. 
 
X-ray crystal structure and small angle X-ray scattering of sEGFRvIIIC16S.  
A previous member of the Ferguson laboratory, Karl Schmitz, determined a 2.5 Å 
resolution X ray crystal structure of sEGFRvIII C16S alone.  Refinement of this structure 
revealed that the part of domain II that is left in EGFRvIII (mature amino acids 274-310) is 
disordered.  Domains III and IV of the sEGFRvIII C16S structure are well ordered and adopt 
a very similar conformation to that observed in other structures of sEGFR (Fig. 5.2B).  
Domain II is not well ordered and very little of this part of the protein can be modeled, 
although fragmented density provide some hints as to the location of this key part of the 
sEGFRvIII molecule.   
There is an antiparallel dimer in the asymmetric unit, with two disordered domain II 
units in apposing molecules facing toward one another.  If this oligomer is populated at the 
cell surface, any unpaired cysteine in domain II of EGFRvIII (such as C16) would be poised 
to form an intermolecular disulfide bond.  However, in the absence of disulfide crosslinking 
the sEGFRvIIIC16S is monomeric as assessed by sedimentation equilibrium analytical 
ultracentrifugation of 8 µM receptor (Figure 5.1).  As noted above, even this form of 
sEGFRvIII with an even number of cysteines has a propensity to form disulfide mediated 
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oligomers when secreted from insect cells, suggesting that there may be some level of 
disulfide mixing in the domain II portion of sEGFRvIII.  For the wild type EGFRvIII both when 
secreted from Sf9 cells and when expressed as the full-length receptors in HEK293T cells, 
there is clear indication that disulfide mediated dimers form.   
 
 
RESULTS 
Small-angle X-ray scattering analysis of sEGFRvIII C16S reveals a larger Rg compared 
to ‘tethered’ sEGFRvIII models. 
 
I turned to small angle X ray scattering (SAXS) analysis of the purified EGFRvIII 
extracellular region – using the monodisperse C16S mutant, as the ‘wild-type’ EGFRvIII 
extracellular region is prone to aggregation – to investigate intrinsic structural properties of 
the EGFRvIII extracellular region in solution that may play a role in its transactivation of other 
RTK’s and its internalization properties.  I performed SAXS experiments at concentrations 
ranging from ~2.5 mg/ml to ~12 mg/ml.  Linear Guiner regions were observed at all three 
concentrations, suggesting no sign of aggregation.  Analysis of the pairwise interatomic 
distance distribution functions calculated by inverse Fourier transformation of the raw 
scattering data revealed a ~5 Å increase in the radius of gyration (Rg) of EGFRvIII C16S 
compared to either models of ‘tethered’ EGFRvIII (based on PDB ID 1NQL) or the model of 
EGFRvIII C16S alone determined by Karl Schmitz. The P(r) interatomic vector distribution is 
overall shifted towards larger distances, but with about the same maximum interatomic 
distance (Dmax) of about 100 Å, consistent with the Dmax calculated for a model of ‘tethered’ 
EGFRvIII alone (97 Å) in CRYSOL (Svergun, 1995).  These data are consistent with the 
ability of domain II being able to adopt alternate conformations and the increased flexibility of 
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the domain III/IV relationship as observed by the altered hinge angles between domains III 
and IV in the X-ray crystal structures of sEGFRvIII.  I speculate that such increased flexibility 
of domain II as a result of a loss of stabilizing interactions with domain I could allow EGFRvIII 
to more accessibly heterodimerize with and cause transactivation of other receptor tyrosine 
kinases and covalently dimerize with other EGFRvIII receptors.  
 
X-ray crystal structure of sEGFRvIII C16S in complex with 34E5 VHH. 
 
I had hoped to stabilize an alternate conformation of domain II to observe 
crystallographically by exploiting a camelid antibody that had been phage display selected for 
binding to EGFRvIII.  The VHH library had been generated from the lymphocytes of lama 
glama that had been immunized with A431 cells (a breast cancer cell line that overexpresses 
EGFR).  I purified and crystallized sEGFRvIII C16S in complex with this EGFRvIII-selected 
VHH domain (34E5).  Crystals of P1 symmetry were produced by the hanging drop vapor 
diffusion method and diffracted to 2.9 Å resolution and the structure was solved by molecular 
replacement by sequentially identifying domain III, IV, and subsequently the VHH.  
The X ray crystal structure of the VHH/sEGFRvIII complex reveals that this 
nanobody/VHH targets a novel epitope on domain IV that is sterically occluded by the 
intramolecular ‘tether’ between domains II and IV observed in wild-type sEGFR structures 
(Figure 5.6).  Similar ‘tethers’ are observed in structures of ErbB3, and ErbB4.  In contrast, 
ErbB2 is constitutive ‘extended’ as a monomer (Lemmon, 2014).   Therefore, this VHH gains 
specificity for EGFRvIII through targeting a sterically occluded epitope in wild-type EGFR that 
is not sterically occluded in EGFRvIII due to its lack of a ‘tether’. 
The conformation of domain III is very similar to that in other sEGFR structures.  
Domain III in the sEGFRvIII C16S/VHH complex overlays with domain III in the 
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sEGFR/cetuximab complex structure (PDB ID 1YY9) with an RMSD of 0.439 Å and with 
domain III in 1NQL with an RMSD of 0.446 Å. Domain IV exhibits a larger ~10 degree ‘swing’ 
out from sEGFR in PDB ID 1YY9 to adopt a more extended conformation.  This domain IV 
trajectory is ~15 degrees in the opposite direction from the antibody unbound structure of 
sEGFRvIII (Figure 5.5). The interface area between the VHH and EGFRvIII is 766 Å2, with a 
shape complementarity statistic of 0.674 (Lawrence, 1993), comparable to therapeutic 
monoclonal antibodies that target EGFR (Li, 2008; Li et al., 2005). 
The majority of the VHH interaction with EGFRvIII domain IV is made by contacts 
from CDR3, which extends into a groove in domain IV between two strands (Figure 5.4C).  At 
the focal point in CDR3, there is a cluster of polar interactions with the region of EGFRvIII 
domain IV that normally interacts with the β hairpin in domain II in tethered sEGFR structures 
(Figure 5.4C).  At the tip of this loop, Arg102 in the VHH forms hydrogen bonds with the 
mainchain backbone carbonyls from Ala559 and Cys558 in EGFRvIII domain IV.  The 
guanidinium moiety of this arginine sidechain is also stabilized in this position by a cation-pi 
interaction with its neighboring residue Tyr101, which also forms several polar mainchain 
interactions with domain IV, as well as an aromatic pi-stacking interaction with the sidechain 
of His591.  Along with another flanking tyrosine, Tyr104 in CDR3, and Tyr37 from CDR1, 
these tyrosines form important van der Waals interactions with EGFRvIII.  An ordered lysine, 
K96 in CDR3 hydrogen bonds with the backbone carbonyl from Pro565 in EGFRvIII.  In 
addition, Gln557 of EGFRvIII hydrogen bonds with the backbone carbonyl of Arg102 in the 
VHH. His594 in EGFRvIII in engaged in a bivalent polar interaction with Asp54 in CDR2 and 
a possible cation-pi interaction with Phe31 in CDR1.  Finally, Ser56 in CDR2 is engaged in a 
hydrogen bond with an ordered Lys585 in EGFRvIII. 
More of domain II can be resolved in this structure than in the antibody-unbound 
structure, possibly due to a weak crystal contact with the portion of the VHH distal to its 
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CDR’s.  In the antibody unbound structure, arginine 44/310 at the domain II/III boundary 
makes a salt bridge interaction with glutamate 110/376 in domain III.  This interaction is also 
observed in other tethered sEGFR structures but is broken in the ligand bound structures due 
to dramatic local conformational change at the domain II/III boundary that must occur for 
EGFR to transitions from the tethered unliganded state to the extended ligand bound 
conformation (Fig. 5.2G).  The conformation of sEGFR with the last disulfide-bonded module 
of domain II (m8) tucked “under” domain III must be favored even in the absence of the 
domain II/IV tether or of an intact domain I/II fragment.  Consistent with this the isotropic 
temperature factors in the domain II/III boundary region of tethered sEGFR are low whereas 
for the ligand bound structures this region has higher than average B-values.    
In the VHH bound structure, electron density for the Arg310 sidechain is clearly 
resolved in one of the two complexes in the asymmetric unit and absent in the other.  In the 
complex with density for R310, it is hydrogen bonding with a Ser117 in the VHH, in a crystal 
lattice contact.  Glu376 is instead engaged in a salt bridge with Arg403 in domain III, in both 
complexes in the asymmetric unit.  Electron density N-terminal to the first disulfide module in 
domain II remains too poorly resolved to accurately model.  Isotropic B factors for the part of 
domain II that is modeled are quite high (>120), suggesting a high degree of disorder and 
possible flexibility in this portion of EGFRvIII. 
 
 
DISCUSSION 
 
Previous work in the Ferguson laboratory showed that the unpaired cysteine in 
EGFRvIII contributes to disulfide-mediated dimerization of EGFRvIII, consistent with a 
previous study that the free cysteine contributes to oligomerization of EGFRvIII (Greenall, 
2015b).  This effect contributes to EGFRvIII being sequestered in early in the secretory 
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pathway, in the endoplasmic reticulum.  While abrogating this effect is not required for MET 
transactivation, it does cause decreased oncogenic potential and greater survival of a murine 
intracranial model of glioma (Ymer, 2011).  This suggests that sequestration of EGFRvIII in 
the endoplasmic reticulum affects its downstream signaling – suggesting that the intracellular 
location of these mutated receptors is critical for their capacity to cause oncogenic signaling.  
There are several well-documented examples of receptor tyrosine kinases having distinct and 
oncogenic signaling properties when their trafficking is and processing in the secretory 
pathway is altered (Choudhary, 2009; Schmidt-Arras, 2009).  One related example of this is 
TrkAIII, another oncogenic alternative splice variant of the RTK TrkA that removes its exons 6 
and 7, resulting in a removal of its D4 Ig-like domain and causing its mislocalization, 
ERGIC/COPI-associated activation, and oncogenic Akt signaling (Farina, 2015).  Two 
examples of internal tandem duplication (ITD) events that cause sequestration of RTKs in the 
endoplasmic reticulum or Golgi apparatus also include FLT3 and KIT (Schmidt-Arras, 2009).  
The c-KIT ITD in its juxtamembrane region, found in childhood acute myeloid leukemia 
(AML), has been linked to ligand-independent KIT activation and transformation of a Ba/F3 
model (Corbacioglu, 2006).    
My solution X-ray scattering analysis of the in vitro purified cysteine to serine 
sEGFRvIII mutant further reveals that domain II flexibility may also be a factor in causing a 
decreased energetic barrier for homo- or hetero-dimerization of EGFR, consistent with our 
hypothesis for extracellular oncogenic point mutations in the EGFR (Bessman, 2014).  This 
dynamic molecular feature of EGFRvIII may result from the loss of autoinhibitory interactions 
from the domain I/II interface that may function normally to stabilize and regulate domain II 
conformation.  Removal of these interactions, as well as N-linked glycosylation sites in 
domain I, may cause an increase in the degrees of freedom in domain II, consistent with its 
low X-ray scattering properties in two X-ray crystal structures.  Some reports have argued 
that EGFRvIII-mediated oligomerization relies on entirely on covalent disulfide mediated 
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oligomerization.  Previous work in the Ferguson laboratory in collaboration with the Carpenter 
laboratory found that covalent dimerization of EGFRvIII through disulfide mixing of cysteines 
in domain II likely contributes to its sequestration and primary localization in the endoplasmic 
reticulum, and hence affecting EGFRvIII signaling.  However, I speculate that instrinsic 
structural flexibility of EGFRvIII ectodomain also may contribute to its ability to transactivate 
other receptor tyrosine kinases, including EGFR and MET. 
My structural analysis of the 34E5 VHH/sEGFRvIII complex reveals a unique mode of 
antibody specificity for an oncogenic EGFR variant, and is the first structure of EGFRvIII 
bound to an antibody with engineered specificity, of which there are several, including 3C10 
and mAb806 (Johns, 2002; Luwor, 2001; Reilly, 2015).  The novel epitope of this VHH with 
engineered specificity for EGFRvIII for the first time reveals a mechanism by which antibody 
specificity for an oncogenic EGFR variant specificity can be achieved through exploitation of 
the presence of the intramolecular ‘tethering’ interaction between cysteine rich domains II and 
IV.   Moreover, because this epitope is only accessible in wild-type sEGFR when this tether is 
transiently broken, the energetic difference, in terms of Gibbs free energy, between 34E5 
binding to wild-type EGFR and EGFRvIII yields a thermodynamic estimate for the energetics 
of ‘tether’ breaking of ~1.7 kcal/mol.  This is the first direct energetic view of the 
thermodynamics of equilibrium between ‘tether’ formation and disruption.   
Antibodies that have been raised to the ErbB/HER family tend to bind to recurring 
epitopes on EGFR.  Cetuximab, panitumumab, and necitumumab, for example, all bind to the 
same region of domain III, and block ligand binding to EGFR, along with two inhibitory VHH 
domains (Li, 2008; Li, 2005; Schmitz, 2009; Schmitz, 2013).  One inhibitory anti-EGFR VHH 
domain and KTN3379, an anti-ErB3 antibody that is currently in phase II trials (Kolltan 
Pharmaceuticals, New Haven, CT), bind to the domain II/III interface and lock the 
conformational transition to the activated dimeric state (Lee, 2015; Schmitz, 2013).  
Trastuzumab/HerceptinTM, an anti-ErbB2/HER2 antibody, targets domain IV of ErbB2/HER2, 
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utilizing a similar utilizing a similar binding mode as the 34E5 VHH for specifically recognizing 
EGFRvIII (Figure 5.6) (Cho, 2003).  Pertuzumab/PerjetaTM, another anti-ErbB2 antibody, 
interacts with the β hairpin in domain II that also forms the intramolecular ‘tethering’ 
interaction in the other ErbB receptors (Franklin, 2004).   
One possible mechanism that may contribute to the recurrence of similar binding 
modes for antibodies that have been selected for binding to specific EGFR variants is a 
‘chaperone’ effect by glycans that surround these epitopes.  For instance, N328, N389, and 
N420 all ‘straddle’ the shared cetuximab, panitumumab, and necitumumab epitope on 
domain III.  In the case of the 34E5 VHH domain, there are two N-linked glycosylation sites 
that may also serve a similar function on N544 and N579.  It is widely established that N-
linked glycosylation plays an important role in both proper folding of the EGFR (Gamou, 
1988; Gamou, 1989), ligand binding (Tsuda, 2000), and membrane interactions (Kaszuba, 
2015).  In addition, complexity of N-linked glycans, including sialylation and fucosylation, has 
recently been reported to play a role in regulating dimerization and activation of EGFR in lung 
cancer cell lines (Liu, 2011).  I suggest that N-linked glycans may also play a role in directing 
anti-ErbB/HER antibodies to their epitopes. 
My discovery of this novel epitope for the EGFRvIII-specific VHH corroborates the 
utility of the intramolecular ‘tether’ interaction in ErbB receptors can be exploited for specific 
antibody targeting of oncogenic EGFR variants lacking this ‘tether’, much like trastuzumab 
and pertuzumab target ErbB2/HER2.  As the buried surface area of the tether is relatively 
small, the smaller VHH paratope is uniquely suited to gain specificity for EGFRvIII through 
this mechanism.  The 25-fold specificity gained for EGFRvIII through this mechanism could 
potentially be exploited to target novel immunotherapies that target EGFRvIII, and suggests 
other possible mechanisms for gaining specificity for ErbB2/HER2 specific antibodies.  
Similar specific recognition of oncogenic forms of RTKs may offer important avenues for 
specific targeting of tumor specific antigens by cancer immunotherapies. 
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METHODS 
Protein production. 
A pFastbac vector for generation of sEGFRvIII was created previously by others in the 
Ferguson laboratory by replacing codons 6 – 273 of wild-type sEGFR (Sugawa et al., 1990) 
with a single glycine codon using standard molecular biology methods.   The plasmid to 
create the cysteine to serine variant of sEGFRvIII was created using standard PCR 
mutagenesis methods.  Both proteins were expressed and purified as secreted proteins in 
baculovirus-infected Sf9 cells exactly as previously described for sEGFR (Ferguson et al., 
2000; Li et al., 2005).  The 34E5 VHH was subcloned into a pET22b bacterial expression 
vector with a C-termal Myc tag followed by a hexahistidine tag, and an N-terminal pelB leader 
sequence to direct periplasmic expression.  This construct was provided generously by the 
laboratory of Dr. Paul van Bergen en Henegouwen (Utrecht University, Utrecht, Netherlands).  
34E5 was expressed and purified from BL21(DE3) E. coli cells expressing pLysS using 
autoinduction (Studier, 2005) at 20 degrees for 20 hours. Periplasms were lysed by one 
round of freeze-thaw of the cell pellet, in 25 mM sodium phosphate 150 mM NaCl pH 7.8 
10% glycerol.  The VHH was purified by Ni-NTA chromatography followed by size exclusion 
chromatography using a Superose 12 column in 25 mM HEPES 150 mM NaCl pH 8, and was 
>95% pure by Coomassie staining. 
 
Surface Plasmon Resonance 
Surface Plasmon Resonance (SPR) experiments were carried out on a Biacore 3000 
instrument exactly as we have previously described (Ferguson et al., 2000).  In brief, EGF 
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(purchased from Chemicon, Inc.) in 10 mM sodium acetate pH 4 was immobilized an 
activated CM5 surface.  A series of samples of the relevant sEGFR protein (in 25 mM 
HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% nonidet-P20, pH 8.0) of different concentrations 
were injected over this surface at a flow rate of 5 µl/min with a contact time of 15 minutes, 
and a dissociation time of 1000 sec., with a 1 minute pulse of regeneration with 10 mM 
sodium acetate pH 4.5 1 M NaCl.  Multiple rounds of regeneration did not impair sEGFR 
binding.  The VHH surfaces were not stable for over a week, and therefore each independent 
experiment was done on a freshly prepared surface. Binding experiments were performed 
independently three times.  The equilibrium SPR responses for each sample plotted against 
the sEGFR concentration, and normalized against the Bmax fitted for sEGFRvIII (applying a 
normalization factor of 1.45 to account for the mass difference between sEGFRvIII and 
sEGFR wild-type).  Data were fit to a simple one-site Langmuir binding model using Prism 6 
(GraphPad Software, Inc., La Jolla, CA). 
 
 
 
Small-angle X-ray scattering (SAXS) 
 
Small angle X ray scattering analysis of sEGFRvIII C16S was performed in house 
using a Rigaku S-MAX3000 pinhole camera system, with a Rigaku 007HF rotating anode 
source and a Rigaku 300 mm wire grid ASM DTR 200 detector, with 60 minute exposures at 
4°C.  Scattering data were radially-averaged, normalized, and reduced to two-dimensional 
plots using the SAXSgui software, and intensity data from buffer exposures were then 
subtracted out. Radius of gyration (Rg) values were determined from Guinier plots using the 
Primus software package using a q range where qRg <1.3 (Konarev et al., 2003).  The 
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scattering intensity at a scattering angle of 0 was also determined from Guinier analysis, and 
was plotted as a function of receptor concentration, to ensure scattering increased linearly 
with receptor concentration (Figure 5.2).  The maximum interatomic distance (Dmax) was 
obtained by examining P(r) curves generated through inverse Fourier transformation by an 
FFT algorithm in the Gnom software package (Svergun, 1992). Briefly, for each scattering 
dataset, P(r) curves were calculated for a range of Dmax from 70 to 150 Å, in 5 Å increments. 
Dmax was determined by identifying the value that gave the best fit to the experimental 
scattering data.  P(r) curves for structural comparison were calculated from structural models 
by using the CRYSOL software package (Svergun, 1995). 
Crystallization, data collection and structure determination 
To purify the sEGFRvIII C16S/34E5 complex, a 2-fold molar excess of the VHH was 
incubated with sEGFRvIII C16S, and the complex purified by size exclusion chromatography 
using a Superose 6 column (GE Healthcare) in 25 mM HEPES pH 8 150 mM NaCl.  The 
complex was concentrated to 70-90 µM and crystallized by hanging drop vapor diffusion at 20 
degrees in 0.5 µl drops that contained a 1:2 v/v protein to reservoir ratio in 100 mM 
ammonium phosphate pH 7.1-7.6 15-20 % PEG3350.  Large plate crystals were grown by 
either cracking the cover slips and sealing over the cracks with grease or by microseeding.  
Crystals appeared within 2 days and were stable for less than a week.  Crystals were briefly 
cryoprotected in 100 mM ammonium phosphate pH 7.1 containing 20% PEG400 and 20% 
PEG3350.  X-ray diffraction data to 2.9 angstrom resolution were collected at APS beamline 
23-ID B using a MAR CCD detector.  The data were processed in HKL2000 (Otwinowski and 
Minor, 1997). Data collection statistics are summarized in Table 1.  The structure of 
sEGFRvIII was solved by the method of molecular replacement (MR) using the program 
PHASER (McCoy, 2007).  As a search model the domains III and IV of wild-type EGFR 
(amino acids 310-480 and 481- 614 from PDB ID 1YY9, respectively) were first located 
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separately and subsequently together.  Solutions for domain III were validated by identifying 
electron density for ordered N-acetylglucosamine residues (omitted from the search model) at 
N-linked glycosylation sites N328 and N389, and these solutions were fixed in subsequent 
searches.   
The VHH was identified by using a sequence related camelid VHH (PDB ID 4NC2) 
with the complementarity determining regions (CDR’s) omitted. The CDR regions were 
manually rebuilt using COOT (Emsley, 2010) after density modification and solvent flattening 
implemented in PHENIX AUTOBUILD (Terwilliger, 2008).  Refinement was performed in 
PHENIX (Adams, 2010) and used iterative rounds of real space refinement with 
Ramachandran restraints followed by unrestrained reciprocal space refinement and model 
rebuilding. 
 
Structure Analysis. 
Structures were overlaid and RMSD values were calculated using the programs 
PYMOL (Delano Scientific, Palo Alto, CA), or COOT (Emsley, 2010), and reflect main chain 
atoms only.  Shape complementarity values were calculated using the Sc module in CCP4 
(Lawrence, 1993), excluding saccharide, ligand, and solvent molecules. Buried interface 
surface area was calculated using the PISA server. Most of the X ray diffraction and 
structural analyses were completed using software compiled on SBGrid (Morin, 2013). 
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CHAPTER FIVE TABLES 
Table 5.1.  Equilibrium binding constants of sEGFRvIII and sEGFRvIIIS16C binding to 
immobilized EGF, FabC225, and 34E5 VHH.  
 
 
Immobilized Ligand 
KD values for binding of indicated analyte 
sEGFR 
wild-type 
sEGFRd3 
sEGFRvIII 
(monomeric) 
sEGFRvIIIC16S 
EGF 130± 3 nM 1.7 ± 0.1 µM 2 ± 0.13 µM 2.2 ± 0.22 µM 
FabC225 2.3± 0.5 nM 1.7 ± 0.1 nM N.D. 1.1 ± 0.1 nM 
34E5 VHH 668.3±107.8 
nM 
N.D. 35.6±11.3 nM 
40.1±3.5 nM 
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. Table 5.2. X-ray diffraction data collection and refinement statistics 
 
 
 sEGFRvIII C16S/34E5 VHH 
Data collection  
Space group P1 
Cell dimensions    
    a, b, c (Å) 66.5, 80.5, 92.2 
    α, β, γ  (°)  107.04, 103.58, 104.56 
Resolution (Å) 2.9 (3.0-2.89)   
Rmerge 0.087 (0.76) 
I / σI 23.7 (1.7) 
Completeness (%) 96.6 (83.3) 
Redundancy 3.8 (3.3) 
  
Refinement  
Resolution (Å) (dmin) 43-2.9 (2.97-2.89) 
No. unique reflections 35,331 
Rwork / Rfree 0.263/0.283 (0.433/0.509) 
No. atoms  
    Protein 6,694 
    Ligand/ion 11 
    Waters  
B-factors  
    Protein 75.8 
    Ligand/ion  
    Water  
R.m.s. deviations  
    Bond lengths (Å) 0.002 
    Bond angles (°) 
Ramachandran favored (%) 
Ramachandran outliers (%) 
Rotamer outliers (%) 
0.615 
92.5 
0.7 
0 
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CHAPTER FIVE FIGURES 
 
A 
 
B 
 
Fig. 5.1. Structural and biochemical properties of sEGFRvIII and sEGFRvIII C16S.  (A) 
Sequence alignment of EGFRvIII with wild-type EGFR.  Unpaired cysteine at position 16 in 
EGFRvIII is highlighted in red.  (B) Sedimentation equilibrium analytical ultracentrifugation 
analysis demonstrates that EGFRvIII has a molecular mass of 55 kDa, corresponding to a 
glycosylated sEGFRvIII monomer (protein only molecular weight 41.1 kDa).   
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Fig. 5.2 Small angle X ray scattering analysis of EGFRvIII reveals domain II flexibility.  
(A) P(r) pairwise interatomic vector distribution functions calculated from solution X-ray 
scattering data of sEGFRvIII C16S (red) or calculated from indicated models. A ‘tethered’ 
EGFRvIII model was derived from PDB ID 1NQL (green). The experimentally determined 
sEGFRvIII C16S with a limited portion of domain II modeled is shown in blue. Reciprocal 
space Rg of sEGFRvIII C16S is 33.48, where that of a ‘tethered’ EGFRvIII model, derived 
from PDB ID 1NQL is 28.74.  (B)  Intensity at scattering angle 0 (I0) plotted as a function of 
sEGFRvIII C16S concentration.  (C) Raw scattering data plotted with maximum likelihood-
derived errors in the fit to the calculated P(r), at a concentration of 6 mg/ml  (D) Guinier 
region of the data shown in panel (C) shows no sign of protein aggregation under the 
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conditions of the experiments.  (E) Kratky analysis of the data shown in (C) shows that the 
protein is globular and not denatured.  
 
 
 
  
 
 
 
Figure 5.3 34E5 VHH has engineered specificity for EGFRvIII. Samples of the indicated 
concentrations of sEGFR and variants were passed over Biacore surfaces to which the VHH 
34E5 had been immobilized.  34E5 samples were immobilized on Biacore CM5 chips using 
amine coupling.  Binding assay and data processing were conducted as described in the 
experimental procedures.  Representative, normalized binding curves are shown and mean 
KD values are reported in Table 5.1. 
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Figure 5.4 Structural basis for specific targeting of EGFRvIII by 34E5 VHH. (A) The X-
ray crystal structure of 34E5 VHH in complex with EGFRvIII reveals that 34E5 VHH binds to 
domain IV of EGFRvIII, to a region that is sterically occluded by the intramolecular ‘tethering’ 
interaction between domains II and IV, as shown in panel (B).  (C)  A detailed view of the 
molecular basis of 34E5 targeting of EGFRvIII.  As shown, and discussed in the results 
section, the majority of the 34E5 interaction with EGFRvIII is driven by CDR3 hydrogen-
bonding and van der Waals interactions, with some contributions from Asp54 in CDR2 and 
CDR1 (not shown). 
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Figure 5.5 Structural comparison of sEGFR and sEGFRvIII C16S domain 
conformations.  Structural overlay of domain III from known ‘tethered’ EGFR structures 
reveals distinct interdomain relationships.  In red and green is the tethered structure 
determined at low pH with EGF (PDB ID 1NQL), in gray is the tethered structure observed in 
the cetuximab complex structure (PDB ID 1YY9).  The blue and cyan models are of 
EGFRvIII.  The cyan model is the structure of EGFRvIII C16S alone, determined previously.  
The blue model is of EGFRvIII C16S in complex with 34E5 VHH reported here.  Comparison 
of domain IV conformation relative to domain III reveals a range of hinge angles between the 
two domains in tethered sEGFR models. The domain II/III interface also has two distinct 
geometries – one that is more like the inactive, low pH structure, and one that is more like the 
cetuximab complex structure.  The part of domain II that can be modeled in the EGFRvIII 
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C16S structure in complex with the 34E5 VHH (blue) more closely resembles the cetuximab 
bound conformation of domain II (gray). 
 
 
 
 
 
Figure 5.6 34E5 VHH utilizes a similar binding mode to specifically target EGFRvIII as 
trastuzumab uses to target ErbB2/HER2.   Domain III from EGFRvIII was overlaid with (aa. 
310-480) from the ErbB2/trastuzumab structure (PDB ID 1N8Z).  34E5 VHH is shown in cyan 
and targets a similar region of domain IV of EGFRvIII as trastuzumab for ErbB2/HER2. 
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CHAPTER SIX 
Conclusions and Perspectives 
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In this dissertation, I have presented work that identifies novel extracellular 
mechanisms of oncogenic dysregulation of the Epidermal Growth Factor receptor (EGFR).  
One such extracellular mechanism, as discussed in Chapter Two, is enhancement of ligand 
binding affinity without measureable alteration of homo-dimerization energetics in vitro 
(Bessman, 2014).  The linkage of ligand binding and dimerization equilibria in the EGFR has 
previously been thought to be weak (Johannessen, 2001).   We report that it is competitive, 
and that these extracellular GBM mutations may alter the thermodynamic linkage of ligand 
binding and receptor dimerization (Bessman, 2014).  These observations can be structurally 
rationalized by the view that domain I/II interactions function normally to restrict the 
conformation of domain I, and breaking these interactions make it energetically more 
favorable for domain I to come closer to domain III to form a high affinity ligand binding site.  
It is possible that alterations in the linkage of the thermodynamic equilibria may alter 
relationships between homo- and hetero-oligomerization energetics of ErbB/HER receptors in 
the context of the intact full-length receptors expressed on the cell surface, thereby stabilizing 
distinct receptor dimer species that may contribute to constitutive signaling. Stabilization of 
these alternate heterodimeric species may mimic the effects of some EGFR ligands, such as 
EGF, which binds preferentially to EGFR/ErbB2 heterodimers (Macdonald-Obermann, 2014).    
Another possibility is that contributions from the membrane and/or the intracellular 
region of EGFR are key to this oncogenic mechanism, and is lacking in our current analyses.  
Such non-additivity or interdependence of contributions from the extra- and intra-cellular 
regions of EGFR would be consistent with the observation that negative cooperativity of intact 
EGFR is lost in studies of the isolated extracellular region of human EGFR, but not in the 
Drosophila melanogaster ortholog (Alvarado et al., 2010).  Such allosteric linkage is also 
implicit in the observation that these extracellular activating mutations alter the differential 
sensitivity of EGFR inhibition by lapatinib and erlotinib.  Lapatinib, binds preferentially to the 
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kinase inactive conformation and has slow off-rate relative to gefitinib (Wood, 2004), where 
erlotinib can bind both active and inactive kinase conformations (Park, 2012).  These 
extracellular, activating mutations therefore sensitize EGF receptor to an inhibitor known to 
bind preferentially to the kinase inactive conformation, suggesting that structural allostery is 
at play in this extracellular mode of oncogenic dysregulation.  Experimental tools for 
evaluating allostery and the relative contributions of extra- and intra-cellular interactions to 
receptor-mediated dimerization are inherently limited by the size of the receptor and the 
quantities that can be purified in a cost-effective manner.  In Chapter Three, I have presented 
preliminary progress towards application of hydrogen/deuterium exchange coupled to mass 
spectrometry towards understanding the relative contributions of extra- and intra-cellular 
interactions to dimerization energetics.  It is possible that extracellular activating mutations 
alter the linkage of extra- and intra-cellular dimerization energy rather than just simply 
enhancing extracellular-mediated dimerization, and HDX/MS would be a useful tool to study 
this mode of dysregulation.  Specifically, HDX/MS analyses of ligand-induced protection of 
full-length EGFR could directly report on dimerization energetics in peptides that are known 
from crystallographic analyses to be in either extra- or intra-cellular dimerization interfaces.  
Analyses of receptor dynamics through both experimental and computational techniques has 
recently progressed our understanding of transmembrane regulation of the EGFR (Arkhipov 
et al., 2013; Endres et al., 2013), as well as mechanisms by which it can be oncogenically 
dysregulated by mutations in its tyrosine kinase domain (Shan, 2012).   
Another extracellular oncogenic mechanism, as discussed in Chapter Five, is an 
alteration of trafficking and increased flexibility of domain II and altered inter-domain 
relationships.  Deletion of parts of the extracellular region of EGFR can cause improper 
folding of the intact receptor, thereby causing its sequestration of its proper trafficking to the 
plasma membrane, as has previously been observed for EGFRvIII (Wikstrand, 1997).  In 
previous work, the Ferguson laboratory in collaboration in the Carpenter laboratory, showed 
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that the unpaired cysteine of EGFRvIII causes a similar sequestration of these mutated 
receptor molecules early in the secretory pathway through disulfide-mediate dimerization, 
consistent with recently published work (Ymer, 2011).  I compliment these data with solution 
scattering analysis of the EGFRvIII extracellular region, which suggest intrinsic structural 
flexibility in domain II, consistent with its low X-ray scattering properties in two X-ray 
structures.  This alteration of domain II conformation and dynamics may lower the energetic 
barrier associated with hetero-dimerization, rationalizing published reports that EGFRvIII 
hetero-dimerizes with and trans-activates other receptor tyrosine kinase, such as MET 
(Huang, 2007; Johnson, 2012).  This transactivation relies on activity of EGFRvIII, which is 
not understood in structural terms.  However, a separate report suggests that the constitutive 
activation of EGFRvIII relies on co-expression and activity of wild-type EGFR (Fan, 2013).  
Taken together, both observations would be consistent with the view that EGFRvIII 
dynamically hetero-oligomerizes with other receptor tyrosine kinases, including both EGFR 
and MET (Greenall, 2015).  The precise structural basis for this hetero-oligomerization, and 
whether EGFRvIII is a preferred ‘receiver’ or preferred ‘activator’ in the asymmetric dimer 
(Zhang, 2006), and the mechanism of cooperation between EGFRvIII and EGFR, remains 
unknown.  It is clear, however, that this hetero-oligomerization requires activity of EGFRvIII 
(Greenall, 2015), in contrast to ErbB2-hetero-olgiomerization with EGF receptor.  Specifically, 
kinase activity of ErbB2 is not required for its hetero-oligomerization with and modulation of 
EGFR activity (Qian, 1994a; Qian, 1994b).  There also remain formidable technical 
challenges to being able to address the question of how EGFRvIII transactivates and 
cooperates with other RTK’s, as a result of the range of structural techniques that can 
currently be used on intact membrane proteins of a similar size as EGFRvIII. 
Both oncogenic mechanisms rely on alteration of structural relationships between the 
subdomains of the EGFR extracellular region.  The point mutations studied in Chapter Two 
disrupt autoinhibitory interactions between domains I and II that likely serve to restrict the 
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conformation of domain II in an inactive state in the inactive ‘tethered’ structure.  
Unrestraining the domain I/II relationship therefore may allow domain II to adopt 
conformations distinct from those observed in ‘tethered’ X-ray crystal structures.  Loss of 
these autoinhibitory interactions therefore may lower the energetic barrier for domain II 
conformational remodeling, that is required for ErbB homo-dimerization or hetero-
dimerization (Dawson, 2005; Dawson et al., 2007) and consequently result in constitutive 
receptor activation and oncogenic signaling. 
In a second focus, I studied two distinct mechanisms of antibody recognition of the 
EGFR – one in the context of resistance to a currently clinically used antibody drug, and the 
other in the context of an oncogenic alternative splice variant that renders a unique, tumor-
specific antigen.  In the first focus, my work on the structural basis for high affinity 
necitumumab binding to the S468R cetuximab resistance mutation identifies a hydrophobic 
cavity in between the VH and VL domains in necitumumab that is a result of CDR H3 
conformation.  This hydrophobic cavity can accommodate genetic mutations that introduce 
bulky residues, where cetuximab cannot as a result of its flatter paratope.  In my X-ray crystal 
structure of isolated EGFR domain III containing the S468R mutation bound the Fab fragment 
from necitumumab (Fab11F8), this cavity contains a buried water molecule that is 
coordinated by a serine in the VH domain that, along with several cation-pi and polar 
interactions, stabilizes the arginine sidechain in this region of low dielectric constant.  
Analysis of the four complexes in the asymmetric unit identified a structural ‘wobble’, 
suggesting that the antibody is less rigidly bound to the mutated EGF receptor domain III 
compared to the wild-type domain III (Li, 2008).   
Although the presence of this buried hydrophobic cavity does not alter the common 
quantitative measure for shape complementarity of protein/protein interfaces (Lawrence, 
1993), comparison of the paratopes of cetuximab and necitumumab to those of other 
therapeutic antibodies reveals a structural class of antibodies that contain similar buried 
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cavities, as opposed to the ‘flatter’ paratope of some antibodies such as cetuximab.  The 
origin of this cavity is due primarily to CDR H3 conformation, which is known to be 
hypervariable and adopt a structurally diverse set of conformations, driven by a C-terminal 
kink (Sircar, 2009; Weitzner, 2015).  It is also thought that affinity maturation of antibodies 
can ‘bias’ the conformation of CDR H3 (Xu, 2015).  These studies highlight the importance of 
development of computational tools to classify CDR H3 conformation and distinguish surface 
features of antibody paratopes.   Some existing tools, such as contact analysis (MacCallum, 
1996), may be useful for identifying whether newer antibodies contain similar cavities.  
Further studies are needed to evaluate whether antibodies that contain similar cavities are 
capable of exhibiting a similar degree of structural plasticity as necitumumab, and whether 
they are less susceptible to resistance through epitope mutations.    Our analysis also reveals 
that paratope shape may also be a property of antibodies that could be utilized in synergistic 
modes for combinatorial therapies. 
I also discovered a mechanism by which antibody specificity for a commonly found 
oncogenic EGFR variant, EGFRvIII, can be engineered.  EGFRvIII is a target antigen for 
many evolving cancer immunotherapies, including both a CD3-bispecific antibody (Choi, 
2013) as well as chimeric antigen receptor expressing T cells (Johnson, 2015). I discovered 
in an X-ray crystal structure of an EGFRvIII-specific heavy chain only antibody or VHH 
domain that the VHH domain functionally mimics the intramolecular ‘tethering’ interaction 
present in wild-type EGFR but absent in EGFRvIII as a result of its exclusion of mature amino 
acids 6-273.  The VHH targets an epitope on EGFR domain IV that is sterically occluded as a 
result of this intramolecular ‘tethering’ interaction, thereby gaining specificity for EGFRvIII.  
This EGFRvIII-targeted VHH domain therefore gains specificity for EGFRvIII in a manner 
analogous to how trastuzumab/HerceptinTM and pertuzumab/PerjetaTM gain specificity for 
ErbB2/HER2, as a result of it being constitutively ‘extended’ as a monomer (Cho, 2003; 
Franklin, 2004).  Trastuzumab targets a very analogous epitope on ErbB2 domain IV, and 
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pertuzumab targets an epitope on domain II, both of which are sterically occluded in EGFR, 
ErbB3, and ErbB4 as a result of the presence of the intramolecular ‘tether’ between domains 
II and IV in the absence of ligand (Bouyain, 2005; Cho, 2002; Ferguson et al., 2003).   
This EGFRvIII-specific VHH domain may be useful as an imaging agent, or in 
therapeutic applications. VHH domains, as a result of their small size, have improved tumor 
and tissue penetration properties compared to larger monoclonal antibodies, and are 
emerging as potential imaging agents (Schmitz, 2013).   As VHH domains can also be used 
as ‘cassettes’ or modules to combine synergistic paratopes into one agent (Roovers, 2011; 
Schmitz, 2013), specific recognition of EGFRvIII with the 34E5 VHH domain could potentially 
be combined with other paratopes that recognize tumor-specific cell surface antigens, or in 
the context of chimeric antigen receptor expressing T cells.  Identification of this novel 
mechanism by which oncogenic EGFR variant III can be specifically targeted is important for 
the development of this VHH domain for these potential applications.   
Overall, this dissertation has contributed to our understanding of both extracellular 
mechanisms and antibody targeting of the epidermal growth factor receptor family.  The work 
in the first part leads us towards being able to ask questions about how the epidermal growth 
factor receptor functions as an intact molecule.  The first step in understanding allosteric 
regulation of the ErbB/HER family is to understand the allosteric alterations of the intact 
receptor imposed by ligand binding within an EGFR homodimer.  Development of structural 
techniques to analyze transmembrane allosteric regulation of the ErbB/HER family of 
receptor tyrosine kinases (RTK’s) are ongoing, and hydrogen/deuterium exchange coupled to 
mass spectrometry holds promise for addressing how extracellular oncogenic mechanisms 
relay information across the plasma membrane.  Future studies that may build upon the work 
presented in this dissertation may rationalize differences in tyrosine kinase inhibitor sensitivity 
and inform future development of antibodies or other therapeutic agents with engineered 
specificity for these mutated receptor molecules.  
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Our preliminary advances in understanding extracellular mechanisms by which the 
Epidermal Growth Factor receptor can be allosterically dysregulated may have lessons that 
are general for how transmembrane proteins are allosterically regulated in general.  An 
alteration of coupling of thermodynamic equilibria may stabilize distinct heteromeric species 
on the cell surface and alter trafficking of these receptors, for example, and thereby cause 
oncogenic signaling.  Our efforts at understanding transmembrane alllostery by exploiting 
hydrogen/deuterium exchange coupled to mass spectrometry could impact future efforts at 
understanding structural allostery in membrane proteins using HDX/MS.  In principle, 
membrane bound receptors are in many ways similar to allosterically regulated enzymes for 
which mechanisms have been described over the past half century (Levitzki, 1969).  The 
distinction between such enzymes and receptor tyrosine kinases, however, is the presence in 
the latter of a transmembrane domain as well as a membrane composed of an asymmetric 
lipid composition through which such allosteric information may be relayed.  Juxtamembrane 
regions of RTK’s, which may interact directly with these lipid headgroups, and thereby play 
roles in amplifying these signals— leading to structural arrangements that favor autoinhibited 
or activated states of these receptors.  Indeed, in the EGFR, many interactions between the 
juxtamembrane regions and kinase (Jura, 2009; Red Brewer, 2009), and Thr654 
phosphorylation are already known to affect transmembrane communication (Defize, 1989; 
Felder, 1992; Lund, 1990).  For example, Protein Kinase C phosphorylation of Thr654 inhibits 
high affinity EGF binding and slows EGFR internalization (Lund, 1990).  These 
juxtamembrane interactions may serve to restrict the conformational freedom of the tyrosine 
kinase domains until they are relieved by ligand binding.  There are other receptor systems 
that are thought to be allosterically regulated for which interactions with the membrane may 
also be autoinhibitory, such as the T-cell receptor, in which Wucherpfennig and colleagues 
have proposed that the cytoplasmic tyrosine-based motifs (ITAM’s) are buried in the 
membrane prior to release by peptide-MHC engagement (Xu, 2008).  
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Another possible mode of allosteric dysregulation is ‘unlinkage’ of the relative 
contributions of extracellular and intracellular contributions to receptor dimerization.  Such 
non-additivity of extra- and intra-cellular energetics within receptor dimers harkens back to 
nonadditivity principles in closed thermodynamic systems (Mark, 1994), or context-dependent 
effects of a thermodynamic perturbation on a closed system, which in this case is ligand 
binding.  Preliminary progress presented in this dissertation could be expanded to utilize 
HDX/MS to measure the simultaneous ligand-induced protection factors in peptides that are 
known to be in dimerization interfaces.  Such relative protection factors could be interpreted 
as relative contributions of extra- and intra-cellular dimerization energetics, and used to 
compare how a mutated receptor would ‘spread’ its dimerization energy relative to a wild-type 
receptor. 
The second part of this dissertation identifies new mechanisms of plasticity and 
specificity for antibody targeting of the EGFR, either in the context of retaining high affinity for 
mutantions that cause resistance to currently used therapeutic antibodies like cetuximab, or 
in the context of specifically targeting oncogenic variants of the EGFR, like EGFRvIII.  Our 
work in the first part both identified a structural mechanism for necitumumab inhibition of EGF 
receptor variants that cause acquired resistance to cetuximab.  Our analysis suggests that 
necitumumab belongs to a structural class of antibodies that may be defined by conformation 
of CDR H3 that contain buried cavities between their VH and VL domains.  These cavities 
facilitate structural plasticity in accommodating genetic mutations that may cause a decrease 
in binding energetics to an antibody with a relative flat paratope incapable of accommodating 
such changes.  Therefore, our analysis suggests that paratope shape may be a useful 
property of antibodies that could be used in synergistic modes in the context of resistance to 
one therapeutic antibody.  My second focus corroborates the utility of the extracellular ‘tether’ 
interaction in the ErbB/HER family for gaining antibody specificity to an oncogenic EGFR 
variant.  Both focuses reveal that antibody specificity and plasticity are not mutually exclusive, 
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and future work will have to be done on these and other antibody systems to reveal the limits 
of how much affinity or specificity can be achieved without compromising plasticity. 
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